---
document_datetime: 2023-09-21 18:49:03
document_pages: 85
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/vyndaqel-epar-public-assessment-report_en.pdf
document_name: vyndaqel-epar-public-assessment-report_en.pdf
version: success
processing_time: 62.2312182
conversion_datetime: 2025-12-19 00:24:01.416927
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 September 2011 EMA/729083/2011 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Vyndaqel

tafamidis meglumine

Procedure No.:

EMEA/H/C/002294

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone

+44 (0)20 7418 8400

Facsimile

+44 (0)20 7523 7455

E-mail

info@ema.europa.eu

Website

www.ema.europa.eu

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

Note ............................................................................................................ 1

| 1. Background information on the procedure ..............................................5                               |                                                                                                            |
|--------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................       | 5                                                                                                          |
| 1.2. Steps taken for the assessment of the product .......................................................               | 6                                                                                                          |
| 2. Scientific discussion ................................................................................6               | 2. Scientific discussion ................................................................................6 |
| 2.1. Introduction ...................................................................................................... | 6                                                                                                          |
| 2.2. Quality aspects ..................................................................................................  | 7                                                                                                          |
| 2.2.1. Introduction ...................................................................................................  | 7                                                                                                          |
| 2.2.2. Active Substance.............................................................................................     | 8                                                                                                          |
| 2.2.3. Finished Medicinal Product ................................................................................       | 9                                                                                                          |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects.............................                        | 11                                                                                                         |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                | ..................... 11                                                                                   |
| 2.3. Non-clinical aspects..........................................................................................      | 11                                                                                                         |
| 2.3.1. Introduction .................................................................................................    | 11                                                                                                         |
| 2.3.2. Pharmacology...............................................................................................       | 11                                                                                                         |
| 2.3.3. Pharmacokinetics ..........................................................................................       | 13                                                                                                         |
| 2.3.4. Toxicology....................................................................................................    | 17                                                                                                         |
| 2.3.5. Ecotoxicity/environmental risk assessment........................................................                 | 22                                                                                                         |
| 2.3.6. Discussion on non-clinical aspects....................................................................            | 23                                                                                                         |
| 2.3.7. Conclusion on the non-clinical aspects ..............................................................             | 27                                                                                                         |
| 2.4. Clinical aspects ................................................................................................   | 27                                                                                                         |
| 2.4.1. Introduction .................................................................................................    | 27                                                                                                         |
| 2.4.2. Pharmacokinetics ..........................................................................................       | 30                                                                                                         |
| 2.4.3. Pharmacodynamics........................................................................................          | 33                                                                                                         |
| 2.4.4. Discussion on clinical pharmacology .................................................................             | 35                                                                                                         |
| 2.4.5. Conclusions on clinical pharmacology ...............................................................              | 36                                                                                                         |
| 2.5. Clinical efficacy ................................................................................................  | 36                                                                                                         |
| 2.5.1. Dose response studies....................................................................................         | 36                                                                                                         |
| 2.5.2. Main study ...................................................................................................    | 37                                                                                                         |
| Ancillary analyses...................................................................................................    | 47                                                                                                         |
| 2.5.3. Discussion on clinical efficacy ..........................................................................        | 59                                                                                                         |
| 2.5.4. Conclusions on the clinical efficacy...................................................................           | 63                                                                                                         |
| 2.6. Clinical safety ..................................................................................................  | 64                                                                                                         |
| 2.6.1. Discussion on clinical safety ............................................................................        | 72                                                                                                         |
| 2.6.2. Conclusions on the clinical safety.....................................................................           | 73                                                                                                         |
| 2.7. Pharmacovigilance............................................................................................       | 74                                                                                                         |
| 2.8. User consultation .............................................................................................     | 78                                                                                                         |
| 3. ...........................................................................78 Benefit-Risk Balance                    |                                                                                                            |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADL            | activities of daily living                                                |
|----------------|---------------------------------------------------------------------------|
| AE             | adverse event                                                             |
| ALP            | alkaline phosphatase                                                      |
| ALT            | alanine aminotransaminase                                                 |
| ANCOVA         | analysis of covariance                                                    |
| ANOVA          | analysis of variance                                                      |
| AST            | aspartate aminotransaminase                                               |
| ATTR           | transthyretin amyloidosis                                                 |
| ATTR-CM        | transthyretin amyloid cardiomyopathy                                      |
| ATTR-PN        | transthyretin amyloid polyneuropathy                                      |
| AV             | atrioventricular                                                          |
| BUN            | blood urea nitrogen                                                       |
| Ca             | calcium                                                                   |
| ECG            | electrocardiogram                                                         |
| eCRF           | electronic case report form                                               |
| EU             | European Union                                                            |
| FAP            | familial amyloid polyneuropathy                                           |
| FAPWTR         | Familial Amyloidotic Polyneuropathy World Transplant Registry             |
| FDA            | Food and Drug Administration                                              |
| FOI            | fraction of initial                                                       |
| GCP            | Good Clinical Practice                                                    |
| GGT            | gamma-glutamyl transferase                                                |
| HCV            | hepatitis C virus                                                         |
| HIV            | human immunodeficiency virus                                              |
| HRDB           | heart rate response to deep breathing                                     |
| ICH            | International Conference on Harmonisation                                 |
| ID ITT         | identification intent-to-treat                                            |
| IVRS           | interactive voice response                                                |
|                | system FoldRx Pharmaceuticals, Inc. immunoturbimetric stabilization assay |
| ITTSA          | Kansas City Cardiomyopathy Questionnaire                                  |
| KCCQ           |                                                                           |
| kg             | kilogram                                                                  |
| LL             | lower limb                                                                |
|                | Mean Least squares                                                        |
| LS mBMI        | mean modified body mass index                                             |
| MCH            | mean corpuscular hemoglobin                                               |
| MCHC           | mean corpuscular hemoglobin concentration                                 |
| MedDRA         | Medical Dictionary for Regulatory Activities                              |
| NCS            | nerve conduction studies                                                  |
| NIS-LL         | Neuropathy Impairment Score - Lower Limb                                  |
| NOAEL          | No observed adverse event level                                           |
| NOEL           | No observed effect level                                                  |
| Norfolk QOL-DN | Norfolk Quality of Life - Diabetic Neuropathy                             |
| NSAID          | non-steroidal anti-inflammatory drug                                      |
| NT-pro-BNP     | N-terminal prohormone brain natriuretic peCo-Rapide                       |
| NYHA           | New York Heart Association                                                |
| OTC            | over-the-counter                                                          |
| PD             | pharmacodynamic                                                           |
| PK             | pharmacokinetic(s)                                                        |
| PT             | prothrombin time                                                          |
| QD             | once a day                                                                |

<div style=\"page-break-after: always\"></div>

| QOL    | quality of life                              |
|--------|----------------------------------------------|
| QOL-DN | Quality of life - diabetic neuropathy        |
| QST    | quantitative sensory testing                 |
| RBC    | red blood cell count                         |
| RPB    | Retinal protein binding                      |
| SAE    | serious adverse event                        |
| SAS    | statistical analysis system                  |
| SD     | standard deviation                           |
| SOC    | system organ class                           |
| T4     | total thyroxine                              |
| TEAE   | treatment-emergent adverse event             |
| TK     | toxicokinetic(s)                             |
| TQOL   | Total Quality of Life                        |
| TSH    | thyroid-stimulating hormone                  |
| TTR    | transthyretin                                |
| ULN    | upper limit of normal                        |
| UTI    | urinary tract infection                      |
| V30M   | valine replaced by methionine at position 30 |
| VDT    | vibration detection threshold                |
| WBC    | white blood cell count                       |
| WHO    | World Health Organization                    |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The  applicant  Pfizer  Specialty  UK  Limited  submitted  on  28  July  2010  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMA)  for  Vyndaqel,  through  the  centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP during its meeting on 15-18 February 2010.

Vyndaqel was designated as an orphan medicinal product EU/3/06/401 on 28 August 2006. Vyndaqel was  designated  as  an  orphan  medicinal  product  in  the  following  indication:    Treatment  of  familial amyloid polyneuropathy. The calculated prevalence of this condition was less than 0.1 per 10,000 EU population.

Following  the  CHMP  positive  opinion  on  this  marketing  authorisation,  the  Committee  for  Orphan Medicinal Products (COMP) reviewed the designation of Vyndaqel as an orphan medicinal product in the approved  indication.  The  outcome  of  the  COMP  review  can  be  found  on  the  Agency's  website: ema.europa.eu/Find Medicine/Human medicines/Rare disease designations.

The applicant applied for the following indication: oral treatment of transthyretin amyloidosis in adult patients with symptomatic polyneuropathy.

## The legal basis for this application refers to:

## Article 8.3 of Directive 2001/83/EC

The  application  submitted  is  composed  of  administrative  information,  complete  quality  data,  nonclinical  and  clinical  data  based  on  applicants'  own  tests  and  studies  and  bibliographic  literature substituting/supporting certain tests or studies.

## Information on Paediatric requirements

Pursuant  to  Article  7  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/147/2010 on the granting of a product-specific waiver.

## Information relating to orphan market exclusivity

## Similarity

Not applicable.

## Market Exclusivity

Not applicable.

## Applicant's request for consideration

## New active Substance status

The applicant requested the active substance tafamidis contained in the above medicinal product to be considered as a new active substance in itself.

<div style=\"page-break-after: always\"></div>

## Protocol Assistance

The applicant received Protocol Assistance from the CHMP on 26 June 2008. The Protocol Assistance pertained to quality, non-clinical and clinical aspects of the dossier.

## Licensing status

A new application was filed in the following country: United States of America.

The product was not licensed in any country at the time of submission of the application.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Philippe Lechat

Co-Rapporteur:

Helder Mota-Filipe

-  The application was received by the EMA on 28 July 2010.
-  The procedure started on 18 August 2010.
-  The Rapporteur's first Assessment Report was circulated to all CHMP members on 9 November 2010. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 10 November 2010.
-  During the meeting on 13-16 December 2010, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 16 Decembert 2010.
-  The applicant submitted the responses to the CHMP consolidated List of Questions on 17 March 2011.
-  The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 6 May 2011.
-  During the CHMP meeting on 16-19 May 2011, the CHMP agreed on a List of Outstanding Issues to be addressed in writing by the applicant.
-  The applicant submitted the responses to the CHMP List of Outstanding Issues on 20 June 2011.
-  The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of List of Outstanding Issues to all CHMP members on 5 July 2011.
-  During the meeting on 18-21 July 2011, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation under exceptional circumstances to Vyndaqel on 21 July 2011.

## 2. Scientific discussion

## 2.1. Introduction

Familial transthyretin amyloidosis (ATTR) is characterised by a slowly progressive peripheral sensorimotor neuropathy and autonomic neuropathy as well as cardiomyopathy, nephropathy, vitreous

<div style=\"page-break-after: always\"></div>

opacities and CNS amyloidosis. The onset of the disease is usually in the third to fifth decade. ATTR, the most frequently inherited amyloidosis, is caused by an accumulation of insoluble fibrillar proteins (amyloid) in the tissues. Typically, sensory neuropathy starts in the lower extremities and is followed by  motor  neuropathy  within  a  few  years.  Autonomic  neuropathy  may  occur  as  the  first  clinical symptom  of  the  disease.  The  symptoms  of  autonomic  dysfunction  include  orthostatic  hypotension, constipation  alternating  with  diarrhoea,  attacks  of  nausea  and  vomiting,  delayed  gastric  emptying, sexual impotence, anhidrosis and urinary retention or incontinence.

The  TTR  protein  normally  circulates  in  serum  or  plasma  as  a  soluble  protein  with  a  tetrameric structure.  Pathogenic  mutations  in  the  TTR  gene  cause  conformational  change  in  the  TTR  protein molecule disrupting the stability of the TTR tetramer, which is then more easily dissociated into proamyloidogenic monomers. The most frequent pathogenic mutation is VAL30MET (V30M) and it is the one most often detected in Portuguese and Swedish families.

The  prevalence  of  this  disease  is  extremely  rare;  in  Europe,  the  overall  population  of  patients  with ATTR-PN  is  estimated  at  approximately  2,700  to  3,500,  which  would  correspond  to  a  worldwide prevalence of 5,000 to 10,000 patients.

To date, the only effective therapy for the neuropathy of familial TTR amyloidosis is the orthotopic liver transplantation  (OLTX),  which  removes  the  main  production  site  of  the  amyloidogenic  protein. Successful OTLX results in rapid disappearance of variant TTR protein from the serum and thus helps disrupt  progression  of  peripheral  and/or  autonomic  neuropathy.  Of  the  more  than  1,500  liver transplants reported to the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR) since  1995,  more  than  80%  were  performed  in  V30M  ATTR-PN  patients  confirming  the  worldwide prevalence of this mutation. Limited clinical follow-up studies showed that the neuropathy appears to stabilize following transplantation in many patients. In the cases reported to the FAPWTR for which 5and  10-  year  data  were  available,  the  five-  and  ten-year  survival  rates  for  the  ATTR-PN  patients undergoing  liver  transplantation  were  77%  and  71%,  respectively.  However,  the  first-year  posttransplant mortality rate is approximately 10%.

The effect of liver transplantation in the cardiac involvement of the neuropathic form is less clear, with a persistence of cardiac disease progression in most cases.

OLTX  is  not  effective  in  the  non-neuropathic  forms  of  familial  TTR  amyloidosis  (e.g.  cardiac amyloidosis).

Tafamidis is a compound that binds non-cooperatively to the two transthyretin (TTR) binding sites and was developed as an oral specific stabiliser of TTR tetramer. It is intended for the oral treatment of transthyretin amyloidosis in adult patients with symptomatic polyneuropathy. Tafamidis is a stabilizer of  both  tetrameric  wild-type  TTR  and  of  amyloidogenic  variants  of  TTR.  By  binding  to  the  native tetrameric form of TTR, tafamidis inhibits tetramer dissociation, the rate limiting step in the formation of  TTR  amyloid.  By  inhibiting  TTR  amyloid  formation,  this  novel  class  of  TTR  stabilizer  drug  has  a potential to disrupt the progression of ATTR. The specificity of the binding to TTR limits tafamidis to the treatment of TTR amyloidosis only, with no activity anticipated for other types of amyloidosis.

## 2.2. Quality aspects

## 2.2.1. Introduction

Vyndaqel  is  presented  in  an  immediate-release  dosage  form  consisting  in  a  soft  gelatin  capsule containing 20 mg of micronized tafamidis meglumine. Other ingredients are:

<div style=\"page-break-after: always\"></div>

Capsule shell: gelatin, glycerine, sorbitol liquid (E420), titanium dioxide (E171), purified water Capsule contents:  polyethylene glycol 400, sorbitan monooleate polysorbate 80 Printing ink: opacode Black, n-Butyl alcohol, propylene glycol The capsules are packed in polyvinyl chloride/aluminium blisters.

## 2.2.2. Active Substance

Tafamidis  meglumine  which  has  the  chemical  name  d-Glucitol,  1-deoxy-1-(methylamino)-,2-(3,5dichlorophenyl)-6-benzoxazolecarboxylate is a is the micronized meglumine salt of Tafamidis. It is a white  to  pink  solid  which  is  a  slightly  soluble  molecule  in  water  and  pH  dependant.  The  chemical structure of the active substance is:

<!-- image -->

Three solid state forms of tafamidis have been detected: two crystalline forms (Form M and Form I) and an amorphous form. The M and the I forms are the same polymorphic form based on XRPD and DSC analysis. The drug substance manufacturing process controls for the production of the M form. Tafamidis does not have chiral center.

## Manufacture

Tafamidis meglumine is synthesised in a six-step process, starting from 1 key starting material.

Adequate  In-Process  Controls  are  applied  during  the  manufacture  of  the  active  substance.  The specifications  and  control  methods  for  intermediate  products,  starting  materials  and  reagents,  have been presented and are satisfactory.

## Specification

The  active  substance  specification  includes  tests  for  appearance,  identification  (IR,  NMR-1H,  HPLC), water  content,  specific  rotation,  residue  on  ignition,  heavy  metals,  lithium,  assay  (HPLC,  98.0101.0%), polymorph, assay of meglumine (IC), particle size (Lasser diffraction), Escherichia coli (Ph Eur), purity (HPLC),and residual solvents (HS-GC).

The specifications reflect all relevant quality attributes of the active substance and were found to be adequate to control the quality of the active substance.

Batch  analysis  data  of  5  batches  of  active  substance  are  provided.  The  results  are  within  the specifications and consistent from batch to batch.

## Stability

Stability studies were carried out for non micronized (3 batches) and for micronized drug substance (3 batches) under ICH conditions (up to 6 months at 40°C / 75 % RH and up to 60 months at 25°C / 60 % RH). Parameters  studied  were:  appearance,  water  content,  assay  by  HPLC,  purity  by  HPLC  and

<div style=\"page-break-after: always\"></div>

polymorphism for all conditions. Tests for agglomerization assay and E. coli control were added for the long term condition study and for the micronized drug substance only.

A photostability study for a batch of tafamidis was performed according with ICH guidelines.

The proposed retest period is justified based on the stability results.

## 2.2.3. Finished Medicinal Product

## Pharmaceutical Development

The  physicochemical  and  biopharmaceutical  properties  of  the  active  substance  that  are  relevant  for product performance were identified and assessed. In order to better control the particle size of the drug substance a jet milling step was added into the production of the tafamidis drug substance for use in primary drug product stability studies and for commercial product.

During development it was shown that tafamidis active substance, when formulated in a hard gelatin capsule  with  standard  excipients,  formed  a  rigid  gel  structure  upon  contact  with  aqueous  vehicles thereby affecting the dissolution rate from the solid dosage. Based on the initial dissolution results, it was decided to further enhance drug dispersibility and the dissolution rate using a soft gelatin capsule dosage form.

Based on this the strategy was to prepare a water-dispersible drug suspension that would not form a gel  upon  contacting  water  and  encapsulate  the  suspension  in  a  soft  gelatin  capsule.  A  suspension formulation was required as tafamidis showed poor solubility in many of the vehicles commonly used in formulating soft gelatin capsules and thus eliminated the option of developing the drug in a solution form.

The selection of excipients and their corresponding levels was based on in vitro dispersion, stability, and  in  vivo  bioavailability  studies.  The  selection  and  optimization  of  individual  components  of  the proposed  commercial  formulation  were  discussed  in  detail.  The  chosen  excipients  in  the  capsule  fill solution are: polyethylene glycol (suspending vehicle), sorbitant monoolate (surfactant/wetting agent), polysorbate 80 (surfactant/wetting agent). The excipients in the capsule shell are: gelatine, propylene glycol, purified water, 'Sorbitol special-glycerin blend' (d-sorbitol, 1,4 sorbitan, mannitol and glycerin) and titanium dioxide (E 171) and black printing ink.

All  excipients  used  to  manufacture  of  Vyndaquel  meet  compendial  requirements  except  for  Opatint White and Opacode Black ink.It is reported that Opatint White is a mixture of titanium dioxide (EP/USP) and glycerine (EP/USP). In-house specifications are described for Opatint White and Opacode Black.

A detailed description of the formulations used in the clinical studies is provided. The composition of the finished product used in the pivotal clinical trials is identical to that proposed for marketing.

The  primary  packaging  product  protective  components  are  Aclar  thermoformed  individual  product blister cavities containing one capsule. The cavity is heat sealed closed with an aluminum foil barrier lid stock.  The  primary  blister  packaging  components  are  commonly  used  in  pharmaceutical  blister packaging.  Stability  studies  showed  that  the  selected  blister  components  provide  adequate  product protection and are compatible with the dosage form.

## Adventitious agents

The only excipient used in the manufacture of Vyndaqel that is from human or animal origin is gelatin. The gelatin is obtained from bovine bones that are free from skulls, spinal cord and vertebrae.

<div style=\"page-break-after: always\"></div>

The gelatin used meets the criteria described in the monograph 'Products with the risk of transmitting agents  of  animal  spongiform  encephalopathies'  (no.  1483,  Ph.  Eur.  4th  Ed.  and  any  subsequently revised version). A TSE Certificate of Suitability for the gelatin has been provided.

## Manufacture of the product

The preparation of the 20 mg tafamidis bulk capsules takes place in primarily in four steps. The first step  is  used  to  form  the  soft  gelatin  capsules.  The  second  step  is  the  preparation  of  the  20  mg tafamidis  suspension.  The  third  step  is  the  encapsulation  of  the  tafamidis  suspension  into  the  soft gelatin capsule and the fourth step is polishing and printing of the capsules.

The manufacturing process includes four major operations: production of the semi-solid gelatin mass material, preparation of the suspension, encapsualation and polishing and printing of the capsules,

Manufacturing process is well described and in-process controls are defined.

Considering  the  orphan  drug  status  of  tafamidis,  full  validation  data  are  acceptable  post  approval. Nevertheless, detailed data obtained all along manufacturing of the three half scale batches already manufactured  have  been  asked  to  confirm  that  the  process  is  under  control.  All  the  data  are  not available yet so an enhancement of validation protocol is asked and results of validation batches are asked to be submitted post approval.

## Product specification

The  specification  includes  tests  by  validated  methods  for  appearance,  ,identity  (HPLC,  PDA),  assay (HPLC, 95.0%-105%), impurities (HPLC), uniformity of dosage, dissolution, capsule fill water content, microbial limits (Ph Eur).

The test and limits of the release and shelf life specification for the finished product are appropriate to control the quality of this medicinal product for the intended purpose.

3  pilot  batches  representative  of  the  commercial  drug  product  and  6  development  batches  for supportive  stability  studies  data  were  provided  for  pilot  and  production  batches  and  indicate satisfactory uniformity as well as compliance with the specification.

## Stability of the product

Six months stability results are presented for 3 pilot batches packaged in ACLAR blister, stored under long-term (25 C/60% RH), intermediate (30°C/65 % RH)  and accelerated (40 °C/ 75 % RH). These batches  were  tested  for  the  following  stability  parameters:  appearance,  assay,  purity,  dissolution, capsule fill moisture, and capsule shell moisture. Microbial testing will be conducted every 12 months. The provided stability results are within specifications.

Photostability  of  the  packaged  product  was  proven.  The  thermal  cycling  study  was  successfully performed. 12 month stability data were provided for one pilot batch and showed no change in stability parameters.

Stress testing was performed to demonstrate the stability indicating nature of the analytical method used for the assay and impurities.

On the basis of the stability data available, the proposed shelf life and storage conditions as stated in the SmPC are acceptable.

<div style=\"page-break-after: always\"></div>

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been  presented  in  a  satisfactory  manner.  The  results  of  tests  carried  out  indicate  consistency  and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in the clinic.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC.  Physicochemical  and  biological  aspects  relevant  to  the  uniform  clinical performance of the product have been investigated and are controlled in a satisfactory way.

The CHMP has identified the following measures necessary to address the identified quality developments issues that may have a potential impact on the safe and effective use of the medicinal product:

-  Validation data obtained on the 3 first commercial batches should be provided post approval.
-  The identification for the primary packaging components should be added as a specification

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

Tafamidis was developed as a specific stabiliser of TTR tetramer. It is intended for the oral treatment of transthyretin amyloidosis in adult patients with symptomatic polyneuropathy. This drug is an orphan medicinal product.

The nonclinical  development  of  tafamidis  was  designed  to  comply  with  the  (ICH)  M3  [R1]  guideline 'Maintenance of the ICH guideline on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals' and relevant notes for guidance. Primary and secondary pharmacodynamics was performed  in  vitro,  by  non-GLP  assays.  Critical  safety  pharmacology  and  pharmacokinetic  assays complied with GLP, although repeated dose pharmacokinetics was not performed.

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

The pharmacologic activity of tafamidis was demonstrated only in vitro , through its binding to TTR at the thyroxine binding sites and stabilisation of the TTR tetramer under non-physiologic (acid and urea denaturation conditions) and physiologic conditions. The potency of tafamidis as a TTR stabiliser was reflected in the binding constants of tafamidisis derived from the monomeric subunit exchange time course experiments (KD1=2 nM and KD2=154 nM) and from isothermal titration calorimetry (KD1=3 nM and KD2=278 nM), conducted with purified TTR.

In  order  to  further  assess  the  ability  of  tafamidis  to  stabilise  TTR,  an  in  vitro  study  was  performed using purified wild-type TTR and the two most prevalent amyloidogenic variants (V30M TTR and V122I TTR) at a physiologically  relevant  TTR  protein  concentration  (3.6  µM)  and  using  acidic  denaturation conditions (pH 4.4-4.6). Tafamidis effectively inhibited fibril formation induced by acid denaturation in a concentration-dependent manner with similar potency for wild-type TTR, V30M TTR and V122I TTR,

<div style=\"page-break-after: always\"></div>

reaching  its  EC50  at  a  tafamidis:TTR  stoichiometry  of  &lt;1  (EC50  was  in  the  range  of  2.7-3.2  µM, corresponding to a tafamidis: TTR stoichiometry range of 0.75-0.9).

Tafamidis is metabolized to an acylglucuronide in the nonclinical species (mouse, rat and dog) and in humans.    The  propensity  for  the  acylglucuronide  metabolite  to  bind  to  the  transthyretin  thyroxine binding site was not established (see the Discussion).

The extent of tafamidis binding to plasma proteins was evaluated using animal and human plasma. Although tafamidis binds to both TTR and albumin, the affinity of tafamidis for TTR (KD1=2 nM and KD2=154 nM) is substantially greater than that for albumin (KD = 2,500 nM).  Hence, despite the significantly higher concentration of albumin (600 μ M) relative to TTR (3.6 µM) in plasma, tafamidis was observed to bind specifically to TTR.

Primary pharmacodynamic studies in vivo were not performed by the applicant (see the Discussion).

## Secondary pharmacodynamic studies

The applicant provided in vitro binding/ inhibition data  from  a  non-GLP  study  testing  more  than  50 receptors/enzymes/ion  channels  including  the  thyroxine  receptor.    Beyond  binding  to  TTR,  the  only other notable binding activity of tafamidis was observed on the δ -2 opioid receptor [in vitro binding affinity (IC50) = 8.3 mM], while no significant affinity was demonstrated for the kappa and mu opioid receptors.    In  a  non-GLP  functional  assay  using  the  hamster  vas  deferens  to  assess  the  functional significance  of  the  binding  to δ -2  receptors,  tafamidis  displayed  an  agonistic  activity.  However,  the modest δ -opioid  agonistic  activity  of  tafamidis  (EC 50 &gt;10  mM)  combined  with  its  very  high  plasma protein binding (&gt;99%) suggest that adverse effects mediated through an interaction with the δ -opioid receptor would not be expected at the mean human steady-state Cmax of 7.4 mM (2.28 µg/ml).

Non-GLP  assays  for  cyclooxygenase  (COX-1  and  COX-2)  inhibition  by  tafamidis  were  performed  on recombinant enzymes and in human whole blood, demonstrating absence of inhibitory effects.

Although tafamidis binds to TTR at the thyroxine binding sites, the applicant maintained that treatment with tafamidis is not anticipated to result in an impact on thyroid function.  The main plasma carriers of thyroxine  are  thyroid  binding  globulin  (carrying  75%  of  the  total  circulating  T4)  and  albumin,  TTR being a tertiary carrier protein of plasma thyroxine, with only 1% of TTR tetramers transporting T4.  In the pivotal clinical study Fx-005, there was no change in free or total plasma thyroxine levels and no effects on retinol-binding protein, thus showing the absence of effect of tafamidis on plasma thyroxine and retinol levels.

## Safety pharmacology programme

The safety pharmacology of tafamidis was evaluated in the core battery of tests as specified in ICH S7A and S7B guidelines.

In a single-dose study (GLP) in rats assessing central nervous system changes, the oral administration of tafamidis at dose levels of 10, 30 or 100 mg/kg resulted in no behavioural changes when compared to the vehicle-treated group. However, a significant body weight loss was observed at the high dose in both males (2%) and females (3.1%).

In an in vivo cardiovascular and respiratory study (GLP) in telemetered Beagle dogs, following single oral doses of up to 300 mg/kg there were no dose-dependent or biologically significant tafamidisrelated findings on heart rate, hemodynamic parameters, respiratory rate, arterial blood gases and core body temperature during the 24-hour post-dose monitoring period. A prolongation of QRS interval

<div style=\"page-break-after: always\"></div>

(3% and 6% at 100 and 300 mg/kg, respectively) and a shortening of QTc interval (3 to 5% at 100 mg/kg and 4 to 6% at 300 mg/kg) was observed. In in vitro assays , a dose-dependent stimulation of IKr current attaining 10% at 300 mg/kg was detected.

In the same study, the mean maximum plasma concentration of tafamidis achieved in dogs following the 300 mg/kg dose was 141 µg/ml at 5 hours post-dose, corresponding to a concentration up to 62 times the mean human clinical steady-state Cmax (2.28 µg/ml).  Clinical observations of emesis (n=4) (see table 1), salivation (n=1) and leg twitching (n=1) were observed post-dose in the dogs at 100 and 300 mg/kg.

Table 1. Study SY100009

| Study Type                          | Study Number (location)                        | Species/ Strain   | Dose (mg/kg)) Route        | Design                     | Clinical Observations                                             |   Cmax (μg/mL) Emesis NOEL | Mean Exposure (μg/mL) at 30 minutes postdose   |
|-------------------------------------|------------------------------------------------|-------------------|----------------------------|----------------------------|-------------------------------------------------------------------|----------------------------|------------------------------------------------|
| Safety Pharmacology/ Cardiovascular | SY100009 (Module 2.6.3,|Beagle [Tahle 2.6.3.4) | Dog/              | 0,10,100, 300/ Oral gavage | 4 females, escalating dose | 100 mg/kg: Emesis in 2/4 animals 300 mg/kg: Emesis in 4/4 animals |                         34 | 10 mg/kg: 31.2 100 mg/kg: 92.5 300 mg/kg: 99.2 |

Cmax = Maximum (peak) observed drug concentration; NOEL, = No observed effect jevel.

## Pharmacodynamic drug interactions

The applicant did not conduct specific pharmacodynamic drug interaction studies.

In a screening with small molecules, NSAIDs (diflunisal and diclofenac) were observed to exhibit TTR stabilisation through binding to the TTR thyroxine binding sites. As no PD interaction studies with NSAIDs were performed, the applicant presented the binding constants for tafamidis, diflunisal and diclofenac measured by isothermal titration calorimetry (ITC), see table 2.

Table 2

| Drug         | Transthyretin (TTR)   | Transthyretin (TTR)   | Albumin   |
|--------------|-----------------------|-----------------------|-----------|
|              | Kd1 (nM)              | Kd2 (nM)              | Kd (nM)   |
| Diclofenac  | 60                    | 1,200                 | N/A       |
| Diflunisal * | 75                    | 1,100                 | N/A       |
| Tafamidis    | 3                     | 278                   | 2,500     |

## 2.3.3. Pharmacokinetics

The in vivo absorption, distribution, metabolism and excretion of tafamidis following single and/or repeated oral and intravenous administration was evaluated in 23 non-GLP and 10 GLP pharmacokinetic/toxicokinetic studies performed in mice, rats, rabbits and dogs.  A non-GLP study to examine placental transfer and excretion in milk was performed in rats as part of the reproductive toxicity programme.

 Miller, SR, Sekijima Y and Kelly JW.  Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004 May;84(5):545-52.

Vyndaqel

<div style=\"page-break-after: always\"></div>

Most of the pharmacokinetic parameters presented for inter-species comparison were obtained from acute administration. Data presented from repeated dose studies were obtained from the toxicokinetic data (see Discussion).

## Method of analysis

The biological samples in the pharmacokinetic and toxicokinetic studies were analyzed by validated LC/MS/MS methodologies.  14C-tafamidis was used in the ADME study and in the placental and milk transfer study.  Radioactivity was measured by liquid scintillation spectroscopy according to the laboratory's Standard Operating Procedures.  The assessment of radioactive stability prior to and immediately after treatments showed that 14C-tafamidis was stable under the conditions used.

## Absorption

In in vitro studies, tafamidis crossed readily Caco-2 monolayers in a passive transcellular pattern. Tafamidis was not a substrate of OAT (organic anion transporter), OCT (organic cation transporter), MRP2 (multidrug resistance-associated protein 2) or P-gp (P-glycoprotein) transporters, but showed an inhibitory effect on the OATP (organic anion transporting polypeptide), BCRP (breast cancer resistance protein) and MRP (multidrug resistance-associated proteins) transporters. Slight inhibition was observed on P-gp transporter at higher concentrations.

Bioavailability studies conducted over a 24-hour period in rats at doses 2 mg/kg and in dogs at doses 1 mg/kg demonstrated absolute bioavailability of 100% and 91%, respectively (based on AUC0-24).

Drug exposure as measured by Cmax and AUC0-inf was dose-proportional up to a single dose of 30 mg/kg and showed an asymptotic trend to saturation with higher doses.

Pharmacokinetic parameters of tafamidis after a single oral administration (from preclinical studies conducted over a 168-hour period) are summarised in table 3 below:

Table 3

| Species   |   Dose (mg/kg) a | Detection method   |   T 1/2 (hours) |   T max (hours) |   C max ( μ g/ml) |   AUC 0-inf ( μ g*hr/ml) |   V Z /F b (ml/kg) |
|-----------|------------------|--------------------|-----------------|-----------------|-------------------|--------------------------|--------------------|
| Rat c     |                3 | 14 C               |            43.1 |             2   |             11.3  |                      368 |                265 |
| Rat       |                3 | LC-MS/MS           |            41.9 |             1   |              9.06 |                      216 |                331 |
| Rat       |               10 | LC-MS/MS           |            28.5 |             0.5 |             35.3  |                      512 |                283 |
| Rat       |               30 | LC-MS/MS           |            29   |             4   |            102    |                     2590 |                294 |
| Dog       |               30 | LC-MS/MS           |            62.3 |             2   |             87.6  |                     1455 |                342 |
| Dog       |               60 | LC-MS/MS           |            54.7 |             1.5 |            130    |                     2260 |                461 |
| Dog       |               80 | LC-MS/MS           |            56.5 |             1.5 |            160    |                     3390 |                500 |

a  Dose levels are expressed as Fx-1006 active ingredient.  Human dose levels are based on a 60 kg body weight.

b  VZ/F have been calculated from the data presented in this table as dose (mg/kg)*1000/Cmax (µg/ml)

c Only values from male animals in plasma are reported for this study to allow comparison with other nonclinical studies which were conducted in male animals

Tafamidis half life in plasma was approximately 29-43 hours in rats and 55-62 hours in dogs.

Following repeated doses, saturation of absorption in dogs and accumulation in all species tested, i.e. mice, rats, rabbits and dogs, was observed.

In rats, decreased exposure to tafamidis was observed with food intake.

There were no marked gender differences in pharmacokinetic parameters in mice, rats and dogs.

<div style=\"page-break-after: always\"></div>

## Distribution

Upon  single  oral  administration  in  rats,  tafamidis  was  subject  to  a  widespread  distribution  and accumulated  preferentially  in  the  liver  and  in  harderian  glands.    Except  for  these  two  organs,  the organ/plasma ratio was always &lt;1, indicating a selective distribution in the plasma compartment. The Cmax values for the majority of tissues occurred at 2 hours post-dose. Presence of tafamidis was still detected in most tissues at 168 hours post-dosing.

Tafamidis was observed to cross the placental barrier and distribute to the foetal tissues to an extent of 3-4% of the administered dose in rats.  More than 30% of the dose of tafamidis was transferred to milk  when  administered  to  lactating  rats.  This  matter  is  adequately  reflected  in  section  4.6  of  the SmPC.

Upon entering the blood stream, tafamidis was highly bound (&gt; 97%) to plasma proteins and did not enter blood cells. In vitro, a mean percentage of plasma protein-bound tafamidis was 97.1, 99.0, 99.1 and ≥ 99.2% in mouse, rat, dog and human plasma, respectively.

Distribution volumes, as measured following intravenous administration of tafamidis, were small (316 ml/kg in  rats  and  317  ml/kg  in  dogs)  and  corresponded  to  the  extracellular  water  content  for  both species.

In  studies  with  oral  administration  of  tafamidis,  the  apparent  distribution  volume  of  tafamidis  was constant (around 300 ml/kg) irrespective of the species, at doses of up to 30 mg/kg. Above 30 mg/kg, it increased linearly with dose, presumably due to saturation of absorption.

## Metabolism

In in vitro metabolism studies using subcellular fractions of liver from the non-clinical species (mouse, rat, rabbit and dog) and humans, relative metabolic stability of tafamidis was observed, with ≥ 94% of the parent molecule unchanged across all species. The small percentage of metabolic transformation was  identified  as  a  monoglucuronide  (acylglucuronide)  metabolite  in  mouse,  rat,  dog  and  human microsomal incubation mixture and as a monoxide metabolite in mice. No apparent qualitative gender differences were seen in the metabolite profiles.

In vivo, major metabolic pathways of tafamidis were described by plasma metabolite identification in mouse, rat, rabbit and dog.  Three metabolic pathways were proposed: glucuronidation mediated by UGT,  mainly  1A9,  1A1  and  1A3  and  in  a  minor  extent  1A6,  1A7,  1A8  and  2B7,  sulphation  and oxidation. Table 4 below summarises in vitro and in vivo metabolites identified in the species tested.

Table 4: In vitro hepatic and in vivo plasma metabolites of tafamidis

| Species and strain   | In vitro Metabolites* (Study N° 400447)   | Metabolite* Relative Quantity (%) (Study N° 400447)   | In vivo Plasma Metabolites   | Metabolite Plasma Relative Quantity (%)   | Study number ( In vivo corresponding study number)   |
|----------------------|-------------------------------------------|-------------------------------------------------------|------------------------------|-------------------------------------------|------------------------------------------------------|
| Mice CByB6F1 hybrid  | acylglucuronide monooxide                 | 9%                                                    | acylglucuronide monooxide    | 4.1 - 12.2 0.5 - 1.2                      | 400554 (SYI00064)                                    |
| Rats Sprague- Dawley | acylglucuronide                           | 1%                                                    | acylglucuronide              | 3.5 - 16.1 0.3 - 11.9                     | 400979 (SYI00012) 420372                             |
| Rabbits New Zealand  | none detected                             | 0%                                                    | monooxide                    | 1.7 - 9.2                                 | 400605 (SYI00040)                                    |

<div style=\"page-break-after: always\"></div>

| Species and strain   | In vitro Metabolites* (Study N° 400447)   | Metabolite* Relative Quantity (%) (Study N° 400447)   | In vivo Plasma Metabolites        | Metabolite Plasma Relative Quantity (%)   | Study number ( In vivo corresponding study number)   |
|----------------------|-------------------------------------------|-------------------------------------------------------|-----------------------------------|-------------------------------------------|------------------------------------------------------|
| white                |                                           |                                                       |                                   |                                           |                                                      |
| Dogs Beagle          | acylglucuronide                           | 2%                                                    | acylglucuronide sulfate conjugate | 0.99 - 6.31 0.05 - 0.98                   | 400980 (SYI00013)                                    |
| Humans               | acylglucuronide                           | 1%                                                    | acylglucuronide                   | 1.2 - 12.8                                | 400553 and 400699 (Fx-002)                           |

*Hepatic microsome

Tafamidis  did  not  significantly  inhibit  CYP2C9/19,  1A2,  2D6  and  3A4/5.  It  showed  a  moderate inhibitory effect on CYP2C8.

Tafamidis induced CYP3A4 in cryopreserved human hepatocyte cultures from female but not from male donors. This effect was minimal in the presence of albumin. (See also PK drug-drug interactions).

## Excretion

Following a single oral dose of 3 mg/kg 14C-tafamidis to rats, excretion was quite slow in both sexes with less than 67% of the administered radioactivity excreted by 48 hours post-dose.  Excretion rates and routes were similar for both male and female rats, although excretion via urine appeared to be greater in males than in females.  Excretion recoveries were greater than 87% in both sexes by 168 hours post-dose.

Tafamidis was readily excreted in the bile as the unchanged parent and the acylglucuronide metabolite, with nearly 50% of the radioactivity excreted via the bile in both male and female rats during the first 72 hours following administration.  Additionally, enterohepatic recycling of approximately 42-77 % of biliary excreted radioactivity was observed.

Elimination  of  radioactivity  occurred  by  both  the  urine  and  faeces,  the  majority  of  the  administered radiolabelled compound (67-79%) being recovered in the faeces over the period 0 to 168 h post-dose, and 7-19% recovered in the urine over the same time period.

Metabolite analysis of faeces and urine samples showed that tafamidis was eliminated unchanged in faeces, whereas the major urinary metabolite was acylglucuronide.

## PK drug-drug interactions

Tafamidis exhibited moderate inhibitor effects on CYP2C8.

Induction of CYP3A4 was observed in female (n=2), but not male (n=1) human hepatocyte cultures. More  than  90%  tafamidis  was  bound  to  TTR  or  albumin  in  plasma.  Exposure  of  hepatocytes  to tafamidis was much lower in presence of albumin and its effects on CYP3A4 were reduced.  In a study where  hepatocytes  from  one  donor  were  exposed  to  tafamidis  in  the  presence  of  the  physiological concentration of 40 mg/ml albumin, tafamidis exhibited minimal impact on CYP3A4 activity.

Tafamidis  did  not  interfere  with  the  binding  of  cyclosporine,  tacrolimus  and  warfarin  (&gt;90%  initial binding to plasma proteins) and decreased the binding of prednisone by ~10% (79% initial binding to plasma protein).  The clinical relevance of this displacement is unknown as the pharmacologic activity of prednisone requires metabolism to prednisolone, the active metabolite.

<div style=\"page-break-after: always\"></div>

The effect of other drugs on the binding of tafamidis to TTR has not been evaluated.

## 2.3.4. Toxicology

## Single dose toxicity

Single dose toxicity was assessed in Beagle dogs (see Table 5). No mortality or serious adverse effects were observed with single oral doses up to 600 mg/kg.

Table 5

| Species/ Sex   | Dose/Route                                                    | Approx. lethal dose/ observed max non- lethal dose   | Major findings                                                                                                          |
|----------------|---------------------------------------------------------------|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
| Beagle dog/M+F | 0 (M), 30 (M), 100 (M), 300 (M), 600 (M+F) mg/kg; oral gavage | 600 mg/kg                                            | 1 Mat 600mg/kg: ↑ ALP. This was not observed in repeated dose studies and was not associated to increase in ALT or AST. |

## Repeat dose toxicity

In repeat dose toxicity studies tafamidis administered orally was tested in mice up to 28 days, in rats up to 26 weeks and in Beagle dogs up to 39 weeks. At high doses, tafamidis caused mortality in mice (at  doses ≥ 240 mg/kg), in rats (at doses ≥ 100 mg/kg) and in dogs (at doses ≥ 100  mg/kg).  The NOAEL were 10 mg/kg in mice, 3 mg/kg in rats, 5 mg/kg in female dogs and 15 mg/kg in male dogs.

Table 6 summarises the main repeat-dose toxicity studies and their findings.

Table 6

| Species/ Number/ group                              | Dose* (mg/kg/day) Route                    | Duration   |   NOAEL (mg/kg/day) | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------------------------------------------------|--------------------------------------------|------------|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mice/CByB6F1 hybrid 10/sex/group (TK: 20/sex/group) | 0, 10, 30, 45, 60, 120, 240 a , 480 b Oral | 28 days    |                  10 | ≥ 30 mg/kg : Centrilobular single cell necrosis ≥ 120 mg/kg : Centrilobular hypertrophy ↑ AST and ALT (only at this dose in males) ↓ corpora lutea ≥ 240 mg/kg : Mortality (9M/10 and 5F/10 at 480 mg/kg and 6M/10 and 1F/10 at 240 mg/kg). ↓ motor activity, impaired gait, seizures, laboured respiration and hunched appearance, ↑ AST and ALT (only at this dose in females) White powder contents in the stomach Vaginal hyperkeratosis Estrous disruption Lymphoid depletion |

<div style=\"page-break-after: always\"></div>

| Rats/SD 10/sex/group (TK: 6/sex/group Recovery: 5/sex/group for control and HD groups)                                                   | 0, 10, 30, 100, 300 c Oral   | 28 days + 14 days of recovery              |   10 | ≥ 30 mg/kg: ↑ liver relative weight, ↑ liver absolute weight (in females) ↑ creatinine (in males) ≥ 100 mg/kg: Mortality (3F at 100 mg/kg and 7M and 2F at 300 mg/kg) Scant faeces, hunched posture lethargy, rough hair coat, urine stained perineum, ↓ body weight, ↓ food consumption (in females), ↑ ALT, Cholesterol (in males) ↑ creatinine, ↑ glucose (in females) ↓ heart weights (in males) ↓ epididymis absolute weight ↑ uterus weights ↑ ovaries and thyroid absolute weight (in females) Thymic depletion (in females) Gastric impaction due to test material accumulation. 300 mg/kg: ↓ RBC, Hb, HCT, (in males only, no recovery) ↑ ALT and AST (in females) ↑ bilirubin and TG Stomach necrosis and distension with accumulation of test article Thymic depletion (in males) Tubular proteinosis and accumulation of red pigment in the tubules (in females)   |
|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|--------------------------------------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rat/SD 10/sex/group for the 13-w phase 10/sex/group for the 26-w phase (TK: 6/sex/group Recovery: 6/sex/group for control and HD groups) | 0, 3, 10, 30 Oral            | 13 weeks + 4 weeks of recovery OR 26 weeks |    3 | ≥ 10 mg/kg : ↑ BUN (in males) ↑ bilirubin (in females) ↑ liver relative weight (in males) 30 mg/kg : ↓ Hb and ↑ PT (in females) ↑ fibrinogen and ↑ creatinine (in males) ↑ liver absolute weight (in males) Enlarged or discoloured lymph nodes Thymus atrophy Renal pelvis dilation Enlarged pituitary gland                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dog/Beagle 3/sex/group (Recovery: 2/sex/group for control and HD group)                                                                  | 0, 10, 100, 300 → 200 d Oral | 28 days + 14 days of recovery              |   10 | ≥ 100 mg/kg : Mortality (3 at HD and 2 at MD). Vomiting and abnormal feces. Enhanced salivation, lethargy, thinness, ataxia, head bobs, twitching, coldness to touch. ↑ Ca (in females) Discoloration of spleen and thymus. Enlarged cervical lymph node. 300 → 200 mg/kg: ↓ food consumption ↓ monocytes and ↑ MCHC (in males). ↑ PAL, GGT, bilirubin, BUN (in males) ↓ cholesterol (in females) Reddish discoloration of the gastric and intestinal mucosa (in 1F)                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Dog/Beagle                                                                                                                      | 0, 5, 15, 45   | 13 weeks +                      | 5 (F) 15 (M)   | ≥ 15 mg/kg : ↑ RBC, Hb in females) ↓ ovaries absolute weight 45 mg/kg : ↑ incidence of soft, mucoid, feces and feces with apparent blood. ↑ Monocytes and ↓ eosinophils (in females)   |
|---------------------------------------------------------------------------------------------------------------------------------|----------------|---------------------------------|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3/sex/group for the 13-w phase 3/sex/group for the 39-w phase (TK: 6/sex/group Recovery: 2/sex/group for control and HD groups) | Oral           | 4 weeks of recovery OR 39 weeks |                | discolored ↑ Pituitary absolute weights ↑ increase in emesis (in female)                                                                                                               |

a Treatment discontinued at D3

* Expressed as Fx-1006 equivalents

b Treatment discontinued at D8

c Treatment discontinued at D10

d  The high dose was reduced from 300 mg/kg to 200 mg/kg on Day 8 for females and Day 9 for males

## Genotoxicity

Tafamidis  was  tested  in  the in  vitro bacterial  reverse  activation  mutation  assay  (Ames  test),  the in vitro human lymphocyte chromosomal aberration assay and the in  vivo oral  rat  micronucleus assay. The Ames test and the micronucleus test were negative. In the chromosomal aberration assay, a dosedependant increase of polyploidy was observed at 100 and 200 µg/ml in the presence of S9 .

## Carcinogenicity

A 26-week carcinogenicity study in transgenic rasH2 mice was conducted by the oral (gavage) route of administration - see table 7 below.

Table 7:

| Species/ Number/ group                                           | Dose (mg/kg/day) Route                           | Duration   | NOAEL (mg/kg/day)                                                     | Major findings                                                                                                                                                                                                                                                                                                                                                        |
|------------------------------------------------------------------|--------------------------------------------------|------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mouse/Tg.rasH2 25/sex/group (TK: Mouse/CGyB6F1 10 or 40/sex/grp) | Fx-1006A 0 (vehicle), 0 (water), 10, 30, 90 Oral | 26 weeks   | NOAEL (general toxicity) = 10 (M) 30 (F) NOAEL (carcinogenicity) ≥ 90 | No treatment-related neoplastic lesions. Higher incidence of spleen and lung tumors with the positive control urethane. ≥ 30 mg/kg: ↓ body weight (in males) ↑ liver weight and ↓ kidney weight (in males) Nephrosis (in males) Centrilobular hypertrophy and single cell necrosis (in males) 90 mg/kg: Centrilobular hypertrophy and single cell necrosis (in males) |

No long-term studies were conducted by the applicant. Tafamidis did not show carcinogenic potential in the  model  which  is  recognised  as  responsive  to  both  genotoxic  and  non-genotoxic  carcinogens.  The carcinogenic potential of tafamidis was not studied in a long term rodent carcinogenicity study. This was considered acceptable given the severity and low incidence of the disease together with the fact that no alert signals were identified in the nonclinical studies conducted including the TgrasH2 mouse model.

<div style=\"page-break-after: always\"></div>

## Reproduction Toxicity

The  reproductive  toxicity  of  tafamidis  was  studied  in  line  with  the  requirements  of  the  S5  ICH guideline.

The main reproductive and developmental studies and their findings are summarised in table 8.

Table 8

| Study type/ Study reference / GLP                          | Species; Number/ sex/group                | Dose (mg/ kg/day) Route                   | NOAEL (mg/kg/day)                                                                  | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|------------------------------------------------------------|-------------------------------------------|-------------------------------------------|------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FERTILITY AND EARLY EMBRYONIC DEVELOPMENT                  | FERTILITY AND EARLY EMBRYONIC DEVELOPMENT | FERTILITY AND EARLY EMBRYONIC DEVELOPMENT | FERTILITY AND EARLY EMBRYONIC DEVELOPMENT                                          | FERTILITY AND EARLY EMBRYONIC DEVELOPMENT                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Fertility and general reproduction toxicity (SYI00060) GLP | Rat/SD 25/sex/group                       | Fx-1006A 0, 5, 15, 30 Oral                | NOAEL (parental toxicity) ≥ 30 (M) =15 (F) NOAEL (reproduction) ≥ 30               | Males: No treatment-related findings Females: 30 mg/kg: ↓ body weight and body weight gain, ↓ food consumption                                                                                                                                                                                                                                                                                                                                                       |
| EMBRYO-FETAL DEVELOPMENT                                   | EMBRYO-FETAL DEVELOPMENT                  | EMBRYO-FETAL DEVELOPMENT                  | EMBRYO-FETAL DEVELOPMENT                                                           | EMBRYO-FETAL DEVELOPMENT                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Developmental Toxicity Study in Rats SYI00039 GLP          | Rat/SD 25F/group (TK: 6F/group)           | Fx-1006A 0, 15, 30, 45 Oral               | NOAEL (maternal toxicity) = 30 NOAEL (reproduction) ≥ 45 NOAEL (development) = 15  | ≥ 30 mg/kg: ↓ maternal body weight gain (during the first 3 days of treatment at MD). ↓ fetal weight 45 mg/kg: maternal mortality (4 dams) associated with dehydration, hypothermia, hunched posture, sparse hair, abnormal feces. ↓ maternal body weight and body weight gain No effects on reproduction parameters. No teratogenic effects                                                                                                                         |
| Developmental Toxicity Study in Rabbits SYI00040 GLP       | Rabbit/NZW 20 F/group (TK: 3F/group)      | Fx-1006A 0, 0.5, 2, 8 Oral                | NOAEL (maternal toxicity) = 0.5 NOAEL (reproduction) = 2 NOAEL (development) = 0.5 | ≥ 2 mg/kg: ↓ maternal body weight gain ↑ number of supernumerary thoracic ribs and thoracic vertebrae ↓ number of lumbar vertebrae 8 mg/kg: Abortion in 2F, Abnormal feces ↓ body weight and food consumption Increased late resorptions, ↓ fetal body weight, ↑ number of fetuses and litters with any alteration observed, In 3 fetuses from 2 litters: depressed eye bulges, small eyes and small eye sockets. ↓ number of ossified fore- and hind-limb phalanges |

<div style=\"page-break-after: always\"></div>

| PRE- AND POSTNATAL DEVELOPMENT                                            | PRE- AND POSTNATAL DEVELOPMENT   | PRE- AND POSTNATAL DEVELOPMENT   | PRE- AND POSTNATAL DEVELOPMENT               | PRE- AND POSTNATAL DEVELOPMENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Developmental and peri/postnatal reproduction toxicity study SYI00068 GLP | Rat/SD 25F/group                 | Fx-1006A 0, 5, 15, 30 Oral       | NOAEL (F0) = 5 NOAEL (F1) = 5 NOAEL (F2) = 5 | F0 dams: ≥ 15 mg/kg: Mortality (4F/25 at MDand 20F/25 at HD were sacrified due to no surviving pups). ↓ body weight gain, ↓ food consumption 30 mg/kg: Sparse hair coat F1 generation: ≥ 15 mg/kg: ↓ number of pups, ↓ pup body weight ↓ viability index and live litter size. ↑ number of litter with no milk band, not nursing and with purple or black discoloration ↑ number of pups with no milk present in stomach. 15 mg/kg: ↑ number of pups with domed head, microphtalmia, lacrimation, peri-orbital alopecia, chromodacryorrhea ↓ body weight in the post-weaning period and food consumption Mortality (2M: 1 dead at PND38 and 1 sacrificed at PND111) Retardation in preputial separation ↑ number of animals who failed to learn during session of the watermaze No effect on mating or reproductive performance. No histopathological alteration of the brain. 30 mg/kg: All pups died between PND 1 to 4 ↑ number of pups with stomach and intestines filled with gas F2 fetuses 15 mg/kg: ↓ fetal body weight (F) Rotated limbs |

ns: not statistically significant

## Toxicokinetic data

Exposure margins based on AUC and Cmax from repeated dose, carcinogenicity and reproductive toxicity are summarised in table 9.

Table 9

| Type of study         | Species   | Duration   | NOAEL (mg/kg/day)   | AUC tafamidis ( μ g.h/ml) at NOAEL a   | Cmax tafamidis ( μ g/ml) at NOAELa   | Exposure margin b based on   | Exposure margin b based on   |
|-----------------------|-----------|------------|---------------------|----------------------------------------|--------------------------------------|------------------------------|------------------------------|
| Type of study         | Species   | Duration   | NOAEL (mg/kg/day)   | AUC tafamidis ( μ g.h/ml) at NOAEL a   | Cmax tafamidis ( μ g/ml) at NOAELa   | AUC                          | Cmax                         |
| Repeated dose         | Mouse     | 28 days    | 10                  | 137.5                                  | 14.6                                 | 3                            | 6                            |
| Repeated dose         | Rat       | 26 weeks   | 3                   | 368.5                                  | 24.6                                 | 7                            | 11                           |
| Repeated dose         | Dog       | 39 weeks   | 15 (M)              | 567                                    | 51.5                                 | 11                           | 23                           |
| Repeated dose         |           | 39 weeks   | 5 (F)               | 444                                    | 30.2                                 | 9                            | 13                           |
| Carcinogenicity       | Mouse     | 26 weeks   | 90                  | 1599.5                                 | 96.9                                 | 32                           | 43                           |
| Reproductive toxicity | Rat       | Segment II | 15                  | 1090                                   | 72.8                                 | 22                           | 32                           |
| Reproductive toxicity | Rabbit    | Segment II | 0.5                 | 157                                    | 8.14                                 | 3                            | 4                            |

<div style=\"page-break-after: always\"></div>

- a: AUC and Cmax on the last time point. Gender and time point of determination are only specified if the difference was considered relevant. Otherwise, average values are given.

b Animal/human exposure ratios calculated from tafamidis human steady state values of Cmax=2.28 μ g/ml and AUC24h= 49.75 μ g.h/ml obtained in typical subject of 70 kg, less than 60 years old, with normal hepatic function and with unknown food intake following 20 mg daily dosing (Study Fx-PopPK-001)

## Local Tolerance

No local tolerance studies were performed.

## Other toxicity studies

Tafamidis was not phototoxic in a study in pigmented rats. No specific immunotoxicity studies were submitted. With respect to impurities, one synthetic intermediate (DCBC) gave a positive genotoxic response in silico. DCBC is highly reactive and unstable in aqueous media and thus, no Ames test could be conducted.

## 2.3.5. Ecotoxicity/environmental risk assessment

At the time of the tafamidis application for orphan medicinal product designation, the applicant estimated the prevalence of Familial Amyloid Polyneuropathy (FAP) in the European Union as 0.1 in 10,000 persons. The predicted environmental concentration (PEC) in surface water was calculated as follows.

<!-- formula-not-decoded -->

Maximum daily dose of active ingredient consumed per inhabitant [20 mg/day]

Fpenrefined

Fraction of market penetration [0.00001]

WASTEWinhab

Amount of Wastewater per inhabitant per day [200 L/inh/d]

Dilution

Dilution factor [10]

PECsurfacewater  Local surface water concentration  μ g/L 

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

The resulting PECsurfacewater of 0.0001 μ g/l  was below the action limit of 0.01 μ g/l. (See discussion).

DOSEai

<div style=\"page-break-after: always\"></div>

Table 10 Summary of main study results

| Substance (INN/Invented Name):Tafamidis meglumine                   | Substance (INN/Invented Name):Tafamidis meglumine   | Substance (INN/Invented Name):Tafamidis meglumine   | Substance (INN/Invented Name):Tafamidis meglumine   |
|---------------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| CAS-number (if available): 951395-08-7                              | CAS-number (if available): 951395-08-7              | CAS-number (if available): 951395-08-7              | CAS-number (if available): 951395-08-7              |
| Phase I                                                             |                                                     |                                                     |                                                     |
| Calculation                                                         | Value                                               | Unit                                                | Conclusion                                          |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0.0001                                              |  g/L                                               | > 0.01 threshold No                                 |
| Other concerns (e.g. chemical class)                                |                                                     |                                                     | No                                                  |

## 2.3.6. Discussion on non-clinical aspects

## Pharmacology

Tafamidis  is  a  stabilizer  of  the  transthyretin  (TTR)  tetramer.  By  binding  to  TTR  tetramer,  tafamidis inhibits  tetramer  dissociation  and  can  disrupt  progression  of  ATTR  by  preventing  dissociation  into monomers. The extent of tafamidis binding to plasma proteins was evaluated using animal and human plasma. Compared to other plasma proteins, tafamidis was observed to bind to TTR with high affinity.

Tafamidis is metabolized to an acylglucuronide in the nonclinical species (mouse, rat and dog) and in humans.  The CHMP considered that the propensity for the acylglucuronide metabolite to bind to the TTR thyroxine binding site was not established, but was of the view that this metabolite would not be likely  to  contribute  to  the  pharmacological  activity  of  tafamidis,  as  it  was  not  detected  in  human plasma following a single 20 mg/kg dose of  14 C-labeled tafamidis meglumine.

No in  vivo studies  were  performed  by  the  applicant.  The  CHMP  considered  that  at  the  time  of  the preclinical development of tafamidis, an animal model of ATTR-PN that would reflect the clinical disease or resemble the pathology was not available, and that none of the transgenic animals described in the literature  reproduce  the  pathology  seen  in  ATTR  patients.  The  CHMP  agreed  to  the  justification  for absence of these studies.

With respect to secondary pharmacodynamic effects, a dose-dependent agonistic effect at δ -2 opioid receptors was observed. Considering that δ -2 opioid agonists are known to activate the chemoreceptor trigger zone (CTZ) leading to the stimulation of the vomiting center (VC)  and following observation of emesis in dog induced in a concentration dependent manner, the CHMP discussed clinical relevance of this  putative  effect  on  the  CNS,  especially  after  repeated  administration.  In  this  context,  the  CHMP considered that tafamidis was not associated with increased incidence of nausea or vomiting in clinical studies  and  that,  given  the  limited  accumulation  potential  of  tafamidis,  plasma  concentrations  in humans were not likely to reach sufficient levels to cause emesis in the clinical setting. Thus, the CHMP concluded that this non-clinical finding was not of a clinical relevance.

The safety pharmacology of tafamidis was evaluated in the core battery of tests as specified in ICH S7A and S7B guidelines.

Tafamidis  was  tested  for  its  effects  on  CNS  in  an  acute  neurotoxicity  study  in  rats.  It  induced  no adverse neurological effects  up  to  300  mg/kg,  although  body  weight  loss  was  observed  at  the  high dose in a small percentage of both males (2%) and females (3%). The CHMP was of the view that this finding was of no clinical relevance.

 Blancquaert et al, 1986; Kohl and MacDonald, 1991

<div style=\"page-break-after: always\"></div>

In vivo, no significant tafamidis-related findings on heart rate, hemodynamic parameters, respiratory rate, arterial blood gases and core body temperature were seen in beagle dogs.  However, the canine cardiovascular  safety  pharmacology  assessment  of  tafamidis  identified  a  statistically  significant shortening of the QTc interval and lengthening of the QRS interval at doses 100 and 300 mg/kg. The CHMP considered these ECG observations in the context of clinical relevance and was of the opinion that given the severity of the disease and the fact that no cardiovascular safety concerns arose from clinical assessment, these non-clinical findings would not impact negatively on the positive benefit-risk balance of the product.

Emesis, salivation and leg twitching were observed post-dose in the dogs at high doses ( ≥ 100 mg/kg). These findings were coherent with those observed at similar doses in the toxicology studies and their clinical relevance was considered limited by the CHMP, as these effects were observed at dose levels and  maximum  plasma  concentrations  significantly  higher  than  those  relevant  to  the  clinical  use  of tafamidis.

The CHMP considered that no pharmacodynamic interaction studies were conducted, in particular those with  non-steroid  anti-inflammatory  drugs  (NSAIDs),  as  NSAIDs  (diclofenac  and  diflunisal)  were observed to bind to the TTR thyroxine binding sites. The applicant presented the respective binding constants (see Results - table 2), suggesting that tafamidis will preferentially bind to TTR, even in the presence of diflunisal or diclofenac and that no significant pharmacodynamic drug interaction would be expected. This was accepted by the CHMP.

## Pharmacokinetics

The  PK  studies  addressed  pharmacokinetics  of  tafamidis  adequately.  Nevertheless,  the  CHMP  noted that  most  of  the  pharmacokinetic  parameters  presented  for  inter-species  comparison  were  obtained from single administration studies. Data presented from repeated dose studies were obtained from the toxicokinetic studies. During their review, the CHMP discussed the level of information these available data  give  about  ADME  at  pharmacological  doses  and  data  necessary  to  establish  the  best  dosing regimen. Since there is no relevant preclinical disease model, the CHMP considered that the best dose regimen was established from understanding of in vitro and ex vivo PK/PD experiments, combined with an  extrapolation  of  clinically  observed  pharmacokinetics  to  select  a  dose  that  would  achieve therapeutically relevant concentrations. In this context, the CHMP accepted that multiple dose studies in nonclinical species at pharmacologically relevant doses were not used for that purpose. Furthermore, as  clinical  data  were  considered  sufficient  to  endorse  the  therapeutic  use  of  tafamidis,  the  CHMP concluded that no further non-clinical data need to be generated.

The  methods  of  analysis  applied  to  study  the  pharmacokinetics  of  tafamidis  were  adequate  for  the identification and quantification of the parent compound and metabolites in the performed assays.

Bioavailability of tafamidis was complete. Saturation of absorption in dogs and accumulation in mice, rats and dogs after repeated dosing was observed. Tafamidis was widely distributed, highly bound to albumin and crossed the placental barrier. The CHMP considered that as there are no adequate data on the use of tafamidis in pregnant women and the potential risk for humans is unknown, section 4.6 of the  SmPC  will  specify  that  tafamidis  is  not  recommended  during  pregnancy  and  in  women  of childbearing potential not using contraception.

The  metabolism  of  tafamidis  was  not  extensive.  The  major  metabolite  identified  across  all  tested species (except for rabbits) was acylglucuronide; in humans, this was the only metabolite detected. The  CHMP  considered  that  acylglucuronides  were  increasingly  identified  as  reactive  electrophilic metabolites  capable  of  undergoing  intermolecular  reactions  with  proteins,  leading  to  covalent  drugprotein adducts and initiating toxicity/immune responses, the liver being the target  organ  .

 Bailey and Dickinson, 2003; Skonberg et al, 2008

<div style=\"page-break-after: always\"></div>

Considering the observed hepatic accumulation of tafamidis with concomitant increase in liver weight and  also  alteration  of  liver  enzymes  in  all  tested  species  following  administration  of  high  doses  of tafamidis, the CHMP was of the opinion that the pharmacovigilance strategy as described in the Risk Management Plan needs to be in place to monitor whether this potential toxic mechanism could be of clinical  relevance.  In  particular,  AE-specific  questionnaires  are  to  be  utilised  on  receipt  of  a  report suggestive of hepatotoxicity in order to obtain complete details of the event, allowing for a detailed review and establishing its relationship to the drug.

Excretion of tafamidis was slow with a half life of about 45 hours. Studies in rats showed that tafamidis is  subject  to  enterohepatic  re-cycling.  Tafamidis  was  mainly  excreted  in  faeces  as  intact  substance, while  metabolized  material  was  excreted  in  urine  as  acylglucuronide  conjugate,  the  only  metabolite found in humans, detected in plasma at a proportion of 1-12%.

The CHMP considered that the inhibition of CYP2C8 and induction of CYP 3A4 by tafamidis is not likely to interfere with the metabolism of drugs being substrates of these enzymes, as tafamidis was highly bound to proteins in plasma and the free tafamidis concentration does not reach a sufficient level to produce either inhibition of CYP2C8 or induction of CYP 3A4.  Furthermore, the CHMP took into consideration that in healthy volunteers, tafamidis did not induce CYP3A4.

## Toxicology

The applicant submitted comprehensive results of non-clinical toxicology testing.

No mortality or serious adverse effects were observed with single oral doses of up to 600 mg/kg in Beagle dogs. This is approximately 1 900 fold of the intended clinical human dose (0.175 mg/kg or 12.2 mg/70 kg human tafamidis equivalent), demonstrating a large safety margin for acute toxicity of the  drug.  Thus,  the  CHMP  considered  that  the  acute  oral  toxicity  of  tafamidis  is  low,  this  being indicative of a low risk for overdose.

In repeat dose toxicity studies tafamidis administered orally was tested in mice up to 28 days, in rats up to 26 weeks and in Beagle dogs up to 39 weeks. The NOAEL in mice was 10 mg/kg, the safety margins were quite large ranging from 3 and 6 (from 28-day mouse repeat dose study) to 32 and 42 (from the mouse carcinogenicity study) based on AUC and Cmax ratio, respectively, i.e. indicating a good safety profile of tafamidis. Tafamidis was also considered to be well-tolerated in the rat at dose levels up to 10 mg/kg/day for 26 weeks, providing AUC exposure ratios of at least 24-fold based on the human AUC at steady state. In the dog, at dose levels up to 15 mg/kg in males and 5 mg/kg in females for 39 weeks, the exposure ratios of at least 11-fold in males and 9-fold in females based on the human AUC at steady state were achieved at the no-observable-effect level.

The CHMP noted that liver appeared as the target organ for toxicity in the different species tested. Increased  liver  weight,  increased  bilirubin  and  changes  in  liver  enzymes  were  observed  in  rats  and dogs. The CHMP considered that the hepatic findings were observed at safety margins &gt;3 and were reversible. Furthermore, the CHMP was of the opinion that liver function can be easily monitored via standard biochemical parameters in clinical practice and concluded that monitoring the potential risk of hepatotoxicity  in  the  post-authorisation  setting,  as  described  in  the  Risk  management  plan  was appropriate.

Tafamidis  was  tested  in  the  conventional  battery  of  genotoxicity  tests.  The  Ames  test  and  the micronucleus test were negative. The CHMP noted that in the chromosomal aberration assay in human peripheral lymphocytes, a dose-dependant increase of polyploidy was observed in the presence of S9. Considering the unclear relevance of the finding and the large safety margins regarding micronucleus induction (&gt;70) as well as the safety margin regarding polyploidy in the chromosome aberration assay (=18), the CHMP concluded that in the context of a serious disease with a lack of therapeutic options, this finding did not impact negatively on the benefit-risk balance of tafamidis.

<div style=\"page-break-after: always\"></div>

No carcinogenic potential was observed in transgenic rasH2 mice treated with doses of up to 90 mg/kg for 26 weeks. The CHMP noted that no long-term studies were conducted, but given the therapeutic indication,  particularly  the  severity  of  the  disease,  this  was  considered  acceptable.  Some  deviations from GLP were observed in the conduct of the carcinogenicity study, but the CHMP was of the opinion that these would not hamper the scientific validity of the results.

The CHMP considered that the fertility study in rats did not reveal any concerns regarding reproductive toxicity in males or females. Because no reproductive effects occurred at the highest dosage tested, the paternal and maternal NOEL for reproductive toxicity of tafamidis is greater than 30 mg/kg/day, providing a human equivalent dose (HED) of 4.8 mg/kg; this is a dose level approximately 17 times the anticipated clinical human dose of 0.285 mg/kg.

In the rat developmental (embryo-foetal) study, tafamidis induced maternal toxicity (decreased body weight at 30 mg/kg, mortality at 45 mg/kg) and foetotoxicity (decreased body weight at 30 mg/kg), but was not teratogenic.

In a developmental (embryo-foetal) toxicity study in rabbits, a slight increase in skeletal malformations and variations, abortions in few females, and reduction in foetal weights were observed at an AUC ratio of 3.2-fold, based on the human AUC at steady state.

In the rat peri- and post-natal development study with tafamidis, decreased pup survival and reduced pup weights were noted following maternal treatment during pregnancy and lactation at doses of 15 and  30  mg/kg.  Decreased  foetal  weights  in  males  were  associated  with  delayed  sexual  maturation (preputial  separation)  and  impaired  performance  in  a  water-maze  test  for  learning  and  memory. Furthermore, hyperactive-like behaviour was identified in the pups. The CHMP discussed the possibility that  some  mild  disturbance  of  the  maternal  thyroid  function  during  foetal  development  might  have been the cause of the neuro-behavioural dysfunction in the pups. However, this possibility was not confirmed and the CHMP agreed that further investigation is not required. The NOAEL for viability and growth  in  the  F1  generation  offspring  following  maternal  treatment  during  pregnancy  and  lactation with tafamidis was 5 mg/kg (HED=0.8 mg/kg), a dose approximately 2.8-times the anticipated clinical human dose.

Non-clinical  data  relevant  to  reproductive  toxicity  are  summarised  in  section  5.3  of  the  SmPC  and reproductive  toxicity  is  listed  among  the  important  potential  risks  in  the  RMP.  In  the  absence  of relevant clinical data the CHMP was of the opinion that tafamidis should not be recommended during pregnancy and contraceptive measures need to be advised. This is reflected in section 4.6 of the SmPC as follows:

## 'Women of childbearing potential

Contraceptive  measures  should  be  used  by  women  of  childbearing  potential  during  treatment  with Vyndaqel, and for one month after stopping treatment, due to the prolonged half life.

## Pregnancy

There  are  no  data  on  the  use  of  Vyndaqel  in  pregnant  women.  Studies  in  animals  have  shown reproductive toxicity. Vyndaqel is not recommended during pregnancy and in women of childbearing potential not using contraception.'

Despite making this recommendation, the CHMP acknowledged that in clinical practice women treated with  tafamidis  may  become  pregnant  and  considered  that  a  monitoring  programme  (Tafamidis Enhanced Surveillance for Pregnancy Outcomes, TESPO) will be in place in order to collect relevant clinical data, as described in the RMP.

<div style=\"page-break-after: always\"></div>

Furthermore, the CHMP considered that thyroid function was not measured in pregnant animals and since  tafamidis  binds  to  one  of  the  thyroxin  binding  proteins,  a  subtle  effect  could  have  occurred without a clear expression on the thyroid weight or histopathology in the pre-clinical testing. Therefore, even  though  relevant  effect  on  the  thyroid  function  was  not  identified  in  the  pre-clinical  or  clinical setting, the CHMP was of the opinion that it cannot be excluded that tafamidis treatment may have subtle impact on the thyroid function due to the competition to the binding proteins. In this context, the  CHMP  was  of  the  opinion,  that  changes  of  thyroid  function  should  be  listed  as  an  important potential risk in the RMP.

No local tolerance studies were performed by the applicant. The CHMP considered that the effects on the gastrointestinal tract were evaluated during the repeated dose toxicity studies.

## Other studies

One  synthetic  intermediate  (DCBC)  gave  a  positive  genotoxic  response in  silico .  DCBC  is  highly reactive  and  unstable  in  aqueous  media  and  thus,  no  Ames  test  could  be  conducted.  The  CHMP considered that the manufacturing process is able to purge an excess of un-reacted DCBC if present from step 1, DCBC was not observed within the assay limits with a LOQ of 8 ppm. The CHMP concluded on a negligible risk for the treated population.

## Environmental risk assessment

Tafamidis PEC surface water value is below the action limit of 0.01 µg/l. Therefore, the CHMP agreed that a phase II risk assessment was not needed.

Given  the  fact  that  tafamidis  is  an  ionisable  compound,  the  CHMP  recommended  that  the  applicant should conduct study OECD 107 to determine log Dow and perform assessment of the persistent bioaccumulative and toxic (PBT) potential of tafamidis accordingly.

## 2.3.7. Conclusion on the non-clinical aspects

In the context of the obligation of the MAH to take due account of technical and scientific progress, the CHMP recommends the following point to be addressed:

With  respect  to  the  Environmental  Risk  Assessment,  the  Applicant  should  perform  a  log  Dow determination  according  to  the  OECD  107  guideline  and  assess  the  persistent  bio-accumulative  and toxic (PBT) potential of tafamidis accordingly. It is noted that the results should be available by the end of IQ 2012.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The  applicant  has  provided  a  statement  to  the  effect  that  clinical  trials  conducted  outside  the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<div style=\"page-break-after: always\"></div>

##  Tabular overview of clinical studies

| Table 11   | Table 11       | Table 11                        | Table 11                                                                                                                                                                            | Table 11                                                                                                                                                                                                                                                                         |
|------------|----------------|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Protocol   | Phase          | Status                          | Population                                                                                                                                                                          | Endpoints                                                                                                                                                                                                                                                                        |
| Fx-002     | I              | Completed                       | Healthy male and female volunteers (N=61; 43 tafamidis, 18 placebo)                                                                                                                 | Safety, tolerability, PK, PD (TTR stabilisation) of single and multiple tafamidis doses                                                                                                                                                                                          |
| Fx-003     | I              | Completed                       | Healthy male volunteers (N=19 tafamidis; 10 fasted, 9 fed)                                                                                                                          | Safety, tolerability, PK (tafamidis PK profile and effects of food on PK), PD (TTR stabilisation)                                                                                                                                                                                |
| Fx-004     | I              | Completed                       | Healthy male volunteers (N=30 tafamidis; 10 (1 x 20 mg) soft gelatine capsule, 10 (2 x 10 mg) soft gelatine capsule, 10 oral solution)                                              | Safety, tolerability, tafamidis PK profile, and bioequivalence of formulations, soft gelatine capsule and solution                                                                                                                                                               |
| Fx1A-105   | I              | Part 1 Completed Part 2 Ongoing | Part 1: Moderately hepatically impaired subjects (N=9) and healthy volunteers (N=9) enrolled Part 2: Mild hepatically impaired subjects (N=9) and healthy volunteers (N=9) targeted | Safety, tolerability, PK (tafamidis profile and effects of hepatic impairment on PK parameters)                                                                                                                                                                                  |
| Fx1A-107   | I              | Completed                       | Healthy volunteers (N=6)                                                                                                                                                            | Safety, tolerability, PK (tafamidis absorption and elimination profiles)                                                                                                                                                                                                         |
| Fx1A-108   | I              | Completed                       | Healthy volunteers (N=14)                                                                                                                                                           | Safety, tolerability, PK (tafamidis profile and effects of food on PK parameters) with final formulation (soft gelatine capsule)                                                                                                                                                 |
| Fx1A-109   | I              | Completed                       | Healthy Volunteers (N=16)                                                                                                                                                           | CYP3A4 induction potential of tafamidis (midazolam); safety and tolerability of co- administration of tafamidis/midazolam                                                                                                                                                        |
| Fx1A-201   | II; open label | Completed                       | Non-V30M ATTR-PN patients (N=21 representing eight different mutations)                                                                                                             | Safety: Adverse events, physical examinations, laboratory testing, ECGs, 24-hour Holter monitoring, echocardiography, vital signs, concomitant medications Efficacy: TTR stabilization, NIS, Norfolk QOL-DN, NCS, Karnofsky Index, HRDB, mBMI, SF-36, NT-pro-BNP and troponin I. |

<div style=\"page-break-after: always\"></div>

| Table 11   | Table 11                                              | Table 11   | Table 11                                                                                                                              | Table 11                                                                                                                                                                                                                                                                                                                               |
|------------|-------------------------------------------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Protocol   | Phase                                                 | Status     | Population                                                                                                                            | Endpoints                                                                                                                                                                                                                                                                                                                              |
| Fx1B-201   | II; open label                                        | Completed  | V122I and wild-type ATTR-CM patients (N=35; 31 wild-type, four V122I)                                                                 | Safety: Adverse events, laboratory testing, echocardiography, ECGs, 24 hr Holter monitoring, chest x-ray, physical examinations, vital signs, concomitant medications Efficacy: NYHA, Patient Global Assessment, TTR stabilisation, cardiac MRI, troponin I and T, NT-pro-BNP levels, 6-minute walk test, KCCQ, SF-36. TTR sequencing. |
| Fx-005     | II/III; double-blind, randomized, placebo- controlled | Completed  | V30M ATTR-PN patients (N=128; 65 tafamidis, 63 placebo)                                                                               | Safety: Adverse events, laboratory testing, ECGs, echocardiography, vital signs, physical and eye examinations Co-primary: NIS-LL and Norfolk QOL-DN; Secondary: TTR stabilisation, NCS, QST, HRDB, mBMI, Σ 7 NTs nds, Σ 3 NTSF nds Pharmacokinetics                                                                                   |
| Fx-006     | II/III; 1-year open-label extension to Fx-005         | Completed  | V30M ATTR-PN patients who complete Protocol Fx-005 (N=86, 45 previously on tafamidis, 41 previously on placebo, 85 received ≥ 1 dose) | Safety: Adverse events, laboratory findings, ECGs, Holter monitoring, vital signs, echocardiography, physical and eye examinations, concomitant medications Efficacy: NIS-LL, Norfolk QOL-DN, TTR stabilization, NCS, QST, HRDB, mBMI, skin biopsy for IENF, troponin I and NT-pro- BNP levels Pharmacokinetics                        |
| Fx1A-303   | III; open- label                                      | Ongoing    | Patients who complete Protocol Fx-006 or Protocol Fx1A-201 (N=100 target)                                                             | Safety: incidence of AEs, physical examinations, use of concomitant medications, and vital signs Efficacy: NIS, Norfolk QOL-DN, Karnofsky                                                                                                                                                                                              |
| Fx1B-303   | III; open label                                       | Ongoing    | V122I and wild-type ATTR-CM patients who complete protocol Fx1B- 201 (N=31)                                                           | Safety: incidence of AEs, ECGs, echocardiography, laboratory testing, physical examinations, use of concomitant medications, and vital signs Efficacy: Patient Global Assessment, NYHA, KCCQ, 6-minute walk test, troponin I and T and NT-pro-BNP, mortality and hospitalisation                                                       |

<div style=\"page-break-after: always\"></div>

## 2.4.2. Pharmacokinetics

## Absorption

In a phase I ADME study with a single 20 mg dose in healthy volunteers (Fx1A-107), tafamidis was rapidly absorbed with a Tmax of 0.5 h and mean Cmax of 1430.93 (SD 91.0) ng/ml.  A mean Cmax of 1574.6 ng/ml (SD108.8) was observed for  14 C-tafamidis equivalents.

The full plasma time profile for tafamidis and 14 C-tafamidis equivalents was well characterised. Mean AUC0-∞ derived from plasma concentration profile for tafamidis and 14 C-tafamidis equivalents was 47 864.31  (SD  11  380.38)  ng.h/ml  and  66  282.59  (SD  15289.28)  ng.h/ml,  respectively.  The  mean apparent total clearance for tafamidis and 14 C-tafamidis equivalents was 0.44 (SD 0.12) l/h and 0.32 (SD 0.07) l/h, respectively. Mean T½ of the terminal elimination phase was 53.86 (SD 16.04) h and 64.23 (SD 16.37) h for tafamidis and  14 C-tafamidis equivalent, respectively.

## Bioequivalence

During the development of tafamidis, three formulations were tested:

-  The initial formulation, a hard gelatin capsule, was abandoned due to low bioavailability and is not described further.
-  Tafamidis in 7.5% vitamin E TPGS solution (used in studies Fx-002 and Fx-003)
-  Formulation of tafamidis meglumine soft gelatin capsules (used throughout the remaining clinical pharmacology studies and all clinical efficacy studies).

In Study Fx-004, bioequivalence was concluded for the 20 mg tafamidis meglumine in solution and as soft gelatine capsule based on the 90% CI for the ratio of the geometric means for AUC0-120 and Cmax.

## Food effect

In  study  Fx-003  (a  phase  I,  parallel-group  study  of  an  orally  administered  single  dose  of  tafamidis meglumine in normal, healthy male volunteers under fed or fasted conditions), Cmax was 32.3% lower and AUC0-120 was 11.1% lower in fed state.

In  a  phase  I  study  evaluating  the  effects  of  food  versus  fasting  state  (Fx1A-108),  following administration of the 20 mg tafamidis soft gelatine capsule, Tmax occurred at a median of 1.75 h postdose  (range  0.50  to  6.00  h)  under  fasted  conditions  as  compared  to  the  median  of  4  h  post-dose (range 1.50 to 12.00 h) under fed conditions. AUClast was equivalent in fed and fasted state and Cmax was 23% lower in fed state.

## Distribution

Distribution  was  estimated  based  on  PK  population  analysis.  Volume  of  distribution  of  the  central compartment (Vc/F) and volume of distribution of the peripheral compartment (Vp/F) estimates were 0.482  L  (95%  CI:  0.366,  0.598,  RSE:  12.3%)  and  18.9  L  (95%  CI:  17.6,  20.2,  RSE:  3.43%), respectively (for a subject less than 60-year old, 70 kg weight, with a normal hepatic function).

Clearance and volume of distribution of tafamidis in central and peripheral compartments were related to body weight linearly for volume of distribution and in the power of 0.75 for clearance.

Tafamidis was highly bound to plasma proteins (&gt;99.5%) as determined in more than one study.

<div style=\"page-break-after: always\"></div>

## Elimination

In a phase I ADME study with a single 20 mg dose in healthy volunteers (Fx1A-107), tafamidis was eliminated slowly with T1/2 of 53.9 h and Cl/F of 0.44 L/h. The major circulating entity identified in plasma was the parent compound. Almost complete recovery (80.9% of the dose) was observed; in faeces and in urine 58.5% and 22.4% of the dose, respectively, was recovered.

Estimates of apparent total clearance (Cl/F) were consistent across studies using the 20 mg dose, i.e. 7.3, 6.5 and 7.0 ml/min from studies Fx1A-107, 108 and 109, respectively, and also with data from the population PK analysis and the renal clearance from study Fx-002.

Glucuronidation  is  considered  the  major  metabolic  pathway  of  tafamidis.  Screening  of  10  cDNAexpressed  recombinant  human  UDP-glucuronyltransferase  (UGT)  enzymes  suggested  that  the  major UGT isoforms responsible for the formation of the monoglucuronide metabolite are UGT 1A9, 1A1 and 1A3. Minor activity was observed with isoforms 1A6, 1A7, 1A8 and 2B7.

Metabolite profiling in human plasma and structural identification of metabolites was carried out by LCMS/MS (Q-Trap) using a combination of full scan and product ion techniques. The metabolite patterns from  several  plasma  samples  collected  from  Study  Fx-002  indicated  that  unchanged  parent  and  its aromatic  carboxylic  monoglucuronide  (acylglucuronide)  were  the  most  prominent  components  in  all investigated samples.

## Dose proportionality and time dependencies

Following single-dosing tafamidis was observed to show linear dose proportionality in Cmax and AUC with doses up to 30 mg; between 30 and 60 mg the exposure was less than proportional indicating saturation  of  absorption  rate  above  30  mg.  The  dose  linearity  was  similar  for  single  and  repeated administration  of  tafamidis.  No  time  dependency  was  detected,  which  is  consistent  with  the  finding that tafamidis has no induction effect.

Steady-state PK parameters were as expected from single and multiple dose PK in healthy subjects. Results of once-daily dosing with 20 mg for 14 days demonstrated that steady-state was achieved by day 14. Cmax(ss) and Cmin(ss) were 2.7 and 1.6 μ g/ml, respectively.

Steady  state  exposure  was  similar  between  males  and  females.  Following  administration  of  20  mg tafamidis  solution  to  females,  exposure  was  similar  to  that  seen  in  males  in  a  separate  food  effect study  (Fx-003).  The  mean  peak  plasma  concentration  was  1.12 μ g/ml  compared  to  1.23 μ g/ml  in males and mean AUClast was 60.8 μ g·h/ml compared to 51.9 μ g·h/ml in males. The mean terminal half-life was also similar between genders.

Estimates of inter-individual variability from population PK analysis expressed as CV% are: 30.6, 25.9 and 13.2 for CL/F, Vp/F and KA, respectively.

Intra-individual variability (ANOVA residual error) was estimated from bioequivalence and food effect studies. The  intra-individual  variability  was  estimated  to  be  14.5  and  12.3%  for  AUC 0-last and  Cmax, respectively.

## Special populations

##  Impaired renal function

No specific PK study in renally impaired patients was performed. The effects of creatinine clearance on tafamidis  PK  were  evaluated  in  the  population  PK  analysis;  pharmacokinetic  estimates  indicated  no difference  in  steady-state  clearance  of  tafamidis  in  patients  with  creatinine  clearance  &lt;80  ml/min compared to those with creatinine clearance&gt;80 ml/min.

<div style=\"page-break-after: always\"></div>

##  Impaired hepatic function

Study  Fx1A-105  (Pharmacokinetics  of  Orally  Administered  Tafamidis  (Fx-1006A)  in  Subjects  with Hepatic Dysfunction) was conducted to describe and compare the pharmacokinetics (PK) of tafamidis in subjects  with  moderate  hepatic  dysfunction  and  gender-,  age-  and  weight-matched  normal  healthy subjects. Subjects with moderate hepatic impairment showed a lower exposure than healthy subjects; in particular, decreased systemic exposure (approximately 40%) and increased total clearance (0.52 l/h vs 0.31 l/h) of tafamidis was observed in patients with moderate hepatic impairment (Child-Plough Score  of  7-9  inclusive)  compared  to  healthy  subjects.  These  findings  are  attributed  to  a  higher unbound fraction of tafamidis in patients with hepatic impairment.

##  Gender

Similar PK profile was observed in males and females. The ratio of the geometric LS Means for AUC0τ (ss)  and  Cmaxss for females to males was 100.53 and 98.48, respectively, with the corresponding 90% confidence intervals (CI) being 83.54 - 120.98 and 82.14 - 118.08.

##  Race

Results from a population PK analysis on a pool of all Phase I and Phase II/III studies showed that race as a covariate was not found to be significant.

##  Weight

Results from a population PK analysis on a pool of all Phase I and Phase II/III studies showed that clearance of tafamidis increased allometrically (coefficient of 0.75) with increasing weight.

##  Children

There is no relevant use of Vyndaqel in the paediatric population.

##  Elderly

Results from a population PK analysis on a pool of all Phase I and Phase II/III studies showed that at steady  state  following  repeated  of  20  mg  doses  once  a  day,  apparent  clearance  for  tafamidis  for subjects  &gt;60  years  was  estimated  to  be  19%  lower  compared  to  those  &lt;60  years.  Based  on  PK simulations the predicted maximum concentrations at steady state (Cmax,ss) estimated for elderly and non-elderly subjects were 2.76 and 2.28 μ g/ml, respectively, indicating a 21% higher Cmax (ss) for elderly compared to non-elderly subjects.

##  Pregnancy

There  is  no  clinical  experience  in  pregnant  women.  No  information  is  available  on  the  presence  of tafamidis in human breast milk.

## Pharmacokinetic interaction studies

##  In vitro

CYP  inhibition  and  induction  studies  with  tafamidis  have  been  performed  using  validated  probe substrates. In vitro, tafamidis did not significantly inhibit CYP1A2, CYP2B6, CYP3A4, CYP2C9, CYP2C19, and CYP2D6; a moderate inhibition of CYP2C8 was observed. In addition, an equivocal effect of the CYP  3A4  induction potential of tafamidis in hepatocytes obtained from  female subjects  was demonstrated, which prompted an in vivo study.

<div style=\"page-break-after: always\"></div>

##  In vivo

In  study  Fx1A-109  utilising  a  CYP3A4  probe  substrate  (7.5  mg  midazolam)  to  evaluate  Cytochrome P450 3A4 Induction Potential, tafamidis did not induce CYP3A4 enzymes since there was no significant effect observed on the pharmacokinetics of midazolam and on the formation of its active metabolite (1-hydroxymidazolam)  when  midazolam  was  administered  prior  to  and  after  a  14-day  regimen  of tafamidis.  The  overall  systemic  exposure  (AUC 0-inf )  and  total  clearance  (CL/F)  of  midazolam  were shown to be equivalent on Day 1 as well as on Day 15 after single dose administrations of midazolam alone and concomitant with steady-state tafamidis.

| Summary of PharmacokineticResults (Study FxlA-109)       | Summary of PharmacokineticResults (Study FxlA-109)       | Summary of PharmacokineticResults (Study FxlA-109)       | Summary of PharmacokineticResults (Study FxlA-109)       | Summary of PharmacokineticResults (Study FxlA-109)       |
|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Means, Ratio of Means, and 90% Confidence Intervals N=16 | Means, Ratio of Means, and 90% Confidence Intervals N=16 | Means, Ratio of Means, and 90% Confidence Intervals N=16 | Means, Ratio of Means, and 90% Confidence Intervals N=16 | Means, Ratio of Means, and 90% Confidence Intervals N=16 |
| Parameter (units)                                        | Midazolam Alone (Day 1)                                  | Midazolam + Tafanidis (Day 15)                           | %Ratio Dayl/Day15                                        | 90% CI                                                   |
| Geometric Mean AUCo-inf (ng-hr/mL)                       | 79.56                                                    | 73.63                                                    | 108.07                                                   | (100.87, 115.78)                                         |
| Least Squares Mean CL/F (mL/hr)                          | 97343.20                                                 | 104345.55                                                | 93.29                                                    | (86.30, 100.28)                                          |

## 2.4.3. Pharmacodynamics

## Mechanism of action

Tafamidis meglumine is a novel specific stabilizer of tetrameric wild-type and amyloidogenic TTR that binds to the native tetrameric form of TTR and thereby inhibits tetramer dissociation and TTR amyloid formation. This novel class of TTR stabilizer drug has a potential to slow the progression of ATTR.

Dissociation  of  the  TTR  tetramer  to  monomers  is  the  rate-limiting  step  in  the  pathogenesis  of  TTR amyloidosis.  The  folded  monomers  undergo  partial  denaturation  to  produce  alternatively  folded monomeric amyloidogenic intermediates. These intermediates then misassemble into soluble oligomers, profilaments, filaments and ultimately, amyloid fibrils (see fig. 1.1). All disease-associated mutations characterized so far destabilize the TTR tetramer and many influence the velocity of ratelimiting tetramer dissociation.

Figure 1. ITR Amyloid Cascade

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Primary and Secondary pharmacology

Four PK/PD studies evaluating stabilisation of TTR in the plasma of healthy volunteers after receiving tafamidis or placebo were conducted: study Fx-002, a single and multiple dose escalating study; study Fx-003,  a  study  of  food  interaction  with  a  single  20  mg  dose;  study  Fx-004,  comparing  tafamidis administered in a solution with a soft gelatine capsule formulation and study Fx1A-105, a PK study of tafamidis administered orally in subjects with hepatic dysfunction.

For each subject in the study, the fraction of initial tetramer concentration (FOI) was determined in duplicate before dosing (FOIbaseline) and  at given time-points after  dosing  (FOIdosed).  The percentage  stabilisation  of  TTR  tetramer  was  defined  as  follows:  %  stabilisation  =  [(aveFOIdosed  aveFOIbaseline)  /  aveFOIbaseline]  *  100.  Consequently,  a  %  stabilisation  of  100%  has  a  twofold increase in the fraction of initial  value  over  baseline  and  a  %  stabilisation  of  200%  has  a  threefold increase thereof.

In study Fx-002, following single and repeated administration of tafamidis the average percentage of TTR stabilisation in the placebo group varied from -2 to 6 for the first part (single dose) and from -17 to  -6  in  the  second  part  of  the  study  (multiple  doses).  Following  both  single  and  repeated  doses, tafamidis demonstrated a concentration dependent stabilisation of the TTR tetramer. Following a single dose of 20, 60 and 120 mg, the average concentrations of tafamidis achieved in plasma samples at Tmax were 3.7, 9.1 and 14.4 μ M, respectively, which resulted in the average percent stabilisation of 69%,  144%  and  189%  respectively.  Following  once  daily  doses  of  15,  30  and  60  mg  tafamidis meglumine for 14 days, the average concentrations of tafamidis achieved in plasma samples on Day 15 were 3.3, 7.8 and 9.8 μ M, respectively, which resulted in the average percent stabilisation of 57%, 100% and 132%, respectively. No stabilisation was observed in the placebo control groups following either single or multiple doses.

A PD assay was performed on the plasma samples obtained in Fx-002. A plateau (range of difference from baseline: 117-234) was reached for the effect of tafamidis on TTR stabilisation above a plasma tafamidis: TTR stoichiometry of 1.2-1.4 see figure 2.

Fig. 2 Percent stabilisation as a function of tafamidis: TTR molar ration in all Fx-002 samples

<!-- image -->

In study Fx-003, tafamidis demonstrated a concentration dependent stabilisation of the TTR tetramer in  both  fed  and  fasted  patients.  Following  a  single  20  mg  dose  as  oral  solution,  the  average concentrations of tafamidis achieved in plasma samples at Tmax were 2.7 and 4.0 μ M for the fed and the  fasted  groups,  respectively,  resulting  in  the  average  percent  stabilisation  of  31%  and  51%, respectively.

<div style=\"page-break-after: always\"></div>

In  the  bioequivalence study (Fx-004) tafamidis meglumine demonstrated a concentration dependent stabilisation of the TTR tetramer in all tested groups, ranging from 40 to 77%.

In  subjects  with  moderate hepatic impairment (study Fx1A-105), the mean molar ratio values were higher in subjects with hepatic impairment due to the lower TTR concentrations and the PK values at 24 h were similar: 24h mean tafamidis plasma concentrations following a single 20 mg dose were 624 ng/ml  in  healthy  volunteers  and  537  ng/ml  in  subjects  with  moderate  hepatic  impairment.  Steadystate 24 h trough concentrations were predicted to be approximately 2.25 μ g/ml in healthy subjects and 1.25 μ g/ml in subjects with moderate hepatic impairment, representing a 44% decrease in steadystate trough levels of tafamidis.

PD analyses were also conducted during the pivotal phase II/III Fx-005 study in ATTR-PN patients. The PD analysis was performed on plasma samples for 10 patients given a daily oral dose of 20 mg blinded study medication at the following time points: pre-dose (Baseline), 1, 4, and 24 h post dose on the first day of dosing and after 8 weeks daily dosing (steady state; sample drawn at anytime post dose). All six subjects with measurable levels of tafamidis demonstrated stabilisation after 8 weeks daily oral dosing, while none of the four patients without detectable levels of tafamidis demonstrated stabilisation at this time point. Additionally, all patients with measurable levels of tafamidis had a time point on the first  day  (1,  4  or  24  h  after  single  dose)  that  showed  stabilisation.  The  average  TTR  percent stabilisation  after  8  weeks  daily  dosing  was  -15%  in  the  four  patients  without  detectable  levels  of tafamidis and 150% in the six patients with measurable levels of tafamidis.

## 2.4.4. Discussion on clinical pharmacology

In general, the CHMP considered the documentation adequate to characterise the pharmacokinetics of the active substance and the proposed dosage form. An early formulation (hard gelatine capsule) was abandoned during the product development and a new dosage form (soft gelatine capsules) was found to be bioequivalent to an oral solution early in the clinical development, thus allowing performance of the majority of clinical studies with an adequate formulation.

With respect to special populations, the CHMP considered the observations made in patients with renal and  hepatic  impairment.  Based  on  the  findings  from  the  population  PK  analysis,  where  the  PK estimates indicated no difference in steady-state clearance of tafamidis in patients based on creatinine clearance, the CHMP was of the view that no dosage adjustment in patients with renal impairment was necessary.

Steady-state  24h  trough  concentrations  were  predicted  to  be  higher  in  healthy  subjects  than  in subjects with moderate hepatic impairment. The reduction in trough concentrations of approximately 44% combined with a 50% reduction in TTR level in moderate hepatic impaired subjects translates to a tafamidis:TTR stoichiometry ratio that is within the therapeutic range. The CHMP considered that the key  factor  in  stabilisation  of  the  TTR  tetramer  is  the  tafamidis:TTR  stoichiometry  and  not  plasma tafamidis concentrations alone. The results suggested that subjects with moderate hepatic impairment would be expected to demonstrate effective stabilisation of the TTR tetramer following chronic dosing with 20 mg once daily.

Findings related to these patient sub-populations are reflected accordingly in section 4.2 of the SmPC as follows: 'No dosage adjustment is required for patients with renal or mild and moderate hepatic impairment. Tafamidis has not been studied in patients with sever hepatic impairment and caution is recommended' and in section 5.2 (Special populations).

The  CHMP  also  discussed  the  difference  in  tafamidis  clearance  and  predicted  Cmax  at  steady  state between subjects below and above 60 years of age (see Results) and, given the adequate non-clinical safety  margins  and  the  clinical  safety  profile  in  this  patient  population,  was  of  the  view  that  the

<div style=\"page-break-after: always\"></div>

differences seen would not be clinically relevant. Therefore, no dosage adjustment was requested for the elderly as reflected in the SmPC section 4.2.

There is no clinical experience in pregnant women. The CHMP also considered that no information is available  on  the  presence  of  tafamidis  in  human  breast  milk  and  that  risk  to  the  newborns/  infants cannot  be  excluded.  Hence,  the  CHMP  concluded  that  tafamidis  should  not  be  administered  during pregnancy or breastfeeding. This is reflected in section 4.6 of the SmPC.

In terms of food effect, the CHMP considered that the 23% to 32.3% difference in Cmax (lower in fed state) could be of significance in a single dose administration; however, for a chronically administered drug it was not likely to have a clinically significant effect. This was further supported by the population PK model showing that the difference between fed and fasted state is only 9% for Cmax and 5% for AUC, and that this  difference  is  unlikely  to  be  clinically  relevant.  These  conclusions  are  reflected  in sections 4.2 and 5.2 of the SmPC.

With  respect  to  pharmacokinetic  interactions, in  vitro there  was  evidence  that  tafamidis  is  not  an inhibitor of the usual CYP450 isozymes CYP1A2, CYP2B6, CYP3A4, CYP2C9, CYP2C19, and CYP2D6. The equivocal induction potential for CY3A4 in vitro prompted an in vivo study. No effects on the PK of the probe drug (midazolam), whether induction or inhibition, were observed in this study. Since the only metabolic pathway identified for tafamidis is glucuronidation, the CHMP concluded that no interaction of potential inhibitors or inducers of CYP450 isozymes on tafamidis PK would be expected.

Pharmacodynamic studies  were  conducted  in  support  of  the  mechanism  of  action  of  tafamidis  (TTR stabilisation) and as a step to dose selection. Tafamidis represents a disease modifying approach to the treatment of TTR amyloidosis. No surrogate markers of clinical efficacy exist to allow short-duration dose-ranging studies. The CHMP considered that the traditional dose findings studies are very difficult to perform, particularly in this orphan condition with a limited patient population. A PK/PD approach was followed to select a dose sufficient to reach the plateau for optimum inhibition of TTR tetramer dissociation.

Stabilization of the wild-type TTR tetramer from healthy volunteers orally dosed with different doses of tafamidis was observed in both single and multiple dose regimens. The stabilization effect reached a plateau above a plasma tafamidis: TTR stoichiometry of 1.2-1.4. This ratio was obtained with a 20 mg dose of tafamidis. The data were considered supportive of the mode of action and dose selection by the CHMP.

## 2.4.5. Conclusions on clinical pharmacology

Overall, the clinical pharmacology data submitted are considered satisfactory.

## 2.5. Clinical efficacy

## 2.5.1. Dose response studies

No dose response studies were performed. The dose was selected based on pharmacodynamic studies and  extrapolated  pharmacokinetic  data  showing  that  a  dose  of  20  mg  resulted  in  sufficient  plasma concentrations to stabilise transthyretin (1.2 - 2.7 µg/ml). (See Clinical Pharmacology).

<div style=\"page-break-after: always\"></div>

## 2.5.2. Main study

The  applicant  conducted  a  single  pivotal  study  Fx-005:  safety  and  efficacy  of  orally  administered tafamidis in patients with familial amyloid polyneuropathy (FAP): a phase II/III, randomised, doubleblind, placebo-controlled study.

## Methods

## Study Participants

Study Fx-005 was conducted at 8 investigational sites, at least one patient was enrolled in each site. The sites were located in France, Portugal, Germany, Spain, Sweden, Argentina and Brazil.

To be eligible to participate in the study, the subjects had to be between 18-75 years old, inclusive. Female  patients  had  to  be  post-menopausal,  surgically  sterilised  or  willing  to  use  two  acceptable methods of birth control throughout the study and for three months from the end of the study, male patients  with  a  female  partner  of  childbearing  potential  had  to  be  willing  to  use  two  acceptable methods of birth control for the duration of the study for at least three months from the end of the study. The inclusion criteria further comprised presence of amyloid documented by biopsy, V30M TTR mutation  and  peripheral  and/or  autonomic  neuropathy  with  a  Karnofsky  Performance  Status ≥ 50. Patients were not eligible for entry into the study if they met any of the following criteria: chronic use of  NSAIDs  other  than  those  allowed  by  the  protocol  (ASA,  etodolac,  ibuprofen,  indomethacin, ketoprofen, nabumetone,  naproxen,  nimesulide, piroxicam  and sulindac), primary amyloidosis, pregnancy or breastfeeding, prior liver transplantation, no recordable sensory threshold for vibration perception in both feet, positive results for hepatitis B and/or hepatitis C and/or HIV, renal insufficiency as defined by creatinine clearance  30ml/min, liver function test abnormalities: ALT and/or AST &gt;2 times the upper limit of normal, NYHA functional classification of ≥ 3, co-morbidity anticipated to limit survival to less than 18 months, investigational drug/device and/or participation in another clinical trial within 60 days before baseline, other causes of sensorimotor neuropathy.

## Treatments

All patients received daily a single oral dose of 20 mg tafamidis meglumine (soft gelatine capsule) or matching placebo for a period of 18 months. The following medication was prohibited during the study: any investigational drug within 60 days before baseline through eighteen months  of study participation, chronic use of NSAIDs  (with the exception of ibuprofen and nimesulid). Liver transplantation  was  not  allowed  during  study  participation,  patients  undergoing  liver  transplantation were to be withdrawn from the study.

## Objectives

The primary objectives of the study were to evaluate the effect of tafamidis on disease progression in patients with familial amyloid polyneuropathy (FAP) and to evaluate the safety and tolerability of its chronic administration in these patients. The secondary objectives of this study were to determine the pharmacodynamic  stabilization  effect  of  tafamidis  on  human  V30M  TTR  and  to  determine  the population pharmacokinetics in patients with FAP.

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

The co-primary efficacy endpoints of this study were:

· Response to treatment at month 18, as indicated by either improvement (decrease from baseline) or stabilization (change from baseline of 0 to &lt;2) in the Neurologic Impairment Score-Lower Limb (NISLL) score

The NIS-LL score for each study visit was based on the average of two scores taken within a one-week period. The NIS-LL was assessed at baseline and at months 6, 12 and 18. For each patient, the rating was performed by the same neurologist throughout the course of the study whenever possible. The NIS-LL composite score ranges from 0 [normal] to 88 [total impairment].

Patients with no disease progression (i.e. improvement or stabilization) were considered responders, patients with disease progression or patients discontinuing their participation prior to month 18 due to liver transplantation or death were considered to be non-responders.

· Change from Baseline to 18 months in the Total Quality of Life score, as measured by the Norfolk QOL-DN

The  Norfolk  QOL-DN  questionnaire  was  assessed  at  baseline  and  at  months  6,  12,  and  18.  The questionnaire  consisted  of  35  scored  items  arranged  thematically  into  five  domains:  physical functioning/large fiber neuropathy, activities of daily living (ADL), symptoms, small fibre neuropathy, and autonomic neuropathy. The total quality of life (TQOL) score was the sum of all five domains (35 questions), with a range of -2 to 135.

The major secondary efficacy endpoints of this study were:

- Change from baseline to months 6, 12, and 18 in NIS-LL
- Change from baseline through month 18 in Sum 7 composite score as measured by nerve conduction studies (NCS), vibration detection threshold (VDT) and heart rate response to deep breathing (HRDB) (i.e. assessment of large fiber function)
-  Change  from  baseline  through  month  18  in  heat  pain  and  cooling  thresholds  as  measured  by Quantitative Sensory Testing (QST) utilizing CASE IV (i.e. assessment of small fiber function)
- Change from baseline through month 18 in the modified Body Mass Index (mBMI)
-  TTR  stabilisation  through  Month  18  as  measured  by  a  validated  immunoturbidimetric  stabilisation assay

## Sample size

The  sample  size  for  the  trial  was  based  on  the  need  to  assess  a  treatment  group  effect  whereby tafamidis  demonstrated  superiority  over  placebo.  The  sample  size  was  based  on  the  co-primary endpoints of: 1) the categorical response to treatment after 18 months of therapy in the NIS-LL; and 2) the change from baseline to month 18 in the TQOL score as measured by the Norfolk QOL-DN. For the NIS-LL categorical responder analysis, assuming a significance level of 0.05 (2-sided), the power of the test of 90%, response rates of 20% for placebo and 50% for tafamidis, a sample size of 58 per treatment  arm  was  required  to  achieve  statistical  significance.  For  the  Norfolk  QOL-DN  (TQOL),  58 patients  per  group  provided  at  least  90%  power  to  detect  a  true  difference  of  0.6  SD  between  the groups with a significance level of 0.05 (2-sided), where SD was the square root mean squared error of  the  ANCOVA  model  for  change  from  baseline  scores.  A  5  to  10%  dropout  rate  was  assumed.

<div style=\"page-break-after: always\"></div>

Therefore,  the  sample  size  required  for  this  study  was  increased  to  61-64  patients  per  arm  to accommodate for a loss to follow-up.

## Randomisation

All patients were randomly assigned in a 1:1 ratio, in randomisation blocks of four, to receive either the tested drug or matching placebo. Interactive voice response system (IVRS) was used to randomise patients to treatment and to assign study identification numbers. The centralized randomisation was stratified by centre.

## Blinding (masking)

The  study  was  conducted  in  a  double-blind  fashion.  Both  tafamidis  and  placebo  were  supplied  as opaque oblong soft gelatin capsules, identical in appearance; packaging of study medication ensured blinding was maintained for both study participants and investigational staff.

## Statistical methods

The following populations were analysed in study Fx-005:

The Intent-to-Treat (ITT) Population was defined as all randomised patients who received at least one dose  of  study  medication  (tafamidis  or  placebo)  and  who  had  at  least  one  post  baseline  efficacy assessment for both the NIS-LL and the Norfolk QOL-DN or who discontinued study due to death or liver transplantation.

The Efficacy Evaluable Population comprised all ITT patients who had non-missing Month 18 NIS-LL and TQOL scores, who took at least 80% of the prescribed study medication and who had no major protocol  violations  that  may  have  impacted  the  assessment  of  efficacy.  The  co-primary  efficacy analysis was conducted on the Efficacy Evaluable Population, as supportive assessments of the ITT coprimary outcomes.

The  Safety  Population  comprised  all  randomised  patients  who  received  at  least  one  dose  of  study medication (tafamidis or placebo). All safety analyses were conducted on the Safety population.

The primary analysis of the co-primary efficacy endpoints and the pre-specified secondary analysis - a sensitivity  analysis  of  the  NIS-LL  in  which  response  was  imputed  for  patients  who  underwent  liver transplantation were based on the ITT population.  The pre-specified secondary analysis - an analysis in patients with non-missing NIS-LL and TQOL scores at Month 18 and no major protocol violations was based on the Efficacy Evaluable Population.

Superior  treatment  efficacy  of  tafamidis  compared  to  placebo  was  demonstrated  if  statistically significant (2-sided; alpha of 0.05) treatment differences favouring tafamidis were demonstrated for each of the co-primary endpoints. The co-primary efficacy analyses were:

Neuropathy  Impairment  Score  -  Lower  Limb  (NIS-LL)  response  to  treatment  at  month  18:  a  Chisquare test for proportions was used to compare NIS-LL response rates between treatment groups. For patients with post-baseline NIS-LL assessments but no assessment at Month 18, the last observation carried  forward  (LOCF)  method  was  used  to  impute  missing  data  at  Month  18.  Patients  who discontinued prior to the 18-month time point due to liver transplantation or death were categorized as non-responders in the primary analysis of NIS-LL.

<div style=\"page-break-after: always\"></div>

Change  from  baseline  to  18  months  in  the  Total  Quality  of  Life  (TQOL)  score  as  measured  by  the Norfolk  Quality  of  Life  -  Diabetic  Neuropathy  (QOL-DN)  Questionnaire:  an  analysis  of  covariance (ANCOVA) with baseline as covariate was used to compare TQOL scores between treatment groups. For patients with post-baseline Norfolk QOL-DN assessments but no assessment at month 18, LOCF was  used  to  impute  missing  data  at  Month  18.  For  patients  without  post-baseline  Norfolk  QOL-DN assessments,  the  mean  change  from  baseline  at  Month  18  for  patients  who  had  post-baseline assessments was used to impute the change from baseline within each treatment group.

## Results

## Participant flow

The study participant flow is shown in the figure 3:

Fig.3

<!-- image -->

VDT=vibration detection threshold; IE = inclusion/exclusion criteria; AE = adverse event.

Patient completion rate and reasons for discontinuation are presented in table 12.

<div style=\"page-break-after: always\"></div>

Table 12

|                                        | Nuinber (%) of patients   | Nuinber (%) of patients   |
|----------------------------------------|---------------------------|---------------------------|
|                                        | Tafamidis (N=65)          | Placebo (N=63)            |
| Total patients completing study        | 47 (72.3)                 | 44 (69.8)                 |
| Total patients discontinued from study | 18 (27.7)                 | 19 (30.2)                 |
| Reason for discontinuation             |                           |                           |
| Adverse event                          | 4 (6.2)                   | 3 (4.8)                   |
| Patient withdrew consent               | 1 (1.5)                   | 2 (3.2)                   |
| Negative genotype                      | 0                         | 1 (1.6)                   |
| Liver transplantation                  | 13 (20.0)                 | 13 (20.6)                 |

Study completion rates and reasons for premature discontinuation were similar between the treatment groups. The incidence of liver transplant was the same between both groups. The majority of patients (19 of 26) underwent liver transplantation prior to the 12-month assessment. Most patients enrolled were already on liver transplant lists and the time to transplant was similar between the treatment groups;  the  proportion  of  patients  on  the  liver  transplant  list  at  the  time  of  enrolment  was  71% (46/65) in the tafamidis group and 67% (42/63) of patients in the placebo group. There did not appear to be any association between treatment group and the time to liver transplant in this study.

## Recruitment

162 subjects were screened across nine investigational centers; 34 subjects were considered screen failures and 128 subjects were randomized in eight of these centres and were treated with at least one dose of study medication. The first patient was randomized (enrolled) in the study on 16 Jan 2007; the last patient was randomized on 12 Dec 2007. The last double-blind phase patient study visit was on 26 May 2009.

## Conduct of the study

The important protocol violations and deviations were observed in four patients treated with tafamidis and 6 patients on placebo and comprised low compliance rate, receipt of wrong drug kit (i.e. incorrect study  medication),  pregnancy,  negative  amyloid  biopsy  and  negative  genotype.  Patients  with  major protocol deviations were excluded from the efficacy evaluable population (two patients with negative amyloid biopsies, one patient who received wrong medication and one pregnant patient).

The original study protocol Fx-005 was dated 10 August 2006. There were seven global amendments and  four  country-specific  (Germany)  amendments.  There  were  a  few  minor  changes  made  to  the analysis from the pre-specified SAP; the SAP was finalized and approved prior to unblinding the study treatment allocation codes. These post hoc efficacy analyses were performed after data availability and unblinding in order to better understand study results. A number of additional safety analyses were not pre-specified in the final SAP (Version 2.0). These post hoc safety analyses were performed to further evaluate the safety profile of tafamidis.

No GCP inspection was conducted.

<div style=\"page-break-after: always\"></div>

## Baseline data

A summary of demographics and baseline disease characteristics for the ITT population is presented in table 13.

Table 13

|                                 | Tafamidis 20 mg 9=N   | Placebo N=61    | p-value   |
|---------------------------------|-----------------------|-----------------|-----------|
| Age, years                      |                       |                 |           |
| Mean (SD)                       | 39.8 (12.7)           | 38.4 (12.9)     |           |
| Median                          | 35.5                  | 34.0            |           |
| Range                           | 25, 74                | 22, 71          | 0.339     |
| Age group, n (%)                |                       |                 |           |
| ≤65 yr                          | 59 (92.2)             | 58 (95.1)       |           |
| >65 yr                          | 5 (7.8)               | 3 (4.9)         | 0.510     |
| Gender, n (%)                   |                       |                 |           |
| Female                          | 32 (50.0)             | 35 (57.4)       | 0.410     |
| Race, n (%)                     |                       |                 |           |
| Caucasian                       | 56 (87.5)             | 54 (88.5)       |           |
| Latin American                  | 6 (9.4)               | 6 (9.8)         |           |
| Not available                   | 2 (3.1)               | 1 (1.6)         | 0.736     |
| mBMI atscreening                |                       |                 |           |
| Mean (SD)                       | 1004.59 (165.2)       | 1011.54 (212.9) |           |
| Median                          | 974.7                 | 983.8           |           |
| Range                           | 655.1, 1510.4         | 533.3, 1581.5   | 0.739     |
| Height, cm                      |                       |                 |           |
| Mean (SD)                       | 166.8 (10.1)          | 166.6 (11.2)    |           |
| Median                          | 167.0                 | 165.5           |           |
| Range                           | 147, 186              | 149, 191        | 0.843     |
| Weight, kg                      |                       |                 |           |
| Mean (SD)                       | 64.1 (11.9)           | 63.9 (13.4)     |           |
| Median                          | 62.0                  | 64.0            |           |
| Range                           | 39, 91                | 32,100          | 0.962     |
| Baseline NIS-LL (scale O to S8) |                       |                 |           |
| Mean (SD)                       | 8.4 (11.4)            | 11.4 (13.5)     |           |
| Median                          | 4.0                   | 6.0             |           |
| Range                           | 0, 54                 | 0,57            | 0.089     |
| Baseline TQOL (scale -2 to 138) |                       |                 |           |
| Mean (SD)                       | 27.3 (24.2)           | 30.8 (26.7)     |           |
| Median                          | 19.0                  | 22.0            |           |
| Range                           | -1, 110               | 0,107           | 0.401     |
| Duration of symptoms, months    |                       |                 |           |
| Mean (SD)                       | 47.0 (48.4)           | 34.7 (32.9)     |           |
| Median                          | 28.0                  | 21.0            |           |
| Range                           | 3, 268                | 2, 133          | 0.319     |

P-values based on Wilcoxon's rank sum test for continuous variables and Cochran-MantelHaenszel test for categorical variables.

Baseline characteristics were also examined for a subgroup of patients (N=13 in each treatment group) who underwent liver transplantation. While there were no statistically significant differences between the  treatment  groups  for  any  baseline  characteristic  in  this  subgroup,  median  symptom  duration  in transplant patients was longer (medians of 57.9 and 34.5 months in the tafamidis and placebo groups, respectively). Consistent with this observation, transplant patients had higher baseline NIS-LL scores (median of 10.0) than non-transplant patients (medians of 4.0).

The  ATTR-PN-related  medical  histories  were  similar  between  the  treatment  groups.  The  ATTR-PN related medical histories are summarized in table 14. Most patients had both peripheral and autonomic

<div style=\"page-break-after: always\"></div>

neuropathy  disorders  reported  in  their  medical  histories  (tafamidis:  73.4%;  placebo:  82.0%). Approximately 20% of patients experienced only peripheral neuropathy disorders (23.4%; and 18.0%, respectively).  Few  patients  experienced  only  autonomic  neuropathy  disorders  (3.1%  and  0.0%, respectively).

Table 14 Most Common (≥10% of Patients in Either Group) ATTR-PNreiatea viedical History Preferred Terms (ITT Population) (Study Fx-005)

| Preferred Tern                     | Tafamidis 20 mg N=64 n (%)   | Placebo N=61 n (%)   | All Patients N=125 n (%)   |
|------------------------------------|------------------------------|----------------------|----------------------------|
| Paresthesia                        | 40 (62.5)                    | 41 (67.2)            | 81 (64.8)                  |
| Weight decreased                   | 23 (35.9)                    | 22 (36.1)            | 45 (36.0)                  |
| Neuralgia                          | 21 (32.8)                    | 20 (32.8)            | 41 (32.8)                  |
| Early satiety                      | 17 (26.6)                    | 14 (23.0)            | 31 (24.8)                  |
| Constipation                       | 15 (23.4)                    | 18 (29.5)            | 33 (26.4)                  |
| Hypoesthesia                       | 15 (23.4)                    | 14 (23.0)            | 29 (23.2)                  |
| Sensory loss                       | 15 (23.4)                    | 15 (24.6)            | 30 (24.0)                  |
| Diarrhea                           | 12 (18.8)                    | 14 (23.0)            | 26 (20.8)                  |
| Anorexia                           | 12 (18.8)                    | 8 (13.1)             | 20 (16.0)                  |
| Urinary retention                  | 10 (15.6)                    | 4 (6.6)              | 14 (11.2)                  |
| Orthostatichypotension             | 8 (12.5)                     | 8 (13.1)             | 16 (12.8)                  |
| Dizziness                          | 8 (12.5)                     | 15 (24.6)            | 23 (18.4)                  |
| Gastrointestinal motility disorder | 7 (10.9)                     | 12 (19.7)            | 19 (15.2)                  |
| Nausea                             | 7 (10.9)                     | 11 (18.0)            | 18 (14.4)                  |
| Vomiting                           | 7 (10.9)                     | 9 (14.8)             | 16 (12.8)                  |
| Fatigue                            | 7 (10.9)                     | 6 (9.8)              | 13 (10.4)                  |
| Pain in extremity                  | 7 (10.9)                     | 6 (9.8)              | 13 (10.4)                  |
| Neuropathy peripheral              | 7 (10.9)                     | 7 (11.5)             | 14 (11.2)                  |
| Muscular weakness                  | 6 (9.4)                      | 8 (13.1)             | 14 (11.2)                  |
| Erectile dysfunction               | 6 (9.4)                      | 8 (13.1)             | 14 (11.2)                  |

Preferred terms were coded using MedDRA v.10. Patients with multiple preferred terms were counted only once.

2 Preferred term codes to alternating diarrhea and constipation.

## Numbers analysed

Definitions of the ITT, Efficacy Evaluable and Safety populations are provided in section 'Statistical methods'. Table 15 below summarises numbers analysed within each of the populations.

Table 15

|                                  | Tafamidis (N=65) n (%)   | Placebo (N=63) n (%)   | Total (N=128) n (%)   |
|----------------------------------|--------------------------|------------------------|-----------------------|
| Intent-to-Treat (ITT) Population | 64 (98.5%)               | 61 (96.8%)             | 125 (97.7%)           |
| Efficacy Evaluable Population    | 45 (69.2%)               | 42 (66.7%)             | 87 (68%)              |
| Safety Population                | 65 (100%)                | 63 (100%)              | 128 (100%)            |

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

Results obtained on the two co-primary criteria (NIS-LL responders and TQOL) for the ITT primary analysis are presented in table 16 below.

Table 16

| Descriptive statistics and estimate variability   | Treatment group                                           | Tafamidis                  | Placebo                    |
|---------------------------------------------------|-----------------------------------------------------------|----------------------------|----------------------------|
| Descriptive statistics and estimate variability   | Number of subjects                                        | 64                         | 61                         |
| Descriptive statistics and estimate variability   | NIS-LL Number (%) of responders                           | 45.3%                      | 29.5%                      |
| Descriptive statistics and estimate variability   | 95% CI                                                    | 33.1%;57.5%                | 18.1%; 41.0%               |
| Descriptive statistics and estimate variability   | TQOL Mean change from baseline Median LSMean (SE)* 95% CI | 2.4 1.0 2.0 (2.3) -2.6;6.6 | 6.9 6.0 7.2 (2.4) 2.6;11.9 |
| Effect estimate per comparison                    | NIS-LL                                                    | Comparison groups          | Tafamidis vs placebo       |
| Effect estimate per comparison                    | NIS-LL                                                    | P-value                    | 0.0682                     |
| Effect estimate per comparison                    | TQOL                                                      | Comparison groups          | Tafamidis vs placebo       |
| Effect estimate per comparison                    | TQOL                                                      | P-value                    | 0.1157                     |

*Baseline Least Square Mean (standard error)

Neuropathy Impairment Score - Lower Limb (NIS-LL)

Higher scores on the NIS-LL indicate more pronounced impairment, i.e. increase from baseline in the score  reflects  a  worsening  in  impairment.  Responders  versus  non-responders  were  defined  with respect to change on the NIS-LL score, worsening ≥ 2 units being the cut-off for non-responders. This worsening in the NIS-LL was pre-defined as clinically meaningful. At the primary timepoint (Month 18), 45.3% of patients in the tafamidis group had an increase in the NIS-LL of &lt;2, compared to 29.5% patients  in  the  placebo  group,  but  the  differences  between  groups  were  not  statistically  significant (p=0.068).

Norfolk QOL-DN (total quality of life, TQOL)

Higher scores on the Norfolk QOL-DN TQOL indicate worse quality of life, i.e. increases from baseline in the score reflect a worsening in quality of life. The placebo-treated patients in the ITT population had progressively worse TQOL scores than tafamidis-treated patients, but the differences between groups were not statistically significant (7.2 versus 2.0, p-value=0.1).

These results are reflected in section 5.1 of the SmPC.

<div style=\"page-break-after: always\"></div>

## Secondary endpoints

## NIS-LL changes from baseline to on-treatment visits

In addition to the categorical analysis of the NIS-LL, a continuous change from baseline analysis was performed. Figure 4 provides a descriptive presentation (LSMeans +SE) of the NIS-LL change scores over time for each treatment group, including assessment at the month 18 primary time point. This analysis provides a picture of the time-course of the treatment effect.

Figure 4

<!-- image -->

Months From Initiation of Treatment

Over  the  18-month  treatment  period,  the  tafamidis  group  demonstrated  significantly  less  average worsening of impairment (as measured by LSMean changes in the NIS-LL) compared to the placebo group (overall treatment effect p-value=0.0247), with the differences statistically significant by month 12. By month 18, the LSMean (SE) difference in NIS-LL between the placebo group and the tafamidis group  was  3.024  (1.351),  95%CI  (-5.699,  -0.348),  p-value=0.0271.  Of  note,  the  CHMP  considered that the relevant analysis for this endpoint is the 'Primary Imputation Results for NIS-LL Change from Baseline Analysis' (presented in section Ancillary analyses, table 21).

## Large fibre function

Composite scores of large fiber function (nerve conduction, vibration threshold and heart rate response to deep breathing - HRDB) were examined over the 18-month treatment period. The LSMean changes from baseline to on-treatment time points for large fiber function are shown in figure 5 below. The outcomes  indicated  that  worsening  in  large  fibre  function  over  18  months  was  approximately  50% slower in the tafamidis group than in the placebo group.

<div style=\"page-break-after: always\"></div>

Fig. 5 Large Fiber Function LSMean (SE) Change from Baseline to On-Treatment Visits Σ 7 NTs nds (ITT Population, Observed Case) (Study Fx-005)

<!-- image -->

## Small fibre function

With respect to small fiber function, the treatment group differences also became apparent as early as the 6 month study visit (see fig.6). The outcomes indicate that worsening in small fibre function over 18 months was approximately 80% slower in the tafamidis group than in the placebo group.

Fig. 6 Small Fibre Function LSMean (SE) Change from Baseline to On-Treatment Visits Σ 3 NTSF nds Over Time (ITT Population, Observed Case) (Study Fx-005)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Modified body mass index (mBMI)

Over  the  course  of  the  18-month  treatment  period,  patients  treated  with  placebo  experienced  an average reduction in their mBMI at each on-treatment study visit; in contrast, patients treated with tafamidis  experienced  an  average  increase  in  their  mBMI  at  each  on-treatment  study  visit  (by  18 months, there was a 73.1-point difference between the tafamidis (LSMean [±SE] change from baseline of  39.3±11.5)  and  placebo  (-33.8±11.8)  groups.  The  placebo  group  demonstrated  an  average worsening in mBMI while the tafamidis group demonstrated an average improvement in mBMI; these differences  between  the  treatment  groups  were  statistically  significant  (p-value&lt;0.0001).  The  CHMP considered that there might be limitations to interpreting the mBMI changes, but was of the view that this  criterion  is  easily  measurable  and  might  be  of  interest  to  evaluate  progression  of  the  disease, particularly the nutritional status.

Results  of  the  major  secondary  endpoints  (NIS-LL  change  from  baseline,  large  fibre  change  from baseline, small fibre change from baseline and mBMI change from baseline) are reflected in section 5.1 of the SmPC.

## TTR stabilisation

TTR  stabilization  (as  defined  by  the  TTR  stabilization  assay)  was  observed  in  97.9%  of  patients  on tafamidis  and  in  no  patients  on  placebo  at  18  months.  Most  patients  with  stabilized  TTR  had measureable concentrations of tafamidis.

The TTR stabilisation status of the population at different time points is presented in table 17 below.

Table 17 TTR Stabilization Status (ITT Population) (Study Fx-005)

|          |                                                                 | Tafamidis 20 mg N=64     | Placebo N=61           | Tafamidis vs. Placebo   |
|----------|-----------------------------------------------------------------|--------------------------|------------------------|-------------------------|
| Week 8   | #Stabilized/#Observations (%) 95% confidence interval p-valuel  | 62/63 (98.4) 95.3%, 100% | 4/60 (6.7) 0.4%, 13.0% | <0.0001                 |
| Month 6  | #Stabilized/# Observations (%) 95% confidence interval p-value1 | 59/59 (100) 100%,100%    | 3/58 (5.2) 0.0%, 10.9% | <0.0001                 |
| Month 12 | #Stabilized/# Observations (%) 95% confidence interval p-value1 | 47/48 (97.9) 93.9%,100%  | 1/50 (2.0) 0.0%, 5.9%  | <0.0001                 |
| Month 18 | #Stabilized/# Observations (%) 95% confidence interval p-value1 | 47/48 (97.9) 93.9%, 100% | 0/44 (0.0) 0.0%, 0.0%  | <0.0001                 |

Based on Chi-square test for proportions.

## Ancillary analyses

The majority of patients enrolled into this study were on a liver transplant list. Liver transplantation in this patient population is performed as early as possible in the course of the disease when an organ match becomes available. The time to event analysis suggested that patients in both treatment groups who  underwent  liver  transplantation  in  the  trial  did  so  not  because  of  disease  progression  or  as

<div style=\"page-break-after: always\"></div>

'salvage' therapy, but when a match was available, and thus categorizing liver transplant patients as non-responders in the primary analysis of the NIS-LL was a conservative statistical approach (i.e. a worst-case analysis). With that consideration, the statistical plan pre-specified a secondary sensitivity analysis imputing the effect of liver transplantation on the NIS-LL response.

Results of this sensitivity analysis are presented in table 18 below:

Table 18

| Descriptive statistics and estimate variability   | Treatment group                 | Tafamidis         | Placebo              |
|---------------------------------------------------|---------------------------------|-------------------|----------------------|
| Descriptive statistics and estimate variability   | Number of subjects              | 64                | 61                   |
| Descriptive statistics and estimate variability   | NIS-LL Number (%) of responders | 54.7%             | 36.1%                |
| Descriptive statistics and estimate variability   | 95% CI                          | 42.5%; 66.9%      | 24.0%; 48.1%         |
| Descriptive statistics and estimate variability   | NIS-LL                          | Comparison groups | Tafamidis vs placebo |
| Descriptive statistics and estimate variability   |                                 | P-value           | 0.0367               |

As  requested  by  the  CHMP,  the  applicant  also  provided  additional  analyses  regarding  the  NIS-LL responders (table 19 and 20) as well as the mean NIS-LL change from baseline (tables 21 and 22). The  analyses  were  based  on  multiple  imputation  and  missing  values  imputed  according  to  their respective treatment group or according to placebo (see Discussion).

Table 19 Primary Multiple Imputation Results for NIS-LL Responder Analysis

|   Multiple Imputation Batch Run* |   Efficacy Estimate |   Standard Error | Confidence Interval   |   p-value |
|----------------------------------|---------------------|------------------|-----------------------|-----------|
|                                1 |               0.146 |            0.095 | -0.041, 0.332         |     0.125 |
|                                2 |               0.144 |            0.095 | -0.042, 0.331         |     0.13  |
|                                3 |               0.146 |            0.095 | -0.041, 0.333         |     0.125 |

* Each batch run represents the results combined from 1000 multiply imputed data sets.

Table 20 Sensitivity Multiple Imputation Results for NIS-LL Responder Analysis, All Missing Values Imputed Using Placebo Model

|   Multiple Imputation Batch Run* |   Efficacy Estimate |   Standard Error | Confidence Interval   |   p-value |
|----------------------------------|---------------------|------------------|-----------------------|-----------|
|                                1 |               0.139 |            0.094 | -0.046, 0.324         |     0.14  |
|                                2 |               0.138 |            0.094 | -0.046, 0.323         |     0.142 |
|                                3 |               0.139 |            0.095 | -0.046, 0.325         |     0.141 |

* Each batch run represents the results combined from 1000 multiply imputed data sets.

<div style=\"page-break-after: always\"></div>

Table 21 Primary Imputation Results for NIS-LL Change from Baseline Analysis

|   Multiple Imputation Batch Run* |   Efficacy Estimate |   Standard Error | Confidence Interval   |   p-value |
|----------------------------------|---------------------|------------------|-----------------------|-----------|
|                                1 |              -2.787 |            1.345 | -5.423, -0.151        |     0.041 |
|                                2 |              -2.815 |            1.351 | -5.464, -0.166        |     0.04  |
|                                3 |              -2.798 |            1.347 | -5.438, -0.157        |     0.04  |

* Each batch run represents the results combined from 1000 multiply imputed data sets.

Table 22 Sensitivity Multiple Imputation Results for NIS-LL Change from Baseline Analysis, All Missing Values Imputed Using Placebo Model

Each batch run represents the results combined from 1000 multiply imputed data sets.

|   Multiple Imputation Batch Run* |   Efficacy Estimate |   Standard Error | Confidence Interval   |   p-value |
|----------------------------------|---------------------|------------------|-----------------------|-----------|
|                                1 |              -2.31  |            1.429 | -5.112, 0.491         |     0.109 |
|                                2 |              -2.333 |            1.427 | -5.130, 0.464         |     0.105 |
|                                3 |              -2.319 |            1.429 | -5.119, 0.481         |     0.108 |

Results  in  the  Efficacy  Evaluable  Population,  i.e.  from  a  pre-specified  secondary  analysis  in  patients with non-missing NIS-LL and TQOL scores at Month 18 and no major protocol violations are presented in table 23 below.

Table 23

| Descriptive statistics and estimate variability   | Treatment group                 | Tafamidis         | Placebo              |
|---------------------------------------------------|---------------------------------|-------------------|----------------------|
| Descriptive statistics and estimate variability   | Number of subjects              | 45                | 42                   |
| Descriptive statistics and estimate variability   | NIS-LL Number (%) of responders | 60.0%             | 38.1%                |
| Descriptive statistics and estimate variability   | 95% CI                          | 45.7%; 74.3%      | 23.4%; 52.8%         |
| Descriptive statistics and estimate variability   | TQOL LSMean (SE)*               | 0.1 (3.0)         | 8.9 (3.1)            |
| Descriptive statistics and estimate variability   | 95% CI                          | -5.8, 6.0         | 2.8, 15.0            |
| Effect estimate per comparison                    | NIS-LL                          | Comparison groups | Tafamidis vs placebo |
| Effect estimate per comparison                    |                                 | P-value           | 0.04                 |
| Effect estimate per comparison                    | TQOL                            | Comparison groups | Tafamidis vs placebo |
| Effect estimate per comparison                    |                                 | P-value           | 0.045                |

*Baseline Least Square Mean (standard error)

In  the  efficacy  evaluable  population,  assessment  of  the  NIS-LL  response  at  Month  18  demonstrated that 60.0% of patients in the tafamidis group had no disease progression at Month 18, compared to 38.1%  patients  in  the  placebo  group  (p=0.04).  The  results  for  TQOL  for  the  efficacy  evaluable population were also statistically significant at 18 months (0.1 in the tafamidis group versus 8.9 in the placebo group, p=0.045).

These results are reflected in section 5.1 of the SmPC.

<div style=\"page-break-after: always\"></div>

## Summary of the main study

The  following  table  summarises  the  efficacy  results  from  the  main  study  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 24 Summary of Efficacy for trial Fx-005

| Title: Safety and Efficacy of Orally Administered Tafamidis (Fx-1006A) in Patients with Familial Amyloid Polyneuropathy (FAP): A Phase II/III, Randomized, Double-Blind, Placebo- Controlled Study   | Title: Safety and Efficacy of Orally Administered Tafamidis (Fx-1006A) in Patients with Familial Amyloid Polyneuropathy (FAP): A Phase II/III, Randomized, Double-Blind, Placebo- Controlled Study                                                                                                                                                                                                                        | Title: Safety and Efficacy of Orally Administered Tafamidis (Fx-1006A) in Patients with Familial Amyloid Polyneuropathy (FAP): A Phase II/III, Randomized, Double-Blind, Placebo- Controlled Study                                                                                                                                                                                                                        | Title: Safety and Efficacy of Orally Administered Tafamidis (Fx-1006A) in Patients with Familial Amyloid Polyneuropathy (FAP): A Phase II/III, Randomized, Double-Blind, Placebo- Controlled Study                                                                                                                                                                                                                        | Title: Safety and Efficacy of Orally Administered Tafamidis (Fx-1006A) in Patients with Familial Amyloid Polyneuropathy (FAP): A Phase II/III, Randomized, Double-Blind, Placebo- Controlled Study                                                                                                                                                                                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                     | Fx-005                                                                                                                                                                                                                                                                                                                                                                                                                    | Fx-005                                                                                                                                                                                                                                                                                                                                                                                                                    | Fx-005                                                                                                                                                                                                                                                                                                                                                                                                                    | Fx-005                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                               | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study                                                                                                                                                                                                                                                                                                                                                           | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study                                                                                                                                                                                                                                                                                                                                                           | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study                                                                                                                                                                                                                                                                                                                                                           | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study                                                                                                                                                                                                                                                                                                                                                           |
| Design                                                                                                                                                                                               | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                   | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                                                                   | 18 months Not applicable                                                                                                                                                                                                                                                                                                                                                                                                  | 18 months Not applicable                                                                                                                                                                                                                                                                                                                                                                                                  |
| Design                                                                                                                                                                                               | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                                                                                                 | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Design                                                                                                                                                                                               | Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                              | Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                              | Not applicable (extension study Fx-006 - 12 months)                                                                                                                                                                                                                                                                                                                                                                       | Not applicable (extension study Fx-006 - 12 months)                                                                                                                                                                                                                                                                                                                                                                       |
| Hypothesis                                                                                                                                                                                           | Superiority                                                                                                                                                                                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                                                                                                                                                                               | Superiority                                                                                                                                                                                                                                                                                                                                                                                                               |
| Treatments groups                                                                                                                                                                                    | Tafamidis                                                                                                                                                                                                                                                                                                                                                                                                                 | Tafamidis                                                                                                                                                                                                                                                                                                                                                                                                                 | Tafamidis 20 mg (1 capsule) once daily for 18 months; number of randomized patients: 65                                                                                                                                                                                                                                                                                                                                   | Tafamidis 20 mg (1 capsule) once daily for 18 months; number of randomized patients: 65                                                                                                                                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                                                    | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                   | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                   | Matching placebo once daily for 18 months; number of randomized patients: 63                                                                                                                                                                                                                                                                                                                                              | Matching placebo once daily for 18 months; number of randomized patients: 63                                                                                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                                                                                                                                                                            | Co-Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                       | NIS-LL                                                                                                                                                                                                                                                                                                                                                                                                                    | Neuropathy Impairment Score - Lower Limb (NIS-LL) response to treatment at Month 18. Responders were defined as patients with no disease progression as measured by an increase from baseline in NIS-LL of less than 2 points.                                                                                                                                                                                            | Neuropathy Impairment Score - Lower Limb (NIS-LL) response to treatment at Month 18. Responders were defined as patients with no disease progression as measured by an increase from baseline in NIS-LL of less than 2 points.                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                            | Co-Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                       | TQOL                                                                                                                                                                                                                                                                                                                                                                                                                      | Change from baseline to 18 months in the Total Quality of Life (TQOL) score as measured by the Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Questionnaire.                                                                                                                                                                                                                                                      | Change from baseline to 18 months in the Total Quality of Life (TQOL) score as measured by the Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Questionnaire.                                                                                                                                                                                                                                                      |
| Database lock                                                                                                                                                                                        | 30 June 2009                                                                                                                                                                                                                                                                                                                                                                                                              | 30 June 2009                                                                                                                                                                                                                                                                                                                                                                                                              | 30 June 2009                                                                                                                                                                                                                                                                                                                                                                                                              | 30 June 2009                                                                                                                                                                                                                                                                                                                                                                                                              |
| Results and Analysis                                                                                                                                                                                 | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                      | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                      |
| Analysis description                                                                                                                                                                                 | Primary Analysis of the co-primary endpoints                                                                                                                                                                                                                                                                                                                                                                              | Primary Analysis of the co-primary endpoints                                                                                                                                                                                                                                                                                                                                                                              | Primary Analysis of the co-primary endpoints                                                                                                                                                                                                                                                                                                                                                                              | Primary Analysis of the co-primary endpoints                                                                                                                                                                                                                                                                                                                                                                              |
| Analysis population and time point description                                                                                                                                                       | Intent-to-Treat (ITT) - all randomized patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment for both NIS-LL and Norfolk QOL-DN or discontinued the study due to death or liver transplant. Both co-primary endpoints were evaluated in the ITT population using the last observation carried forward (LOCF) to impute missing data at Month 18. time point. | Intent-to-Treat (ITT) - all randomized patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment for both NIS-LL and Norfolk QOL-DN or discontinued the study due to death or liver transplant. Both co-primary endpoints were evaluated in the ITT population using the last observation carried forward (LOCF) to impute missing data at Month 18. time point. | Intent-to-Treat (ITT) - all randomized patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment for both NIS-LL and Norfolk QOL-DN or discontinued the study due to death or liver transplant. Both co-primary endpoints were evaluated in the ITT population using the last observation carried forward (LOCF) to impute missing data at Month 18. time point. | Intent-to-Treat (ITT) - all randomized patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment for both NIS-LL and Norfolk QOL-DN or discontinued the study due to death or liver transplant. Both co-primary endpoints were evaluated in the ITT population using the last observation carried forward (LOCF) to impute missing data at Month 18. time point. |
| Descriptive statistics and estimate variability                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability                                                                                                                                                      | Analysis of both variables at Treatment group                                                                                                                                                                                                                                                                                                                                                                             | Analysis of both variables at Treatment group                                                                                                                                                                                                                                                                                                                                                                             | the Month 18 Tafamidis                                                                                                                                                                                                                                                                                                                                                                                                    | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability                                                                                                                                                      | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                        | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                        | 64                                                                                                                                                                                                                                                                                                                                                                                                                        | 61                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability                                                                                                                                                      | NIS-LL Number (%) of responders                                                                                                                                                                                                                                                                                                                                                                                           | NIS-LL Number (%) of responders                                                                                                                                                                                                                                                                                                                                                                                           | 45.3%                                                                                                                                                                                                                                                                                                                                                                                                                     | 29.5%                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability                                                                                                                                                      | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                    | 33.1%;57.5%                                                                                                                                                                                                                                                                                                                                                                                                               | 18.1%; 41.0%                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                                 | TQOL Mean change from baseline Median LSMean (SE)* 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 2.4 1.0 2.0 (2.3) -2.6;6.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 6.9 6.0 7.2 (2.4) 2.6;11.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effect estimate per comparison                  | NIS-LL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Tafamidis vs placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | NIS-LL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0682                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Effect estimate per comparison                  | TQOL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Tafamidis vs placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | TQOL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.1157                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Notes                                           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Analysis description                            | Pre-specified secondary analysis - a sensitivity analysis of the NIS- LL in which response was imputed for patients who underwent liver                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Pre-specified secondary analysis - a sensitivity analysis of the NIS- LL in which response was imputed for patients who underwent liver                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Pre-specified secondary analysis - a sensitivity analysis of the NIS- LL in which response was imputed for patients who underwent liver                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Analysis population and time point description  | transplantation Intent-to-Treat (ITT) - all randomized patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment for both NIS-LL and Norfolk QOL-DN or discontinued the study due to death or liver transplant. Analysis at the Month 18 time point.                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | transplantation Intent-to-Treat (ITT) - all randomized patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment for both NIS-LL and Norfolk QOL-DN or discontinued the study due to death or liver transplant. Analysis at the Month 18 time point.                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | transplantation Intent-to-Treat (ITT) - all randomized patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment for both NIS-LL and Norfolk QOL-DN or discontinued the study due to death or liver transplant. Analysis at the Month 18 time point.                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Tafamidis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 64                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 61                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | NIS-LL Number (%) of responders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 54.7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 36.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 42.5%; 66.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 24.0%; 48.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | NIS-LL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Tafamidis vs placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | NIS-LL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.0367                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Notes                                           | The majority of patients enrolled into this study were on a liver transplant list. Liver transplantation in this patient population is performed as early as possible in the course of disease when an organ match becomes available. The time to event analysis suggested that patients in both treatment groups who underwent liver transplantation in the current trial did so not because of disease progression or as 'salvage' therapy, but when a match was available, and thus categorizing liver transplant patients as non-responders in the primary analysis of the NIS-LL was a very conservative statistical approach (i.e., a worst-case analysis). With that consideration in mind, the statistical plan pre-specified a sensitivity analysis imputing the effect of liver | The majority of patients enrolled into this study were on a liver transplant list. Liver transplantation in this patient population is performed as early as possible in the course of disease when an organ match becomes available. The time to event analysis suggested that patients in both treatment groups who underwent liver transplantation in the current trial did so not because of disease progression or as 'salvage' therapy, but when a match was available, and thus categorizing liver transplant patients as non-responders in the primary analysis of the NIS-LL was a very conservative statistical approach (i.e., a worst-case analysis). With that consideration in mind, the statistical plan pre-specified a sensitivity analysis imputing the effect of liver | The majority of patients enrolled into this study were on a liver transplant list. Liver transplantation in this patient population is performed as early as possible in the course of disease when an organ match becomes available. The time to event analysis suggested that patients in both treatment groups who underwent liver transplantation in the current trial did so not because of disease progression or as 'salvage' therapy, but when a match was available, and thus categorizing liver transplant patients as non-responders in the primary analysis of the NIS-LL was a very conservative statistical approach (i.e., a worst-case analysis). With that consideration in mind, the statistical plan pre-specified a sensitivity analysis imputing the effect of liver |
| Analysis description                            | Pre-specified secondary analysis - analysis in patients with non- missing NIS-LL and TQOL scores at Month 18 and no major protocol violations (Efficacy Evaluable population)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Pre-specified secondary analysis - analysis in patients with non- missing NIS-LL and TQOL scores at Month 18 and no major protocol violations (Efficacy Evaluable population)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Pre-specified secondary analysis - analysis in patients with non- missing NIS-LL and TQOL scores at Month 18 and no major protocol violations (Efficacy Evaluable population)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Analysis population and time point description  | Efficacy Evaluable population - all ITT patients with non-missing Month 18 NIS-LL and TQOL scores, who took at least 80% of study medication, and had no major protocol violations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Efficacy Evaluable population - all ITT patients with non-missing Month 18 NIS-LL and TQOL scores, who took at least 80% of study medication, and had no major protocol violations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Efficacy Evaluable population - all ITT patients with non-missing Month 18 NIS-LL and TQOL scores, who took at least 80% of study medication, and had no major protocol violations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate             | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Tafamidis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate             | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 45                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| variability                    | NIS-LL Number (%) of responders   | 60.0%             | 38.1%                |
|--------------------------------|-----------------------------------|-------------------|----------------------|
| variability                    | 95% CI                            | 45.7%; 74.3%      | 23.4%; 52.8%         |
| variability                    | TQOL LSMean (SE)*                 | 0.1 (3.0)         | 8.9 (3.1)            |
| variability                    | 95% CI                            | -5.8, 6.0         | 2.8, 15.0            |
| Effect estimate per comparison | NIS-LL                            | Comparison groups | Tafamidis vs placebo |
| Effect estimate per comparison | NIS-LL                            | P-value           | 0.04                 |
| Effect estimate per comparison | TQOL                              | Comparison groups | Tafamidis vs placebo |
| Effect estimate per comparison | TQOL                              | P-value           | 0.045                |
| Notes                          |                                   |                   |                      |

*Baseline Least Square Mean (standard error)

## Analysis performed across trials (pooled analyses and meta-analysis)

N.A.

## Clinical studies in special populations

N.A.

## Supportive studies

## Fx-006

This was an open-label extension to study Fx-005, of 12-month duration, evaluating long-term safety and clinical outcomes of tafamidis in patients with ATTR-PN.

The  objectives  of  the  study  were  to  evaluate  the  long-term  safety  and  tolerability  of  chronic administration of tafamidis in patients with ATTR-PN, to evaluate the long-term effects of tafamidis on disease progression in patients with ATTR-PN, to determine the pharmacodynamic (PD) stabilisation effect  of  tafamidis  on  human  V30M  TTR  and  to  obtain  additional  pharmacokinetic  (PK)  samples  for population PK analysis in this patient population.

Male  and  non-pregnant  female  patients  who  completed  the  month  18  visit  of  study  Fx-005  were eligible;  patients  who  had  undergone  liver  transplantation  could  not  be  enrolled.  All  patients  were treated  with  a  single  daily  dose  of  20  mg  tafamidis  for  12  months.  The  treatment  groups  were identified as 'tafamidis-tafamidis' and 'placebo-tafamidis', based on their treatment sequence.

Criteria  for  evaluation  used  in  the  study  were  consistent  with  those  used  in  the  pivotal  trial  and comprised  assessments  of  NIS-LL  (including  subscales),  NIS-LL  responders,  TQOL  and  individual domain scores of Norfolk Quality of Life - DN questionnaire, large fibre function, small fibre function, mBMI.  The  pharmacodynamic  endpoint  TTR  stabilisation  was  measured  at  months  6  and  12  by  a validated immunoturbidimetric assay.

The rate of disease progression as measured by the monthly rate of change in the various endpoints during the 12-month treatment (in study Fx-006) was compared with the rates of change during the

<div style=\"page-break-after: always\"></div>

first 18 months of treatment (in study Fx-005) for the tafamidis group, i.e. sustainability of treatment effect.

The  rate  of  disease  progression  during  12  months  of  tafamidis  treatment  (in  study  Fx-006)  was compared with the previous rate of change during 18 months of placebo treatment (in study Fx-005) for the placebo-tafamidis group, i.e. 'superiority' of treatment effect. Of note, the CHMP argued that due to the design of the study, the analysis should not be considered a superiority analysis.

The change from Fx-005 baseline to the end of study Fx-006 (30 months) was compared between the tafamidis-tafamidis group and the placebo-tafamidis group, i.e. effect of early-start treatment.

The pharmacodynamic analysis (TTR stabilisation) was measured at week 6 and months 6 and 12. The proportion of patients achieving TTR stabilisation and the 95% CI were summarized at each time point.

## Results

Following 18 months of placebo treatment in Study Fx-005, at enrolment into the extension Fx-006 patients switching to tafamidis had more severe disease compared to patients who had been previously treated with tafamidis, as evidenced by the statistically significantly worse NIS-LL scores and worse quality of life. The mBMI was also lower for the placebo-tafamidis patients compared to the tafamidistafamidis patients, but the difference was not statistically significant. Table 25 summarises the baseline disease characteristics for patient continuing in the Fx-006 extension study.

Table 25

## Baseline Disease Characteristics - ITT Population (Study Fx-006)

|                                     |                                     | Tafamidis- Tafamidis N=38           | Placebo- Tafamidis N=33             | All Patients N=71                   | p-value 1                           |
|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| NIS-LL (scale 0 to 88)              | NIS-LL (scale 0 to 88)              | NIS-LL (scale 0 to 88)              | NIS-LL (scale 0 to 88)              | NIS-LL (scale 0 to 88)              | NIS-LL (scale 0 to 88)              |
| Fx-005 baseline                     | Mean (SD)                           | 6.8 (10.0)                          | 11.6 (14.5)                         | 9.0 (12.5)                          | 0.1382                              |
|                                     | Median Range                        | 4.0 0, 49                           | 6.0 2, 57.3                         | 4.0 0, 57.3                         | 0.1382                              |
| Fx-006 baseline                     | Mean (SD)                           | 8.4 (13.2)                          | 17.5 (20.8)                         | 12.6 (17.7)                         | 0.0145                              |
| Fx-006 baseline                     | Median                              | 5.3                                 | 10.0                                | 6.5                                 | 0.0145                              |
| Fx-006 baseline                     | Range                               | 0, 65                               | 0, 75                               | 0, 75                               | 0.0145                              |
| Norfolk QOL-DN (TQOL) (-2 to 138)   | Norfolk QOL-DN (TQOL) (-2 to 138)   | Norfolk QOL-DN (TQOL) (-2 to 138)   | Norfolk QOL-DN (TQOL) (-2 to 138)   | Norfolk QOL-DN (TQOL) (-2 to 138)   | Norfolk QOL-DN (TQOL) (-2 to 138)   |
| Fx-005 baseline                     | Mean (SD)                           | 21.0 (21.1)                         | 27.1 (24.8)                         | 23.8 (22.9)                         | 0.1808                              |
| Fx-005 baseline                     | Median Range                        | 14.0 -1, 110                        | 17.0 0, 107                         | 15.0 -1, 110                        | 0.1808                              |
| Fx-006 baseline                     | Mean (SD)                           | 21.1 (21.9)                         | 38.1 (31.9)                         | 29.0 (28.1)                         | 0.0204                              |
| Fx-006 baseline                     | Median                              | 11.0                                | 28.0                                | 15.0                                | 0.0204                              |
| Large Fiber Function ( Σ 7 NTs nds) | Large Fiber Function ( Σ 7 NTs nds) | Large Fiber Function ( Σ 7 NTs nds) | Large Fiber Function ( Σ 7 NTs nds) | Large Fiber Function ( Σ 7 NTs nds) | Large Fiber Function ( Σ 7 NTs nds) |
| Fx-005 baseline                     | Mean (SD)                           | 5.8 (8.7)                           | 6.8 (8.9)                           | 6.3 (8.8)                           | 0.6242                              |
| Fx-005 baseline                     | Median                              | 3.4                                 | 9.5                                 | 7.2                                 | 0.6242                              |
| Fx-005 baseline                     | Range                               | -8.8, 23.1                          | -10.6, 20.9                         | -10.6, 23.1                         | 0.6242                              |
| Fx-006 baseline                     | Mean (SD)                           | 6.7 (8.5)                           | 10.1 (10.7)                         | 8.3 (9.7)                           | 0.1849                              |
| Fx-006 baseline                     | Median Range                        | 5.0 -6.6, 25.3                      | 10.8 -7.3, 25.1                     | 8.5 -7.3, 25.3                      | 0.1849                              |

<div style=\"page-break-after: always\"></div>

| Small Fiber Function ( Σ 3 NTSF nds)   | Small Fiber Function ( Σ 3 NTSF nds)   | Small Fiber Function ( Σ 3 NTSF nds)   | Small Fiber Function ( Σ 3 NTSF nds)   | Small Fiber Function ( Σ 3 NTSF nds)   | Small Fiber Function ( Σ 3 NTSF nds)   |
|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Fx-005 baseline                        | Mean (SD)                              | 4.3 (4.2)                              | 5.5 (3.7)                              | 4.8 (4.0)                              | 0.2237                                 |
|                                        | Median Range                           | 4.1 -4.4, 11.2                         | 5.0 -1.1, 11.2                         | 4.4 -4.4, 11.2                         |                                        |
| Fx-006 baseline                        | Mean (SD)                              | 4.8 (4.3)                              | 7.1 (4.4)                              | 5.8 (4.5)                              | 0.0195                                 |
|                                        | Median                                 | 4.2                                    | 7.4                                    | 5.5                                    |                                        |
|                                        | Range                                  | -2.5, 11.2                             | -2.1, 11.2                             | -2.5, 11.2                             |                                        |
| mBMI                                   | mBMI                                   | mBMI                                   | mBMI                                   | mBMI                                   | mBMI                                   |
| Fx-005 baseline                        | Mean (SD)                              | 1031.6 (166.5)                         | 1020.2 (244.3)                         | 1026,3 (204.9)                         | 0.9128                                 |
|                                        | Median                                 | 1015.9                                 | 1071.4                                 | 1023.8                                 |                                        |
|                                        | Range                                  | 687.9, 1510.4                          | 533.3, 1581.5                          | 533.3, 1581.5                          |                                        |
| Fx-006 baseline                        | Mean (SD)                              | 1068.4 (142.4)                         | 990.1 (265.0)                          | 1032.6 (209.7)                         | 0.0800                                 |
|                                        | Median                                 | 1038.1                                 | 945.7                                  | 1025.6                                 |                                        |
|                                        | Range                                  | 780.1, 1473.7                          | 567.5, 1583.8                          | 567.5, 1583.8                          |                                        |

Results concerning sustainability of the treatment effect are presented in table 26. Of note, there were no statistically significant differences in the rates of change in NIS-LL and quality of life measurements in the Fx-006 extension study when compared with Study Fx-005. The increase in mBMI over the first 18  months  of  tafamidis  administration  was  not  observed  over  the  last  12  months.  There  was  a decrease  in  mBMI,  translating  into  a  statistically significant  difference  in  the  rate  of  change (p=0.0006).  The  changes  from  Fx-005  baseline  after  30  months  of  tafamidis  for  all  endpoints demonstrated less impairment than what was observed after 18 months of placebo.

Table 26

## Sustainability of  the Treatment Effect: Rate of Change per Month for All Efficacy Endpoints - Efficacy Evaluable Population (Study Fx-006)

|                       | Rate of Change in U/month (SEM)   | Rate of Change in U/month (SEM)   | Rate of Change in U/month (SEM)   | Rate of Change in U/month (SEM)   | Rate of Change in U/month (SEM)   |
|-----------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                       | Tafamidis-Tafamidis (N=30)        | Tafamidis-Tafamidis (N=30)        | Tafamidis-Tafamidis (N=30)        | Tafamidis-Tafamidis (N=30)        | Placebo (N=42)                    |
| Endpoint              | Fx-006 (12 months)                | Fx-005 (18 months)                | p-value 1                         | Fx-005/006 (30 months)            | Fx-005 (18 months) 2              |
| NIS-LL                | 0.07 (0.08)                       | 0.06 (0.06)                       | 0.9638                            | 0.07 (0.04)                       | 0.33 (0.06)                       |
| Norfolk QOL-DN (TQOL) | 0.13 (0.21)                       | -0.19 (0.16)                      | 0.1275                            | -0.08 (0.06)                      | 0.45 (0.17)                       |
| Σ 7 NTs nds           | 0.05 (0.05)                       | 0.05 (0.04)                       | 0.9943                            | 0.05 (0.02)                       | 0.17 (0.04)                       |
| Σ 3 NTSF nds          | 0.05 (0.03)                       | 0.03 (0.02)                       | 0.3896                            | 0.03 (0.01)                       | 0.09 (0.02)                       |
| mBMI                  | -1.88 (1.10)                      | 1.95 (0.81)                       | 0.0014                            | 0.40 (0.45)                       | -1.27 (0.67)                      |

1 P-values (comparing the rate of change for the tafamidis-tafamidis group in Study Fx-006 to the rate of

change in Study Fx-005) based on a mixed model ANOVA. The dependent variable was the measurement at each visit. The independent variables were the study-by-treatment interaction and the time-by-study-by-treatment interaction. The intercept and time variables were modeled as random effects. The test of treatment effect was based on the time-by-study-by-treatment interaction. 2 ITT patients treated with placebo in Study Fx-005.

Table 27 summarises results concerning 'superiority' of the treatment effect. There was a statistically significant difference in the rate of change by month in the NIS-LL, the quality of life and the mBMI over  12  months  of  tafamidis  administration  during  the  Fx-006  extension  study  compared  to  the  18 months of placebo treatment in the Fx-005 study.

<div style=\"page-break-after: always\"></div>

Rate of Change per Month for All Efficacy Endpoints - ITT Population (Study Fx-006)

|                       | Rate of Change in U/month (SEM)   | Rate of Change in U/month (SEM)   | Rate of Change in U/month (SEM)   | Rate of Change in U/month (SEM)   |
|-----------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                       | Placebo-Tafamidis (N=33)          | Placebo-Tafamidis (N=33)          | Placebo-Tafamidis (N=33)          | Tafamidis (N=64)                  |
| Endpoint              | Fx-006 (12 months)                | Fx-005 (18 months)                | p-value 1                         | Fx-005 (18 months) 2              |
| NIS-LL                | 0.16 (0.08)                       | 0.34 (0.06)                       | 0.0103                            | 0.16 (0.05)                       |
| Norfolk QOL-DN (TQOL) | -0.16 (0.21)                      | 0.61 (0.16)                       | 0.0003                            | 0.12 (0.15)                       |
| Σ 7 NTs nds           | 0.11 (0.05)                       | 0.18 (0.04)                       | 0.2133                            | 0.08 (0.03)                       |
| Σ 3 NTSF nds          | 0.04 (0.03)                       | 0.09 (0.02)                       | 0.0551                            | 0.02 (0.02)                       |
| mBMI                  | 5.19 (1.13)                       | -1.77 (0.78)                      | <0.0001                           | 2.05 (0.61)                       |

1 P-values (comparing the rate of change for the tafamidis-tafamidis group in Study Fx-006 to the rate of change in Study Fx-005) based on a mixed model ANOVA. The dependent variable was the measurement at each visit. The independent variables were the study-by-treatment interaction and the time-by-study-by-treatment interaction. The intercept and time variables were modeled as random effects. The test of treatment effect was based on the time-by-study-by-treatment interaction. 2 Efficacy evaluable patients treated with placebo in Study Fx-005.

Table 28 summarises results on the TTR stabilisation status. TTR stabilization (as defined by the TTR stabilization assay) was observed in 91.4% of patients treated with tafamidis for 30 months (tafamidistafamidis patients) and 89.5% of patients on tafamidis for 12 months (placebo-tafamidis patients) at the Month 12 Fx-006 evaluation.

Table 28 TTR stabilisation status - ITT population

|          |                                 | Tafamidis- Tafamidis   | Placebo- Tafamidis   |
|----------|---------------------------------|------------------------|----------------------|
| Week 6   | # Stabilized/# Observations (%) | 35/38 (92.1)           | 30/31 (96.8)         |
|          | 95% confidence interval         | (0.81, 0.99)           | (0.83, 0.99)         |
| Month 6  | #Stabilized/#Observations (%)   | 34/37 (91.9)           | 31/32 (96.9%)        |
|          | 95% confidence interval         | (0.81, 0.99)           | (0.83, 0.99)         |
| Month 12 | #Stabilized/# Observations (%)  | 32/35 (91.4)           | 28/30 (93.3)         |
|          | 95% confidence interval         | (0.80, 0.99)           | (0.77, 0.99)         |

## Fx1A-201

This was an open-label, multicentre, single-arm study of tafamidis in ATTR-PN patients with non V30M TTR  mutation,  evaluating  the  effects  of  tafamidis  on  transthyretin  stabilisation  and  clinical  outcome measures in patients with non-V30M transthyretin amyloidosis.

The study was conducted in 2 parts. Part 1 included a 6-week dosing period, during which all enrolled patients  received  oral  tafamidis  20  mg  once  daily  for  6  weeks.  At  Week  6,  blood  samples  were collected from each patient to determine TTR stabilization. Patients who completed the Week 6 visit

<div style=\"page-break-after: always\"></div>

continued receiving daily oral dose of 20 mg for up to a total of 12 months during Part 2 of this study. As planned in the protocol, if it was determined that a patient was not stabilized at Week 6, the patient was to be discontinued from the study.

The  primary  objective  of  the  study  was  to  determine  transthyretin  stabilisation  at  steady  state,  as measured by a validated immunoturbidimetric assay, in patients with non V30M TTR amyloidosis. The primary  and  secondary  pharmacodynamic  endpoints  were  TTR  stabilisation  at  week  6  compared  to baseline  as  measured  by  a  validated  immunoturbidimetric  stabilisation  assay  (ITTSA)  and  TTR stabilisation at months 6 and 12 compared to baseline, respectively.

The secondary objectives were to evaluate the safety and tolerability of tafamidis in patients with non V30M  TTR  amyloidosis,  to  determine  plasma  concentrations  at  steady-state  time  points  and  to evaluate  clinical  outcomes  in  patients  with  non  V30M  TTR  amyloidosis.  The  exploratory  efficacy endpoints included NIS, NIS-LL, NIS-UL and subscale scores, TQOL, mBMI. Descriptive analyses were performed.

Male and female patients between the ages of 18 and 75 years diagnosed with TTR amyloidosis with documented non-V30M TTR mutation and positive biopsy were eligible for the study. Patients who had undergone liver transplantation could not be enrolled.

Up to 24 patients were planned to be enrolled in this study. A total of 21 patients were enrolled and analyzed. The intent-to-treat (ITT) population consisted of all enrolled patients who received at least one dose of tafamidis meglumine and therefore the ITT and Safety populations for this study are the same.

## Results

21  patients  were  enrolled  in  this  trial,  18  completed  it  and  3  discontinued  early  for  the  following reasons: transient ischemic attack, liver transplant and combined liver/heart transplant.

A summary of the patients´ baseline characteristics is presented in table 29 below.

Table 29 Patient Demographics -ITT Population (Study Fx1A-201)

| Demographic      | Tafamidis 20 mg (N=21)   |
|------------------|--------------------------|
| Age (year)       |                          |
| Mean (SD)        | 63.1 (9.86)              |
| Median           | 64.3                     |
| Range            | 43.9, 76.8               |
| 25th Percentile  | 56.9                     |
| 75th Percentile  | 70.8                     |
| Age group, n (%) |                          |
| ≤65 yr           | 11 (52.4)                |
| >65 yr           | 10 (47.6)                |
| Gender, n (%)    |                          |
| Male             | 13 (61.9)                |
| Female           | 8 (38.1)                 |
| Race, n (%)      |                          |
| Afro-Caribbean   | 1 (4.8)                  |
| Asian            | 1 (4.8)                  |
| Caucasian        | 19 (90.5)                |

SD=standard deviation

<div style=\"page-break-after: always\"></div>

At baseline, patients demonstrated significant neurologic impairment, with a mean NIS total score of 48.7 and a mean NIS-LL total score of 27.6. Disease-specific quality of life was impaired, as evidenced by  a  mean  Norfolk  TQOL  of  47.8,  and  so  was  the  functional  status  (Karnofsky  Performance  Status Scale  mean  score  of  74.8).  However,  overall  nutritional  status  was  preserved,  as  evidenced  by relatively normal mean mBMI of a 1053.

A  review  of  the  ATTR-related  medical  history  demonstrated  expected  neurologic  abnormalities (95.2%),  cardiac  disorders  (57.1%)  including  cardiac  pacemaker  insertion  (14.3%)  arrhythmia (14.3%), cardiac amyloidosis, cardiac failure and cardiac failure congestive (9.5% each), orthostatic hypotension (9.5%), gastrointestinal disorders (52.4%) mainly diarrhoea (23.8%) and musculoskeletal/connective tissue disorders (28.6%).

A summary of the ATTR-related medical history categorised by symptom-classification is presented in table 30.

Table 30 Summary of ATTR-related Medical History Categories by Symptom Classification -ITT Population (Study Fx1A-201)

| Symptom Classification                                 | Tafamidis 20mg (N=21) n (%)   |
|--------------------------------------------------------|-------------------------------|
| Peripheral neuropathy only                             | 3 (14.3)                      |
| Peripheral and autonomic neuropathy                    | 5 (23.8)                      |
|                                                        | 7 (33.3)                      |
| Autonomic neuropathy and cardiomyopathy                | 1 (4.8)                       |
| Peripheral and autonomic neuropathy and cardiomyopathy | 5 (23.8)                      |

The  results  regarding  TTR  stabilisation  (as  defined  by  the  TTR  stabilization  assay)  at  week  6  and months  6  and  12  are  presented  in  table  31.  Treatment  with  tafamidis  over  12  months  in  a  mixed genotype population of patients with ATTR-PN resulted in TTR stabilization in 95% of patients by week 6 and 100% of patients at months 6 and 12, supporting persistence of TTR stabilization with chronic dosing of tafamidis.

Table 31

## TransthyretinStabilization atWeek6-ITT Population(Study Fx1A-201)

| Parameter                          | Tafamidis20mg (N=21)   |
|------------------------------------|------------------------|
| Week 6 transthyretin stabilization | n=19                   |
| Number(%)stabilized                | 18 (94.7%)             |
| 95%confidenceinterval              | 74.0%,99.9%            |

All patients enrolled who received study medication and had both the baseline and postbaselineTTRstabilizationmeasurements.

Note: Percent calculated based on number of patients providing both baseline and Week 6 data.

<div style=\"page-break-after: always\"></div>

TTRStabilization atMonths6 and12-ITTPopulation(Study FxlA-201)

| Parameter                  | Tafamidis 20 mg (N=21)   |
|----------------------------|--------------------------|
| Month 6 TTR Stabilization  | n=18                     |
| Number (%) stabilized²     | 18 (100.0%)              |
| 95% confidence interval    | 81.5%, 100.0%            |
| Month 12 TTR Stabilization | n=17                     |
| Number (%) stabilized      | 17 (100.0%)              |
| 95% confidence interval    | 80.5%, 100.0%            |

All patients enrolled who received study medication and had both the baseline and post-baseline TTRstabilization measurements.

Patient 03-003 was not stabilized at Week 6 but was stabilized at Months 3 and 6. He is reflected stabilized at Month 6

TTR = transthyretin

The  results  regarding  NIS,  NIS-LL  and  NIS-UL  scores  are  summarized  in  table  32.  The  mean  and median scores indicate an impairment of the neurologic function from baseline to month 12. Quality of life (TQOL) remained unchanged over the 12-month period and after a decrease at month 6, a slight improvement in nutritional status (mBMI) was observed at month 12.

Table 32 Baseline and Change from Baseline to Months 6 and 12 in NIS, NIS-LL,

## and NIS-UL Scores -ITT Population (Study Fx1A-201)

| Visit                       | Statistic   | NIS1 (range 0-244)   | NIS-LL (range 0-88)   | NIS-UL1 (range 0-156)   |
|-----------------------------|-------------|----------------------|-----------------------|-------------------------|
| Baseline                    | 1n          | 21                   | 21                    | 21                      |
|                             | Mean (SD)   | 48.7 (44.31)         | 27.6 (24.67)          | 21.1 (21.42)            |
|                             | Median      | 45.0                 | 18.0                  | 13.0                    |
|                             | Range       | 0.0, 131.9           | 0.0, 69.9             | 0.0, 65.6               |
|                             | %S6         | 28.5, 68.9           | 16.4, 38.9            | 11.3, 30.8              |
| Month 6                     | n           | 17                   | 19                    | 17                      |
|                             | Mean (SD)   | 52.3 (49.29)         | 29.2 (26.10)          | 24.1 (25.35)            |
|                             | Median      | 56.0                 | 26.0                  | 15.0                    |
|                             | Range       | 0.0, 142.9           | 0.0, 71.0             | 0.0, 75.4               |
|                             | 95%CI       | 26.9, 77.6           | 16.6, 41.8            | 11.1, 37.1              |
| Month6change                | n           | 17                   | 19                    | 17                      |
| from baseline               | Mean (SD)   | 2.0 (9.52)           | -0.5 (5.73)           | 2.0 (5.56)              |
|                             | Median      | 3.0                  | 0.0                   | 0.0                     |
|                             | Range       | -17.0, 21.5          | -11.0, 8.0            | -6.0, 16.0              |
|                             | I %S6       | -2.9, 6.9            | -3.2, 2.3             | -0.8, 4.9               |
| Month 12                    | n           | 18                   | 18                    | 18                      |
|                             | Mean (SD)   | 60.8 (52.13)         | 34.0 (27.38)          | 26.8 (26.95)            |
|                             | Median      | 57.5                 | 34.8                  | 18.5                    |
|                             | Range       | 0.0, 154.8           | 0.0, 75.0             | 0.0, 80.3               |
|                             | I%S6        | 34.9, 86.7           | 20.4, 47.6            | 13.4, 40.2              |
| Month12change from baseline | n           | 18                   | 18                    | 18                      |
|                             | Mean (SD)   | 5.3 (12.62)          | 2.7 (6.21)            | 2.5 (7.43)              |
|                             | Median      | 1.6                  | 1.0                   | 0.5                     |
|                             | Range       | -16.5, 29.5          | -10.5, 11.5           | -6.0, 18.0              |
|                             | 95% CI      | -1.0, 11.5           | -0.4, 5.8             | -1.2, 6.2               |

For the NIS and NIS-UL scores, 1 patient (patient 03-002) did not complete Part 1 and 3 patients had missing values at Month 6 (02-005, 03-005, and 03-008). However, patient 03-005 did have Month 6 scoresfortheNIS-LL.

<div style=\"page-break-after: always\"></div>

Furthermore, the applicant also provided comparison between the monthly rates of change on the NIS score before vs after treatment with tafamidis. A slower rate of neurologic disease progression over 12 months of tafamidis administration (NIS=0.4 units/month) was observed as compared with the rate during the pre-study period (1.16 units/month), as shown in figure 7.

Figure  7  Monthly  rates  of  change  in  NIS  prior  to  enrolment  (pre-study)  and  during  treatment  with tafamidis

<!-- image -->

## 2.5.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

One  pivotal  phase  II/III  study  (Fx-005)  was  conducted:  safety  and  efficacy  of  orally  administered tafamidis in patients with familial amyloid polyneuropathy (FAP): randomised, double-blind, placebocontrolled, multicentre international study in patients with ATTR-PN due to V30M mutation. There is no dedicated  guideline  regarding  the  condition  but  the  design  of  the  pivotal  trial  (parallel  groups, randomisation, double-blind) is a standard approach to evaluating efficacy. As there is no pharmacological  treatment  available  to  treat  the  disease,  use  of  placebo  is  considered  acceptable. Overall, the CHMP concluded that the design of the pivotal trial was appropriate.

The patient population enrolled in the study is represented by ATTR-PN patients with a V30M mutation, which  is  the  principal  mutation  seen  in  these  patients.  However,  ATTR-PN  can  be  linked  to  other mutations and therefore, validity of data generated in this trial should be interpreted with caution when considering the overall population of ATTR-PN patients. Patients with mutations other than V30M were only included in the open-label Fx1a-201 study. This is discussed further in the sub-section Efficacy data and additional analyses.

The CHMP considered that NIS-LL and TQoL are scores used and validated in diabetic neuropathy and discussed their use as co-primary endpoints in the setting of the ATTR-PN. The observational study Fx1A-OS-001 showed that these scores could discriminate between healthy volunteers and ATTR-PN patients,  but  with  questionable  capacity  to  distinguish  different  levels  of  disease  progression.  The Fx1A-OS-001 study showed differences of mean NIS-LL according to different disease stages, but there was overlap of the values between stages 2 and 3 and uncertain relationship between progression in the  NIS  score    and  the  disease  progression.  The  CHMP  also  considered  that  the  familial  amyloid polyneuropathy is a length-dependent condition with a pre-dominant progressive sensory loss. On the NIS-LL score, the maximum total score possible for the sensory component is 16/88 points compared to the maximum total score possible for the motor component of 64/88. Since the condition manifests

<div style=\"page-break-after: always\"></div>

predominantly a sensory neuropathy, the ability of NIS-LL to properly evaluate disease progression in ATTR-PN was discussed by the CHMP. In order to provide more data on the clinical relevance of the criteria chosen, i.e NIS-LL and Norfolk, the applicant provided comparison between groups on yearly rate of disease progression, based on a regression model from the cross sectional study Fx1A-OS-001 and the data obtained in the Fx-005 study.

## Observed Annual Rate of ChangeinStudyFx-005 (ITT Population) versus theEstimatedAnnual Mean(SE)Rateof Changein

## ObservationalStudyFx1A-OS-001

|        | StudyFx1A-OS-001          | StudyFx-005      | StudyFx-005    | StudyFx-005                       |
|--------|---------------------------|------------------|----------------|-----------------------------------|
| Scale  | Untreated ATTR-PNPatients | Tafamidis (N=64) | Placebo (N=61) | P-value (tafamidisversus placebo) |
| NIS-LL | 3.80 (0.43)               | 1.98 (0.64)      | 4.14 (0.65)    | 0.018                             |

Module 2.7.3 (Section 2.1.12.2)

ObservedAnnualRateofChangeinStudyFx-0o5(ITTPopulation) versustheEstimatedAnnualRateofChangeinObservationalStudy Fx1A-OS-001

|                | StudyFx1A-OS-001          | StudyFx-005      | StudyFx-005    | StudyFx-005                       |
|----------------|---------------------------|------------------|----------------|-----------------------------------|
| Scale          | Untreated ATTR-PNPatients | Tafamidis (N=64) | Placebo (N=61) | P-value (tafamidisversus placebo) |
| Norfolk QOL-DN | 6.6 (0.45)                | 1.47 (1.19)      | 5.54 (1.85)    | 0.121                             |

Module2.7.3(Section2.2.8.6)

Prior to the completion of Study Fx-005, there were no prospectively obtained, longitudinal data on the rate of NIS-LL progression and on the Norfolk QoL progression in untreated ATTR-PN patients. As study Fx-005 included a placebo group followed longitudinally over 18 months, the rate of change in both scores in early ATTR-PN patients could be determined.

The results on annual progression (units/year) based on both scores as observed in study Fx-005 were consistent with the estimated rate of change from Study Fx1A-OS-001, and supported the utility of the NIS-LL  and  TQOL  in  documenting  disease  progression  in  ATTR-PN  even  for  early  stage.  Thus,  the CHMP considered that comparison of the yearly rate of disease progression between groups validated the clinical relevance of the parameters used.

The CHMP also discussed the choice of the percentage of responder on NIS-LL in terms of the cut-off point for response, i.e. change from baseline&lt;2. A \"waterfall\" type plot showing differences in response rate across various possible cut-off points (-4 to 10) was presented by the applicant. % of patients responding to treatment using various NIL-LL score threshold definition was provided. Of note, there was no difference between treatments for clinical improvement of NIS-LL with no change or less than 2. However, when considering threshold of 2 and above, the difference in percentage of responders was always in favor of tafamidis. Overall, the definition of NIS-LL response based on change in the score of &lt;2 from baseline was considered acceptable by the CHMP.

In their discussion of the duration of the pivotal study, the CHMP considered that the proposed primary time-point  (month  18)  for  ATTR-PN  patients  was  determined  empirically,  but  was  supported  by  the

<div style=\"page-break-after: always\"></div>

regression model determining the yearly rate of disease progression. The CHMP was of the view that the study duration can be accepted as sufficient to show an effect.

In  terms  of  baseline  characteristics  of  patients  enrolled  in  study  Fx-005,  the  CHMP  considered  that there  were  numeric  differences  between  the  treatment  groups  with  respect  to  the  baseline  disease. These  differences  were  observed  for  NIS-LL  and  Norfolk  QOL  at  baseline  with  higher  values (corresponding to a more severe disease) in the placebo group compared to the tafamidis group (see Results - Table 13). The CHMP discussed whether these differences may have biased the study results in  favour  of  tafamidis  particularly  on  the  analysis  of  the  mean  change  of  NIS-LL  from  baseline,  but considered that as the adjusted analysis provided by the applicant was statistically significant, these differences were no longer of concern.

The CHMP also took into account that 126 out of 128 patients were of stage 1 of the disease (98%) showing that the study population was homogenous. In this context, the CHMP was of the view that no data  are  available  for  stages  2  and  3  and  requested  that  this  be  reflected  appropriately  in  the indication. Thus, the approved the SmPC makes a specific reference to the stage disease in section 4.1 as follows:

'Vyndaqel  is  indicated  for  the  treatment  of  transthyretin  amyloidosis  in  adult  patients  with  stage  1 symptomatic polyneuropathy to delay peripheral neurologic impairment.'

Furthermore, the CHMP considered the baseline data of patients who underwent liver transplantation during  the  study.  Of  note,  transplanted  patients  presented  with  more  severe  disease  and  longer disease duration than non transplanted patients but were not different between groups. There were no major differences in the delay before transplantation between tafamidis and placebo group. The data on key efficacy endpoints did not seem to show significant differences between transplanted and nontransplanted patients, even though there are limitations to interpreting these data due to the small number of patients per group. Overall, the CHMP was of the view that undergoing liver transplantation tended to be associated with duration of disease rather than with treatment assignment in this study.

## Efficacy data and additional analyses

In the primary analyses statistically significant results were not obtained at month 18 (primary time point) for either of the two co-primary endpoints; at month 18, 45% of patients in the tafamidis group had an increase in the NIS-LL of &lt;2 as compared to 29.5% patients in the placebo group (p=0.068). TQOL  mean  (SD)  change  from  baseline  to  month  18  was  2.4  (14.6)  in  the  tafamidis  group  as compared to 6.9 (22.9) in the placebo group (p=0.1157). Of note, a conservative approach (patients who  underwent  liver  transplantation  before  month  18  were  withdrawn  from  the  study  and  were considered as treatment failures) was applied in the primary analyses.

The  CHMP  considered  that  liver  transplantation  was  scheduled  before  inclusion  in  the  study  and patients on the waiting list for whom an organ became available were allowed to be transplanted for ethical reason. Most of study discontinuations were due to liver transplantation and balanced between groups.

A pre-specified sensitivity analysis was conducted by the applicant in order to impute the transplanted patients;  this  showed  statistically  significant  difference  in  favour  of  tafamidis  (p=0.0367).  However, from  the  available  data,  it  was  unclear  why  the  median  baseline  NIS-LL  was  used  instead  of  the individual subject-specific baseline value and  how  the predicted probability of response  was transformed  into  a  binary  response.  The  approach  used  by  the  company  appeared  to  be  a  single imputation method and such methods are known to produce biased estimates of standard errors of treatment effects. A multiple imputation method was considered more reliable by the CHMP. In order

<div style=\"page-break-after: always\"></div>

to alleviate these concerns, the CHMP requested two additional analyses where the values for patients who stopped treatment for transplantation would be imputed according to 2 different rules:

1st imputation, where missing data of patients should be imputed on the basis of their last known NISLL  value  and  under  the  assumption  of  the  evolution  of  their  respective  group  (estimated  on  the available data, and 2nd imputation: missing data of patients should be imputed on the basis of their last  known NIS-LL value and for both groups under the identical assumption of the evolution of the placebo group (estimated on the available data).

The first approach was considered as the most realistic by the CHMP, since the patients would have continued  their  treatment  if  no  transplant  had  been  available,  whereas  the  second  approach  was considered as more conservative and more adequate from a regulatory viewpoint.

In either case, the CHMP was of the opinion that the uncertainty of the evolution should be handled by multiple  imputation.  The  imputed  dataset  was  generated  by  the  applicant  and  both  the  analysis  of responders and of the mean evolution on NIS-LL was performed.

The results of the supplementary analyses are presented in the section Results (tables 19-22).

The analysis with multiple imputation and missing values imputed according to the treatment group can  be  considered  as  the  'real'  ITT  analysis  and  more  realistic  for  handling  the  missing  data.  The results provided showed that the NIS-LL responders were not statistically different between groups and confirmed that the mean change from baseline in NIS-LL is different between groups with marginally statistical significance (-2.787, p=0.041); this was supportive of the previous results.

The pre-specified secondary analyses performed in the evaluable population (PP) on the co-primary endpoints (NIS-LL % of responders and TQOL) and on several secondary endpoints, such as the mean NIS-LL change from baseline to visit at month 18, favoured tafamidis to placebo.

As  discussed  in  the  Clinical  Pharmacology  section,  results  from  Fx-005  on  the  TTR  stabilisation  are supportive  of  justifying  the  20  mg  once  daily  tafamidis  dosing,  i.e.  adequate  TTR  stabilisation.  The CHMP also considered that this was further supported by TTR stabilisation data obtained in the longterm extension study Fx-006, as the results were consistent with those seen previously. Furthermore, data from study Fx1A-201 indicated that tafamidis is able to stabilize TTR with other mutation than the V30M, as also shown in in vitro studies.

The results of the open-label studies in ATTR-PN patients were evaluated by comparing the disease rate of progression of treated patients for both NIS-LL and TQOL between the treatment period of each study  and  the  disease  rate  progression  calculated  with  the  placebo  arm  of  the  Fx-005  study.  The results  of  these  studies  were  not  considered  as  robust  when  compared  to  the  results  of  controlled studies.  The  analysis  performed  did  not  follow  the  multiple  imputation  technique  and  there  were uncertainties regarding data handling. However, when comparing the evolution of NIS-LL in tafamidis treated  patients  during  the  18-month  double-blind  period  and  the  12-month  open-label  period,  the rate of change in the NIS-LL score was similar for both periods.

## Additional efficacy data needed in the context of a MA under exceptional circumstances

The population enrolled in the pivotal study were patients with V30M mutation at an early stage 1 of the  disease;  the  data  on  patients  with  non-V30M  ATTR-PN  patients  originated  only  from  a  noncontrolled study (Fx1A-201). This study was conducted in 21 patients with non V30M ATTR-PN, which constitutes  a  population  different  from  the  V30M  ATTR-PN  patients  (older  patients,  more  severe

<div style=\"page-break-after: always\"></div>

disease, more cardiac impairment). These patients were included at late stage 1 of the disease (mean NIS-LL  of  27.6  at  inclusion).  In  this  context,  the  CHMP  pointed  at  limitations  of  comparisons  made between different studies (Fx-005 and Fx1A-201) and different patient populations (V30M versus non V30M mutation).  However,  as  the  applicant  also  provided  comparison  between  the  monthly  rate  of change on the NIS score before vs after treatment with tafamidis and the TTR stabilisation data were favourable  irrespective  of  the  mutation,  the  CHMP  considered  that  extrapolation  from  V30M  to  non V30M patients was acceptable.

In their review, the CHMP took into account the fact that due to the rarity of the non V30M patient population  a  standard  double-blind  placebo  study  is  not  feasible  and  that  the  applicant  cannot  be expected to provide comprehensive evidence. In this context, the CHMP concluded that the MA under exceptional  circumstances  should  be  granted  subject  to  a  specific  obligation  to  follow  non-V30M patients in a proposed sub-study of the THAOS registry. (The THAOS registry is a global, multi-centre, disease registry for the purpose of longitudinal data collection in patients with inherited or wild-type transthyretin amyloidosis and for asymptomatic TTR-variant carriers.  The principal aim of the survey is to better understand and characterize the natural history of the disease.)

## 2.5.4. Conclusions on the clinical efficacy

The dossier is based on a single pivotal phase II/III study. In accordance with the Points to consider on application with 1. meta-analyses; 2. one pivotal study (CPMP/EWP/2330/99), a submission based on a single pivotal trial can be sufficient provided that the study results are statistically compelling and show clinical relevance.

The results of the single pivotal phase II/III study on the primary analysis on the co-primary criteria (NIS-LL  and  TQOL)  were  not  met,  with  statistically  significant  results  not  obtained  at  month  18  for either of the criteria. A sensitivity analysis was conducted in order to impute the transplanted patients and  showed  statistically  significant  difference  in  favour  of  tafamidis  (p=0.0367).  Supplementary analyses with different multiple method of imputation provided by the applicant showed that there was no statistical difference between groups regarding NIS-LL percentage of responders. For NIS-LL mean change from baseline, the results with multiple imputations according to the treatment group showed an effect in favour of tafamidis.

The efficacy results are further discussed in the context of the overall benefit-risk balance.

The population enrolled in the pivotal study were patients with V30M mutation at an early stage 1 of the  disease;  the  data  on  patients  with  non-V30M  ATTR-PN  patients  originated  only  from  a  noncontrolled study. The CHMP took into account the orphan status of the product and the fact that due to the  rarity  of  the  non  V30M  patient  sub-population  a  standard  double-blind  placebo  study  is  not feasible, i.e. the applicant cannot be expected to provide comprehensive evidence. As discussed above, the CHMP concluded that the MA under exceptional circumstances should be granted and considered the following measure necessary to address the missing efficacy data in its context:

## Specific obligation:

'Within the planned post-authorisation sub-study of the THAOS registry the MAH shall evaluate in nonV30M patients the effects of Vyndaqel on disease progression and its long term safety as detailed in a CHMP agreed protocol, and shall provide yearly updates on the collected data within the annual reassessment.'

<div style=\"page-break-after: always\"></div>

## 2.6. Clinical safety

## Patient exposure

There were 13 clinical studies (controlled and uncontrolled) in the tafamidis development programme and 2 non-interventional observational studies. Tafamidis exposure across the studies included a total of approximately 210 patients-years in 162 patients (over 175 patient-years of exposure in a total of 127  ATTR-PN  patients  and  over  34  patient-years  in  35  ATTR-CM  patients).  The  clinical  studies supporting the safety evaluation in patients with the target indication (ATTR-PN) were studies Fx-005, Fx-006,  Fx1A-201  and  Fx1A-303  (interim  data).  Phase  I  programme  in  healthy  subjects  provided additional  evidence  for  safety  evaluation.  The  exposure  is  represented  by  308  individuals  (including 128 healthy subjects) who received at least one dose of tafamidis, 147 ATTR patients for at least 6 months, 113 for at least 12 months and 43 for at least 2 years. Out of 128 V30M patients enrolled in the single pivotal phase II/III study (Fx-005), 22 patients were treated with tafamidis for at least 30 months  (these  data  are  included  in  the  dataset  of  study  Fx-006).  Patient  exposure  for  the  studies supporting safety evaluation in the target population is summarised in table 33.

Table 33

|                              | Patients enrolled (safety population)   | Patients exposed (ITT population)   | Patients with long term* safety data   |
|------------------------------|-----------------------------------------|-------------------------------------|----------------------------------------|
| Placebo-controlled           |                                         |                                     |                                        |
| Fx-005                       | 128                                     | 125                                 |                                        |
| Tafamidis group              | 65                                      | 64                                  | 59                                     |
| Placebo group                | 63                                      | 61                                  | 58                                     |
| Open studies                 |                                         |                                     |                                        |
| Fx-006 (extension to Fx-005) | 85                                      | 85                                  | 77                                     |
| Fx1A-201                     | 21                                      | 21                                  | 19                                     |
| Fx1A-303 (interim data)      | 81(planned n=110)                       | 81                                  | 80                                     |
| Post marketing               | NA                                      |                                     |                                        |
| Compassionate use            | NA                                      |                                     |                                        |

* in general this refers to 6 months and 12 months continuous exposure data or intermittent exposure

In the safety population of Fx-005 (128 patients), mean age was 40 years (+/-12.7) in tafamidis group and 38.1 years (+/-12.8) in the placebo group. Only 5 patients in tafamidis group and 3 in placebo group were &gt;65 years. The planned exposure for this study was 18 months.

In the open-label study Fx-006, a total of 85 patients were included in the safety population: 44 in tafamidis-tafamidis  group  and  41  in  placebo-tafamidis  group.  The  mean  age  was  respectively  41.3 years  [26-76]  and  39.6  years  [24-73].  The  percentage  of  the  elderly  patients  ( ≥ 65  years-old)  was 13.6% (n=6) and 7.3% (n=3), respectively. The planned exposure during this study was 12 months.

In  study  Fx1A-201,  a  total  of  21  subjects  who  had  non-V30M  transthyretine  amyloidosis  (mainly elderly) were enrolled and analysed. The planned exposure during this study was 12 months.

<div style=\"page-break-after: always\"></div>

## Adverse events

## Study Fx-005

'Infections and infestations' and 'Gastrointestinal disorders' were the SOC with the highest incidence in the tafamidis group (66.2% and 53.8%, respectively); the incidence of infections and infestations was  slightly  higher  in  the  tafamidis  group  than  in  placebo  group  (66.2%  versus  52.4%),  while  the incidence of gastrointestinal disorders was slightly higher in the placebo group than in the tafamidis group (61.9% versus 53.8%).

Overall, treatment-emergent adverse events (TEAEs) reported more frequently ( ≥ 2%) in the tafamidis group compared to placebo included diarrhoea (26.2% versus 17.5%), urinary tract infections (UTI) (23.1% versus 12.7%), pain in extremity (16.9% versus 9.5%), upper abdominal pain (12.3% versus 3.2%), myalgia (7.7% versus 3.2%) and vaginal infections (6.2% versus 1.6%).

A  total  of  26  (20%)  patients  (13  patients  in  each  treatment  group)  discontinued  due  to  liver transplantation.  Of  the  26  transplanted  patients,  8  (30.8%)  reported  adverse  events  post-liver transplantation, 5 (38.5%) in the tafamidis group and 3 (23.1%) in the placebo group.

## Study Fx-006

'Infections  and  infestations',  'GI  disorders',  'Nervous  system  disorders',  'Injury,  poisoning  and procedural complications' and 'Eye disorders' were the SOCs reported with the highest incidence in this study.

In the tafamidis-tafamidis group, nasopharyngitis was reported more frequently than in the placebotafamidis group (11.4 and 7.3%, respectively). This incidence rate was similar to that observed in the placebo group in study Fx-005 (12.7%).

The  greatest  difference  in  TEAE  incidence  between  tafamidis-tafamidis  and  placebo-tafamidis  (and higher in the placebo-tafamidis group) was observed for influenza (6.8 and 17.1%), headache (4.5% and 14.6%), anxiety (2.3 and 12.2%) and urinary tract infections (11.4 and 17.1%, respectively).

## Study Fx1A-201

The  most  commonly  reported  ( ≥ 10%)  TEAEs  overall  were  falls  (24%),  diarrhoea  (24%),  pain  in extremity  (19%),  dizziness  (14%);  dyspnoea  (14%),  vomiting  (14%)  and  constipation  (14%).  The high  proportion  of  falls  (5/21;  24%)  and  dizziness  (3/21;  14%)  observed  in  elderly  patients  was similar to the one reported in the literature  , i.e. estimated annual incidence of falls between 22 and 30%. Of note, most patients received antihypertensive drugs as concomitant medication.

## Adverse events of special interest

## Urinary tract infections (UTI)

In  study  Fx-005,  treatment-emergent  UTIs  were  reported  more  frequently  in  tafamidis  patients compared to placebo patients, n=15 (23.1%) vs. n=8 (12.7%), respectively. 7 (41%) of 17 tafamidistreated patients and 5 (50%) of 10 placebo-treated patients had a past medical history of relevant urinary  events,  such  as  urinary  retention,  urinary  incontinence  and  prior  UTIs  that  may  have  predisposed  these  patients  to  the  UTIs.  Of  note,  in  the  open  label  study  Fx-006,  UTIs  occurred  more frequently  in  the  first  weeks  in  patients  who  were  switched  from  placebo  to  tafamidis.  A  total  of  5 cases of the UTIs were reported in the tafamidis-tafamidis group and 7 in placebo-tafamidis group.

 Shumway-Cook- 2009; Stevens 2006

<div style=\"page-break-after: always\"></div>

Overall, patients experiencing UTI events in both studies were more frequently women aged around 40 years [23-66]. In both studies, all  except  for  two  had  autonomic  neuropathy  symptoms  at  baseline (predisposing the patient to frequent and recurrent UTI). The majority of events in patients treated with  tafamidis  were  mild  to  moderate  in  severity,  responsive  to  antibiotics  and  not  requiring interruption or discontinuation of the study drug. Given the higher incidence of UTI in tafamidis group, a  causal  relationship  between  tafamidis  and  UTIs  could  not  be  ruled  out.  UTI  are  considered  as  an important identified risk and reflected in the Risk Management Plan (RMP). No UTI cases were reported in study Fx-1A-201.

## Other infections

In  study  Fx-005,  viral  infections  were  reported  more  frequently  in  the  tafamidis  group  (46.2%) compared  to  placebo  (42.9%)  and  were  mainly  represented  by  influenza  (flu  or  flu  syndrome), nasopharyngitis and upper respiratory tract infections.

One serious case of infection required temporary interruption of tafamidis in study Fx-005. This case of atypical pneumonia was unlikely related to study medication, since no re-occurrence of symptoms was observed upon re-challenge of tafamidis.

In study Fx-005, a higher incidence of vaginal infections in women was observed in tafamidis (18.2%) vs  placebo  (8.1%);  all  vaginal  infections  were  mild  and  non-serious  and  none  required  study  drug interruption or discontinuation. Although the mechanism of this event is not known, vaginal infection was considered as an important identified risk and included in the RMP.

## Diarrhoea

In  Fx-005  study,  a  similar  incidence  of  gastrointestinal  motility-type  adverse  events  was  reported between the treatment groups; diarrhoea was the only event of this type reported more frequently in tafamidis patients than in placebo patients (n=19 vs 13).

The  majority  of  patients  in  both  treatment  groups  had  pre-existing  risk  factors  of  gastro-intestinal motility  disorders,  autonomic  neuropathy  or  a  prior  history  of  diarrhoea.  The  majority  of  diarrhoea cases in the tafamidis group was mild to moderate in severity, responsive to symptomatic treatment and  did  not  require  interruption  or  discontinuation  of  tafamidis  treatment.  Although  diarrhoea  is  a characteristic symptom of ATTR-PN, given the higher incidence of diarrhoea in the tafamidis group, a causal relationship could not be ruled out. Diarrhoea is considered as an important identified risk and included in the RMP.

No  relevant  cases  of  dehydration  were  reported  concomitantly  with  diarrhoea  events  in  any  of  the studies.

There were only 2 cases in the tafamidis group in study Fx-005 and one in the placebo-tafamidis group in study  Fx-006  requiring  antibiotics,  suggesting  infectious  aetiology.  Stool  cultures  were  not performed.

## Hepatotoxicity

In the pivotal study, two tafamidis-treated patients and one placebo-treated patient had elevation of GGT, ALT and/or AST values to &gt;3x ULN. In study Fx-006, six patients had GGT elevations &gt;3x ULN at least once post-baseline. In each of these patients the elevations of GGT were &lt;5x ULN, were isolated and not associated with elevations of ALT, AST or bilirubin.

<div style=\"page-break-after: always\"></div>

In  one  case,  liver  function  tests  began  to  increase  at  month  9  with  a  maximum  at  month  18.  The parameters returned within normal range 36 days after tafamidis discontinuation (end of study) and before enrolment in the open label study. Nonetheless, on day 95 during study Fx-006, the patient experienced again hepatic enzyme increase with ALT of 206 U/l (Normal range: 0-47) without any new course of paracetamol and azithromycin (which were confounding factors for the occurrence of liver function test abnormalities during study Fx-005). Additional information revealed that tests for viral, autoimmune and primary liver disorders (e.g. Wilson´s disease) were negative. The patient continued tafamidis during study Fx-006 and was then enrolled in study Fx1A-303. During this study, ALT and AST remained elevated but were decreasing. Tafamidis was interrupted (with a positive de-challenge), but negative re-challenge was noted after re-introduction of tafamidis three months after. Hepatotoxicity is further addressed in the Discussion section.

## Cardiac disorders:

In  the  pivotal  study  Fx-005,  cardiac  disorders  were  mainly  reported  in  the  placebo  group  30.2% compared to 15.4% in the tafamidis group. The main AE reported in tafamidis group with a difference from placebo of &gt;2% was bradycardia (3.1% vs 0). Echocardiography parameters were similar in each group of treatment.

Approximately 40% of patients in both treatment groups had an abnormal ECG at baseline, with the most common abnormalities being abnormal conduction (approximately 30% per group): first degree AV block and left anterior hemiblock.

On-treatment,  the  most  frequent  post-baseline  (overall  at  any  time)  abnormalities  reported  were abnormal rhythm (12.3% tafamidis vs. 6.3% placebo), arrhythmia (approximately 9% in both groups) and  abnormal  conduction  (not  specified)  (3.1%  tafamidis  vs.  11.1%  placebo).  The  most  commonly reported treatment-emergent rhythm abnormalities included sinus tachycardia and atrial fibrillation.

Of note, 4 (6.2%) tafamidis-treated patients and 1 (1.6%) placebo-treated patient had a QTc-F &gt;500 ms  during  the  study.  In  addition,  one  (1.6%)  placebo-treated  patient  (but  no  tafamidis-treated patients) had a change in QTc-F &gt;60 ms during the study.

## Orthostatic hypotension

Analysis  of  changes  of  vital  signs  indicative  of  possible  orthostatic  hypotension  was  performed, because  of  the  high  prevalence  of  cardiovascular  autonomic  dysfunction  and  potential  for  adverse clinical manifestations in ATTR-PN patients. In study Fx-005, a slight increase of vital signs related to possible orthostatic hypotension was observed at weeks 2 and 4, in the tafamidis group compared to placebo (35.9% at 2 weeks and 34.4% at 4 weeks in the tafamidis group versus 25.4% at 2 weeks and  25.8%  at  4  weeks  in  placebo);  this  trend  was  reversed  after  8  weeks.  The  percentage  of orthostatic  hypotension  increased  in  both  groups  compared  with  baseline,  from  less  than  30%  at baseline in both groups compared to 65-70% on treatment. In study Fx-006, the incidence was similar between tafamidis-tafamidis and placebo-tafamidis groups.

According to the data provided, there is no evidence that treatment by tafamidis in study Fx-005 is associated  with  a  higher  incidence  of  orthostatic  hypotension  and  there  are  no  data  suggesting  an increase of this type of events with longer exposure (lower percentage of patients with at least one adverse event of interest in study Fx-006).

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

No  serious  adverse  events  or  deaths  were  reported  in  the  healthy  or  in  the  hepatically  impaired subjects during the Phase I clinical studies.

A summary of the incidence of treatment-emergent serious adverse events in the ATTR-PN patients, sorted by descending incidence in the tafamidis group, is presented in table 34:

Table 34

|                                   |                        |                      | OpenLabel Studies   | OpenLabel Studies   | OpenLabel Studies      | OpenLabel Studies       |                         |
|-----------------------------------|------------------------|----------------------|---------------------|---------------------|------------------------|-------------------------|-------------------------|
|                                   | Fx-005                 | Fx-005               | Fx-006              | Fx-006              | Fx1A-201               | Total                   | Overall                 |
| MedDRAPreferredTerm               | Tafamidis (N=65) n (%) | Placebo (N=63) n (%) | T-T (N=44) n (%)    | P-T (N=41) n (%)    | Tafamidis (N=21) n (%) | Tafamidis (N=106) n (%) | Tafamidis (N=127) n (%) |
| PatientsWithAtLeast1Event         | 6 (9.2)                | 5 (7.9)              | 4 (9.1)             | 4 (9.8)             | 8 (38.1)               | 16 (15.1)               | 22 (17.3)               |
| Urinary tract infection           | 2 (3.1)                | 0                    | 0                   | 1 (2.4)             | 0                      | 1 (0.9)                 | 3 (2.4)                 |
| Vomiting                          | 0                      | 1 (1.6)              | 1 (2.3)             | 1 (2.4)             | 0                      | 2 (1.9)                 | 2 (1.6)                 |
| Fall                              | 0                      | 0                    | 0                   | 0                   | 2 (9.5)                | 2 (1.9)                 | 2 (1.6)                 |
| Anaemia                           | 0                      | 1 (1.6)              | 0                   | 1 (2.4)             | 0                      | 1 (0.9)                 | 1 (0.8)                 |
| Atrioventricularblock             | 0                      | 0                    | 0                   | 0                   | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Conduction disorder               | 1 (1.5)                | 0                    | 0                   | 0                   | 0                      | 0                       | 1 (0.8)                 |
| Coronary artery stenosis          | 0                      | 0                    | 0                   | 0                   | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Faecaloma                         | 0                      | 0                    | 0                   | 0                   | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Nausea                            | 0                      | 1 (1.6)              | 0                   | 1 (2.4)             | 0                      | 1 (0.9)                 | 1 (0.8)                 |
| Subileus                          | 0                      | 0                    | 0                   | 0                   | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Malaise                           | 0                      | 0                    | 0                   | 0                   | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Hypersensitivity                  | 0                      | 0                    | 1 (2.3)             | 0                   | 0                      | 1 (0.9)                 | 1 (0.8)                 |
| Catheter sepsis                   | 0                      | 0                    | 1 (2.3)             | 0                   | 0                      | 1 (0.9)                 | 1 (0.8)                 |
| Infection                         | 0                      | 0                    | 0                   | 1 (2.4)             | 0                      | 1 (0.9)                 | 1 (0.8)                 |
| Localised infection               | 1 (1.5)                | 0                    | 0                   | 0                   | 0                      | 0                       | 1 (0.8)                 |
| Meningitis                        | 0                      | 0                    | 0                   | 1 (2.4)             | 0                      | 1 (0.9)                 | 1 (0.8)                 |
| Osteomyelitis                     | 0                      | 0                    | 0                   | 1 (2.4)             | 0                      | 1 (0.9)                 | 1 (0.8)                 |
| Pneumonia                         | 1 (1.5)                | 0                    | 0                   | 0                   | 0                      | 0                       | 1 (0.8)                 |
| Viral infection                   | 1 (1.5)                | 0                    | 0                   | 0                   | 0                      | 0                       | 1 (0.8)                 |
| Ankle fracture                    | 0                      | 0                    | 0                   | 0                   | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Avulsion fracture                 | 0                      | 0                    | 0                   | 0                   | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Bloodelectrolytesdecreased        | 0                      | 0                    | 1 (2.3)             | 0                   | 0                      | 1 (0.9)                 | 1 (0.8)                 |
| Dehydration                       | 0                      | 0                    | 0                   | 1 (2.4)             | 0                      | 1 (0.9)                 | 1 (0.8)                 |
| Arthritis                         | 0                      | 0                    | 0                   | 0                   | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Lymphoma                          | 0                      | 0                    | 1 (2.3)             | 0                   | 0                      | 1 (0.9)                 | 1 (0.8)                 |
| Transient ischaemic attack        | 0                      | 0                    | 0                   | 0                   | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Urinary retention                 | 0                      | 0                    | 0                   | 0                   | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Skin lesion                       | 0                      | 0                    | 1 (2.3)             | 0                   | 0                      | 1 (0.9)                 | 1 (0.8)                 |
| Urticaria                         | 1 (1.5)                | 0                    | 0                   | 0                   | 0                      | 0                       | 1 (0.8)                 |
| Carpaltunneldecompression         | 0                      | 0                    | 0                   | 0                   | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Cardiac amyloidosis               | 0                      | 1 (1.6)              | 0                   | 0                   | 0                      | 0                       | 0                       |
| Catheter site phlebitis           | 0                      | 1 (1.6)              | 0                   | 0                   | 0                      | 0                       | 0                       |
| Oedema peripheral                 | 0                      | 1 (1.6)              | 0                   | 0                   | 0                      | 0                       | 0                       |
| Cellulitis                        | 0                      | 1 (1.6)              | 0                   | 0                   | 0                      | 0                       | 0                       |
| Lymphangitis                      | 0                      | 1 (1.6)              | 0                   | 0                   | 0                      | 0                       | 0                       |
| Staphylococcal infection          | 0                      | 1 (1.6)              | 0                   | 0                   | 0                      | 0                       | 0                       |
| Burns third degree                | 0                      | 1 (1.6)              | 0                   | 0                   | 0                      | 0                       | 0                       |
| Syncope                           | 0                      | 1 (1.6)              | 0                   | 0                   | 0                      | 0                       | 0                       |
| Pneumothorax                      | 0                      | 1 (1.6)              | 0                   | 0                   | 0                      | 0                       | 0                       |
| Skin ulcer Hypertensive emergency | 0 0                    | 1 (1.6) 1 (1.6)      | 0 0                 | 0 0                 | 0 0                    | 0 0                     | 0 0                     |

Note:T-Treflectstafamidis treatment inbothStudyFx-005andFx-006.P-Treflectsplacebotreatment inStudyFx-005andtafamidis treatment inStudyFx-006.

Overall, 22 of 127 (17.3%) tafamidis treated patients experienced at least one serious adverse event. The  incidence  of  SAEs  was  significantly  higher  in  study  Fx1A-201  (38.1%)  than  in  Studies  Fx-005 (9.2%)  and  Fx-006  (9.1%  for  the  tafamidis-tafamidis  group  and  9.8%  for  the  placebo-tafamidis group). The higher incidence in Study Fx1A-201 was possibly due to the underlying differences in the characteristics of the patient population enrolled, with patients in this study being on average 20 years older than patients in Study Fx-005 and with more co-morbidities reported in medical histories.

<div style=\"page-break-after: always\"></div>

Urinary tract infection, vomiting and falls were the only SAEs reported in more than one patient treated with tafamidis. Each of the serious cases of urinary tract infection occurred in patients with pre-existing risk factors for infection.

The  SAEs  of  infection  included  localized  infection,  pneumonia  and  viral  infection  in  study  Fx-005 patients and catheter sepsis, meningitis, osteomyelitis and infection in study Fx-006. In each of these cases, the infection resolved following appropriate antibiotic treatment. One case of meningitis had an atypical presentation and was ultimately presumed secondary to TB.

The analysis of SAEs by gender revealed similar findings to the overall analysis; there were too few patients older than age 65 to make any meaningful interpretation of the analysis by age. No trend of increasing incidence of SAEs over time (i.e., from the first 6 months of treatment to the later 6-month periods) was observed, at no time was the 6-month incidence rate of SAEs higher than 7.1%.

Treatment-emergent adverse events judged by the investigator to be at least possibly related to study treatment, sorted by descending incidence in the tafamidis group, are summarised in table 35.

Table 35

|                                                                  |                        |                      | OpenLabelStudies   | OpenLabelStudies   | OpenLabelStudies       | OpenLabelStudies        |                         |
|------------------------------------------------------------------|------------------------|----------------------|--------------------|--------------------|------------------------|-------------------------|-------------------------|
|                                                                  | Fx-005                 | Fx-005               | Fx-006             | Fx-006             | Fx1A-201               | Total                   | Overall                 |
| MedDRAPreferredTerm                                              | Tafamidis (N=65) n (%) | Placebo (N=63) n (%) | T-T (N=44) n (%)   | P-T (N=41) n (%)   | Tafamidis (N=21) n (%) | Tafamidis (N=106) n (%) | Tafamidis (N=127) n (%) |
| PatientsWithAtLeastOneSAEAtLeast PossiblyRelatedtoStudyTreatment | 2 (3.1)                | 2 (3.2)              | 1 (2.3)            | 1 (2.4)            | 3 (14.3)               | 5 (4.7)                 | 7 (5.5)                 |
| Ankle fracture                                                   | 0                      | 0                    | 0                  | 0                  | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Lymphoma                                                         | 0                      | 0                    | 1 (2.3)            | 0                  | 0                      | 1 (0.9)                 | 1 (0.8%)                |
| Malaise                                                          | 0                      | 0                    | 0                  | 0                  | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Meningitis                                                       | 0                      | 0                    | 0                  | 1 (2.4)            | 0                      | 1 (0.9)                 | 1 (0.8)                 |
| Transientischaemicattack                                         | 0                      | 0                    | 0                  | 0                  | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Urinary retention                                                | 0                      | 0                    | 0                  | 0                  | 1 (4.8)                | 1 (0.9)                 | 1 (0.8)                 |
| Urinarytractinfection                                            | 1 (1.5)                | 0                    | 0                  | 0                  | 0                      | 0                       | 1 (0.8)                 |
| Urticaria                                                        | 1 (1.5)                | 0                    | 0                  | 0                  | 0                      | 0                       | 1 (0.8)                 |
| Anaemia                                                          | 0                      | 1 (1.6)              | 0                  | 0                  | 0                      | 0                       | 0                       |
| Syncope                                                          | 0                      | 1 (1.6)              | 0                  | 0                  | 0                      | 0                       | 0                       |
| Vomiting                                                         | 0                      | 1 (1.6)              | 0                  | 0                  | 0                      | 0                       | 0                       |

Note:T-Treflects tafamidis treatment inbothStudyFx-005andFx-006.P-T reflects placebotreatment inStudyFx-005 and tafamidis treatment in StudyFx-006.

Overall,  7  of  127  (5.5%)  tafamidis  treated  patients  experienced  at  least  one  serious  adverse  event judged by the investigator to be at least possibly related to study treatment. The incidence of at least possibly related SAEs was higher in study Fx1A-201 than in studies Fx-005 and Fx-006, possibly due to the underlying differences in the characteristics of the patient population enrolled, as described above. No type of SAE judged to be at least possibly related to study medication was reported in more than one patient.

There  were  seven  deaths  in  the  ATTR-PN  patients,  five  in  the  pivotal  study  Fx-005;  these  cases occurred only post liver transplantation: three deaths occurred in patients who were on placebo prior to liver transplantation and 2 deaths occurred in the tafamidis group. Each of these two deaths was attributed to treatment associated with liver transplant, one patient died shortly after liver transplantation  due  to  an  unknown  cause,  while  the  other  died  due  to  cardiac  tamponade  as  a complication  of  pacemaker  insertion  post  liver  transplantation.  Of  note,  patients  undergoing  liver transplantation were discontinued from the study medication prior to the transplantation and thus, the deaths occurred only after patients had already been discontinued from tafamidis. The five cases of death are summarised in table 36:

<div style=\"page-break-after: always\"></div>

Table 36

| Study Nunber   | Treatment   |   Age (yrs) | Sex    |   Duration of exposure (Days) | Diagnosis   | CauseofDeath                                                                                            | Location ofnarrative description           |
|----------------|-------------|-------------|--------|-------------------------------|-------------|---------------------------------------------------------------------------------------------------------|--------------------------------------------|
| Fx-005         | Tafamidis   |          54 | Female |                           328 | ATTR-PN     | Cardiactamponade after cardiac manipulationfor temporary artificial pacemakerpost liver transplantation | Section14.3.3,Clinical Study Report Fx-005 |
|                | Tafamidis   |          37 | Female |                           560 | ATTR-PN     | Death after liver transplantation, unknown cause                                                        |                                            |
|                | Placebo     |          41 | Female |                           457 | ATTR-PN     | Hepaticfailure after transplant                                                                         |                                            |
|                | Placebo     |          63 | Female |                           437 | ATTR-PN     | Sepsis post liver transplant                                                                            |                                            |
|                | Placebo     |          35 | Female |                           336 | ATTR-PN     | Death after liver transplantation, unknown cause                                                        |                                            |

In the ongoing study Fx1A-303, a total of fourteen SAEs have been reported in eight patients (cut-off date:  9  December  2010).  Most  of  them  were  attributed  to  the  underlying  conditions  particularly nervous  system,  gastrointestinal  and  cardiac  disorders.  The  two  deaths  occurring  during  Fx1A-303 study  were  reported  in  patients  with  ATTR-PN  on  tafamidis  and  were  not  associated  with  liver transplantation. These patients were older than the patients who died after liver transplantation and with stage 3 disease at the time of tafamidis initiation. These deaths seemed related to progression of the underlying disease.

## Laboratory findings

There  were  no  meaningful  differences  in  mean  laboratory  parameters  between  the  placebo  and tafamidis  treatment  groups  in  study  Fx-005.  The  overall  tafamidis-treated  population  demonstrated similar trends for the laboratory parameters to those observed in the pivotal study Fx-005.

The  incidence  of  treatment-emergent  potentially  clinically  significant  (PCS)  laboratory  values  was generally  similar  between  the  treatment  groups  in  study  Fx-005,  with  no  apparent  increase  in  PCS values in tafamidis-treated patients. Overall, changes in liver function tests were unremarkable, except for one patient who had increase in liver function tests three times above the upper limit of normal associated with tafamidis treatment during participation in Studies Fx-005 and Fx-006. However, no constitutional signs or symptoms were reported and no increase in bilirubin was noted in this patient.

Average changes over time in vital sign parameters were minor and not clinically relevant; no trends were observed and outcomes were similar between treatment groups and across studies. Changes in both  heart  rate  and  QTcF  (as  well  as  the  other  ECG  parameters)  over  time  were  similar  and  not clinically meaningful between the placebo and tafamidis patients in study Fx-005; the overall tafamidis treatment group demonstrated similar trends over time, indicating that treatment with tafamidis up to 30 months does not meaningfully affect ECG parameters. Tafamidis treatment at doses up to three times  the  dose  to  be  marketed  did  not  impact  cardiac  repolarization  in  healthy  volunteers,  nor  did tafamidis cause significant dysrhythmias in ATTR-PN patients.

Transthyretin  (pre-albumin)  is  a  transport  protein  for  retinol  binding  protein-vitamin  A  complex  and thyroxin. As tafamidis binds to the thyroxine binding site of TTR, a careful assessment of the impact of tafamidis on TTR, RBP and thyroid hormone levels was performed. In Fx-005, mean increases from baseline in TTR (increases ranging from 4 to 6 mg/dl) were observed at every post-baseline study visit for tafamidis-treated patients, with the maximum increase observed at the 8 week visit and no further

<div style=\"page-break-after: always\"></div>

increase was observed at later time points. Similarly to TTR, mean increases in RBP levels (range 2 to 11  mg/dl)  were  observed  in  tafamidis  patients.  In  Fx-006,  TTR  and  RBP  values  in  the  tafamidistafamidis group were constant over time.

With respect to thyroid function no significant changes were observed from baseline; the mean change was similar to placebo treated patients at all time points in the pivotal study Fx-005. The mean and median T4, free T4 and TSH values were within the normal ranges at baseline and at all time points during Fx-006 study (see Discussion).

## Safety in special populations

## Pregnancy

Pregnant and lactating women were excluded from the clinical trial protocols. Nevertheless, in Fx-005, one  pregnancy  occurred  in  a  tafamidis-treated  patient  (healthy  baby)  and  one  in  a  placebo-treated patient. No other pregnancies were reported during other studies.

## Paediatric population

There  was  no  data  in  the  use  of  tafamidis  in  children  and  adolescents  less  than  18  years  old  (the youngest patient in the tafamidis population was 24 years old).

## Elderly population

Overall, data on the elderly population were scarce since only 8 patients &gt;65 years old were enrolled in study Fx-005 (5 patients in tafamidis group and 3 in placebo group).

## Renal impairment population

Data on patients with renal impairment are very scarce since only two patients with CrCl &lt;50ml/min and 10 with CrCl between 50 and 80 ml/min were enrolled in pivotal study.

## Immunological events

In  study  Fx-005  study,  only  one  TEAE  (hypersensitivity)  was  reported  in  the  SOC  'Immune  system disorders' (placebo group). No signal emerged from these data regarding the immunological events.

In study Fx-006, one serious case of hypersensitivity was reported in the tafamidis-tafamidis group. Due to previous treatment with cotrimoxazole (known to trigger allergic reactions) and negative rechallenge, the role of tafamidis was considered doubtful.

## Safety related to drug-drug interactions and other interactions

Tafamidis was highly bound to plasma proteins (&gt;99%) across all species tested and decreased the human plasma protein binding of prednisone by approximately 10%, with no impact on the protein binding of tacrolimus, cyclosporine or warfarin; this indicated no clinical effect during co-administration with other highly protein-bound drugs.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

In study Fx-005, a total of seven (5.5%) patients discontinued due to a treatment-emergent adverse event,  four  (6.2%)  tafamidis-treated  patients  and  three  (4.8%)  placebo-treated  patients.  Adverse events  leading  to  discontinuation  for  the  tafamidis-treated  patients  included  diarrhoea,  nausea, pregnancy and urticaria. AEs leading to discontinuation for placebo-treated patients included cardiac amyloidosis, nausea, fatigue and paresthesia (both in one patient). No patients discontinued study Fx006 due to adverse events.

In Fx1A-201, one 74-year-old female patient with a history of bradycardia, orthostasis, hypertension and ATTR-related congestive heart failure discontinued due to mild transient ischemic attack (occurring 31 days after tafamidis initiation).

In Fx1A-303, except for the two deaths referred to above, no subject was withdrawn from the study due to an adverse event (cut-off date: 9 December 2010).

## Post marketing experience

Not applicable

## 2.6.1. Discussion on clinical safety

Given  the  prevalence  of  the  condition,  the  overall  safety  database  was  considered  reasonable.  The safety evaluation of tafamidis in the target population, i.e. patients suffering from ATTR-PN, was based on clinical studies Fx-005 (pivotal study), Fx-006 and Fx-1A201, data from phase I clinical programme in  healthy  subjects  and  interim  data  from  study  Fx1A-303.  Study  Fx1B-201  in  a  subset  of  ATTR patients with cardiomyopathy (ATTR-CM) generated supportive safety data.

Overall, no major safety concerns were identified in the target population treated with tafamidis. The adverse  events  were  generally  mild  to  moderate  in  severity,  mostly  represented  by  urinary  tract infection,  infections  (mainly  respiratory  infections),  diarrhoea,  headache,  pain  in  the  extremity  and vomiting. In particular, urinary tract infections, diarrhoea, upper abdominal pain and vaginal infection were considered as important identified risks by the CHMP and thus, they were included in the Risk Management Plan and reflected in section 4.8 of the SmPC as follows:

'Adverse reactions are listed below by MedDRA System Organ Class (SOC) and frequency (very common: ≥ 1/10; common: ≥ 1/100 to &lt; 1/10):

Infections and infestations

Very common:  Urinary tract infection

Common:  Vaginal infection

Gastrointestinal disorders

Very common:  Diarrhoea

Common:  Upper abdominal pain'

Based on a significant case of liver function test abnormalities, hepatotoxicity was considered as an important potential risk, even though a negative re-challenge was finally seen in study Fx1A-303 for the affected patient. Several possible mechanisms for the potential hepatotoxicity were outlined by the applicant, such as enzyme induction, metabolism or thyroid hormone disruption. The CHMP considered that only 65 patients were exposed to tafamidis in the pivotal study and therefore, identification of one case  of  hepatotoxicity  might  be  of  clinical  relevance.  In  this  context,  the  CHMP  concluded  that hepatotoxicity  will  be  further  monitored  in  the  post-authorisation  setting  by  means  of  routine pharmacovigilance activities including use of data capture aid for hepatotoxicity, collection of data in

<div style=\"page-break-after: always\"></div>

the  ongoing  study  Fx1A-303  and  collection  of  data  on  adverse  events  in  the  TTR-associated amyloidosis outcomes survey (THAOS). The CHMP considered that the data from the THAOS survey will  be  provided  on  an  annual  basis, i.e.  synchronized  with  the  timing  of  the  annual  re-assessment. These pharmacovigilance measures were deemed satisfactory by the CHMP to further characterize this potential risk.

As described in the non-clinical section, the effect on the thyroid function was also discussed in detail by the CHMP. In the pivotal study Fx-005 no significant changes for thyroid functions were seen from baseline  and  mean  change was similar to placebo treated  patients at  all time  points. The  values  of thyroid  function  parameters  were  also  within  the  normal  ranges  at  baseline  and  at  all  time  points during  study  Fx-006.  Based  on  these  observations  the  CHMP  considered  that  the  theoretical  risk  of tafamidis on thyroid function was unlikely, but could not be completely ruled out. In particular, the CHMP was of the  opinion  that  despite  absence  of  relevant  effect  on  the  thyroid  function,  tafamidis treatment  may  have  subtle  impact  on  the  thyroid  function  due  to  the  competition  to  the  binding proteins.  In  this  context,  the  CHMP  was  of  the  opinion,  that  changes  of  thyroid  function  should  be considered as an important potential risk in the RMP.

Conduction  and  rhythm  disorders  were  thoroughly  analyzed  by  the  applicant.  Based  on  the  data provided, no increased risk of conduction or rhythm abnormalities associated with the use of tafamidis was identified in the studies.

Based  on  the  data  provided,  the  CHMP  considered  that  there  is  no  evidence  that  treatment  by tafamidis in study Fx-005 was associated with a higher incidence of orthostatic hypotension or that the data suggest an increase of this type of events with longer exposure.

The  CHMP  considered  that  data  on  special  populations,  such  as  the  elderly  and  patients  with  renal impairment  are  scarce,  but  considered  this  in  the  context  of  the  rare  nature  of  the  disorder  as acceptable.  Only  one  pregnancy  in  a  patient  treated  with  tafamidis  was  reported.  The  mother  gave birth to a healthy baby without any congenital abnormality. Due to the limited data on pregnancy, no conclusions on the use of tafamidis could be made and the use of the product during pregnancy was not recommended.

## Additional safety data needed in the context of a MA under exceptional circumstances

The population enrolled in the pivotal study were patients with V30M mutation at an early stage 1 of the  disease;  the  data  on  patients  with  non-V30M  ATTR-PN  patients  originated  only  from  a  noncontrolled study (Fx1A-201). This study was conducted in 21 patients with non V30M ATTR-PN, which constitutes  a  population  different  from  the  V30M  ATTR-PN  patients  (older  patients,  more  severe disease, more cardiac impairment). The CHMP considered that as part of the sub-study Fx-R-001-S2 requested  as  a  specific  obligation,  safety  data  in  the  non-V30M  ATTR-PN  patients  will  be  collected, which should contribute to further characterising the safety profile in this particular sub-population of patients.

## 2.6.2. Conclusions on the clinical safety

The safety of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. The safety conclusions are further discussed in the context of the overall benefitrisk balance.

<div style=\"page-break-after: always\"></div>

The CHMP concluded that the MA under exceptional circumstances should be granted and considered the following measure necessary to address the missing safety data in its context:

Specific obligation:

'Within the planned post-authorisation sub-study of the THAOS registry the MAH shall evaluate in nonV30M patients the effects of Vyndaqel on disease progression and its long term safety as detailed in a CHMP agreed protocol, and shall provide yearly updates on the collected data within the annual reassessment.'

## 2.7. Pharmacovigilance

## Detailed description of the pharmacovigilance system

The  CHMP  considered  that  the  Pharmacovigilance  system  as  described  by  the  applicant  fulfils  the legislative requirements.

## Risk Management Plan

The applicant submitted a risk management plan, which included a risk minimisation plan.

Table 37 Summary of the EU-RMP

| Safety concern             | Proposed pharmacovigilance activities (routine and additional)                                                                                                                                                                                                            | Proposed risk minimisation activities (routine and additional)                                                                                                             |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks | Important identified risks                                                                                                                                                                                                                                                | Important identified risks                                                                                                                                                 |
| Urinary tract infection    | Routine pharmacovigilance Continue data collection in ongoing Study Fx1A-303 'Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis'. Transthyretin-Associated Amyloidosis Outcomes Survey (THAOS), amended protocol Fx-R-001. | Routine: Urinary tract infection is included in SmPC Section 4.8 'Undesirable Effects' (Infections and infestations: Very common: Urinary tract infection) and in the PIL. |
| Diarrhoea                  | Routine pharmacovigilance Continue data collection in ongoing Study Fx1A-303 'Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis'. Transthyretin-Associated Amyloidosis Outcomes Survey (THAOS), amended protocol Fx-R-001. | Routine: Diarrhoea is included in SmPC Section 4.8 'Undesirable Effects' (Gastrointestinal disorders: Very common: Diarrhoea) and in the PIL.                              |

<div style=\"page-break-after: always\"></div>

| Upper abdominal pain       | Routine pharmacovigilance Continue data collection in ongoing Study Fx1A-303 'Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis'. Transthyretin-Associated Amyloidosis Outcomes Survey (THAOS), amended protocol Fx-R-001.                                                     | Routine: Upper abdominal pain is included in SmPC Section 4.8 'Undesirable Effects' (Gastrointestinal disorders: Common: Upper abdominal pain), and stomachache and abdominal pain included in the PIL.                                                                            |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Vaginal infection          | Routine pharmacovigilance Continue data collection in ongoing Study Fx1A-303 'Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis'. Transthyretin-Associated Amyloidosis Outcomes Survey (THAOS), amended protocol Fx-R-001.                                                     | Routine: Vaginal infection is included in SmPC Section 4.8 'Undesirable Effects' (Infections and infestations: Common: Vaginal infection) and in the PIL.                                                                                                                          |
| Important potential risks  | Important potential risks                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                    |
| Hepatotoxicity             | Routine pharmacovigilance including use of data capture aid Continue data collection in ongoing Study Fx1A-303 'Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis'. Transthyretin-Associated Amyloidosis Outcomes Survey (THAOS), amended protocol Fx-R-001.                   | Routine: SmPC Section 4.2 'Hepatic and renal impairment: No dosage adjustment is required for patients with renal or mild and moderate hepatic impairment. Vyndaqel has not been studied in patients with severe hepatic impairment and caution is recommended (see section 5.2)'. |
| Hypersensitivity reactions | Routine pharmacovigilance including use of data capture aid (to be developed) Continue data collection in ongoing Study Fx1A-303 'Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis'. Transthyretin-Associated Amyloidosis Outcomes Survey (THAOS), amended protocol Fx-R-001. | Routine: Hypersensitivity to the active substance or to any of the excipients is included in SmPC Section 4.3 'Contraindications' and in the PIL.                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Reproductive toxicity                                       | Routine pharmacovigilance including collection of intrauterine exposure data. Tafamidis Enhanced Surveillance for Pregnancy Outcomes (TESPO). Continue data collection in ongoing Study Fx1A-303 'Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis'. Transthyretin-Associated Amyloidosis Outcomes Survey (THAOS), amended protocol Fx-R-001.   | Routine: Inclusion of 'Women of childbearing potential should use appropriate contraception when taking Vyndaqel (see section 4.6)' in SmPC Section 4.4 'Special Warnings and Precautions for Use', 'Women of childbearing potential: Contraceptive measures should be used by women of childbearing potential during treatment with Vyndaqel, and for one month after stopping treatment, due to the prolonged half life, and 'Pregnancy There are no data on the use of Vyndaqel in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Vyndaqel is not recommended during pregnancy and in women of childbearing potential not using contraception.' in SmPC Section 4.6 'Fertility, pregnancy, and lactation', and corresponding information in the PIL. Additional: Physician Information Leaflet with important details on THAOS registry and TESPO programme.   |
|-------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Changes in Thyroid Function, particularly in pregnant women | Routine pharmacovigilance including collection of intrauterine exposure data Tafamidis Enhanced Surveillance for Pregnancy Outcomes (TESPO). Transthyretin-Associated Amyloidosis Outcomes Survey (THAOS), amended protocol Fx-R-001.                                                                                                                                                           | Routine: Inclusion of 'Women of childbearing potential should use appropriate contraception when taking Vyndaqel (see section 4.6)' in SmPC Section 4.4 'Special Warnings and Precautions for Use', 'Women of childbearing potential: Contraceptive measures should be used by women of childbearing potential during treatment with Vyndaqel, and for one month after stopping treatment, due to the prolonged half life', and 'Pregnancy: There are no data on the use of Vyndaqel in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Vyndaqel is not recommended during pregnancy and in women of childbearing potential not using contraception.' in SmPC Section 4.6 'Fertility, pregnancy, and lactation', and corresponding information in the PIL.                                                                                                         |
| Important missing data                                      | Important missing data                                                                                                                                                                                                                                                                                                                                                                          | Important missing data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Safety and efficacy in elderly patients                     | Routine pharmacovigilance Continue data collection in ongoing Study Fx1A-303 'Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis'. Transthyretin-Associated Amyloidosis Outcomes Survey (THAOS), amended protocol Fx-R-001.                                                                                                                       | In SmPC Section 4.2 'Posology and method of administration': ' Elderly: No dosage adjustment is required for elderly patients ( ≥ 65 years)'.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Longer term safety   | Routine pharmacovigilance Continue data collection in ongoing Study Fx1A-303 'Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis'. Transthyretin-Associated Amyloidosis Outcomes Survey (THAOS registry) Collect data from Study Fx-R-001-S2 'A THAOS Sub-study Evaluating the Effects of Tafamidis on Disease Progression in Patients with Non-V30M Mutations and Symptomatic Neuropathy'. Transthyretin-Associated Amyloidosis Outcomes Survey (THAOS), amended protocol Fx-R-001.   | In SmPC Section 5.1 'Pharmocodynamic properties': 'In the open-label extension study the rate of change in the NIS-LL during the 12 months of open label treatment was similar to that observed in the previous 18 months. Although data are limited (one open label study in 21 patients), taking into account the mechanism of action of Vyndaqel and the results on TTR stabilisation, Vyndaqel may be beneficial in patients with stage 1 TTR amyloid polyneuropathy due to mutations other than V30M.' Additional: Physician Information Leaflet with important details on THAOS registry and TESPO programme.   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

The  CHMP,  having  considered  the  data  submitted,  was  of  the  opinion  that  the  pharmacovigilance activities in addition to the use of routine pharmacovigilance, as summarised in the EU-RMP Summary table (table 37), are needed to investigate further some of the safety concerns.

The CHMP, having considered the data submitted, was of the opinion that the following additional risk minimisation  activity  was  required:  a  Physician  Information  Leaflet  with  important  details  on  the THAOS registry and TESPO programme, as referenced in the EU-RMP Summary table (table 37).

In  addition,  the  CHMP  considered  that  the  applicant  should  take  the  following  minor  points  into consideration when an update of the Risk management Plan is submitted:

1. The assessment of the synopsis for the amended protocol (THOAS Study Fx-R-001): In the objective to collect adverse drug reaction data in patients with TTR amyloidosis treated with tafamidis the safety concerns urinary tract infection, diarrhoea, upper abdominal pain, vaginal infection, safety and efficacy in elderly patients and long term safety are missing. The synopsis should reflect the safety concerns to monitor in line with EU-RMP table 25. Furthermore, the RMP does not mention if the potential risk of thyroid function changes  will be addressed by this study. The  synopsis should be  updated accordingly and the final protocol submitted within three months post Opinion.
2. In EU-RMP section 2.2.1.6 the reference to the specific obligation should be deleted.
3.   In  EU-RMP  table  26  for  the  potential  risk  of  changes  to  thyroid  function  Study  Fx1A-303  is  not mentioned in the action plan but the annual safety report is included as a milestone. The applicant should clarify if Study Fx1A-303 will address this safety concern. In the same context the applicant should clarify if the amended protocol Fx-R-001 will address the potential risk of changes of thyroid function. EU-RMP table 25 should be aligned accordingly.
4.  In EU-RMP table 26 it is not clear why Study Fx1A-303 was removed from titles of protocols row.
5.  The  physician  leaflet  intended  to  highlight  to  HCP  the  existence  of  THAOS  registry  and  TESPO programme should be linked to relevant safety concerns (i.e. potential risk of reproductive toxicity and important missing information on long term safety) in table 27, rather than to each identified risk.

6. The applicant should update EU-RMP table 27 with the status for amended study protocol Fx-R-001 (THAOS  registry)  and  protocol  synopsis  Fx-R-001-S2  (THAOS  sub-study)  and  provide  in  EU-RMP section '2.6. Summary  of  outstanding  actions, including milestones' a tabulated overview of outstanding actions of the pharmacovigilance plan including milestones. The final protocol of Fx-R-001S2 sub-study should be submitted within three months post opinion.

7. The applicant should update EU-RMP table 29 in line with all the above changes.

<div style=\"page-break-after: always\"></div>

## 2.8. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

The  mode  of  action  of  tafamidis  was  supported  by  results  of  the  clinical  pharmacology  and  clinical efficacy studies (pivotal study) and is linked to the physiopathology of the disease, i.e. TTR dissociation followed by accumulation of monomers and deposition of amyloid in several tissues. As discussed in the  Clinical  Pharmacology  section,  results  from  Fx-005  on  the  TTR  stabilisation  were  supportive  of justifying  the  20  mg  once  daily  tafamidis  dosing,  i.e.  adequate  TTR  stabilisation.  The  CHMP  also considered  that  this  was  further  supported  by  TTR  stabilisation  data  obtained  in  the  long-term extension  study  Fx-006,  as  the  results  were  consistent  with  those  seen  previously.  This  TTR stabilisation effect of tafamidis was observed on the wild-type TTR as well as on several TTR mutations including the V30M and non-V30M mutations. In particular, data from study Fx1A-201 indicated that tafamidis  was  able  to  stabilize  TTR  with  other  mutation  than  the  V30M,  as  also  shown  in in  vitro studies.

As  described  in  the  Clinical  efficacy  section,  the  pre-specified  secondary  analyses  performed  in  the evaluable  population  (PP)  on  the  co-primary  endpoints  (NIS-LL  %  of  responders  and  TQoL)  and  on several  secondary  endpoints,  such  as  the  mean  NIS-LL  change  from  baseline  to  visit  at  month  18, favoured tafamidis to placebo. In a supplementary multiple imputation analysis, the mean change from baseline in NIS-LL was statistically different between the treatment groups, supporting the previous results. The CHMP considered that the observed effects were clinically relevant.

Of  note,  tafamidis  is  the  first  oral  pharmacological  treatment  proposed  in  this  indication  for  the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay  peripheral  neurologic  impairment;  currently,  the  only  available  treatment  alternative  is  the orthotopic liver transplantion.

## Uncertainty in the knowledge about the beneficial effects

One pivotal study was conducted in 125 ATTR-PN patients with V30M mutation. The primary objective of this study was to evaluate the effect of tafamidis 20 mg once daily on disease progression over 18 months using two co-primary criteria, i.e. responders on NIS-LL score, defined as patients with a NISLL score change from baseline &lt;2 points at month 18, and change from baseline of the TQOL score (Total Norfolk quality of life score).

Applying a conservative approach (patients who underwent liver transplantation before month 18 were withdrawn from the study and were considered as treatment failures), statistically significant results were not obtained at month 18 (primary time point) for either of the two co-primary endpoints; at month 18, 45% of patients in the tafamidis group had an increase in the NIS-LL of &lt;2 as compared to 29.5% patients in the placebo group (p=0.068).  TQOL mean (SD) change from baseline to month 18 was 2.4 (14.6) in the tafamidis group as compared to 6.9 (22.9) in the placebo group (p=0.1157).

<div style=\"page-break-after: always\"></div>

In this context, the CHMP considered that liver transplantation was scheduled before inclusion in the study  and  patients  on  the  waiting  list  for  whom  an  organ  became  available  were  allowed  to  be transplanted for ethical reason. Most of study discontinuations were due to liver transplantation and balanced between groups. When the evaluable population is taken into account, the responder on NISLL  scores  were  statistically  different  between  tafamidis  and  placebo  at  month  18.  A  statistically significant difference in favour of the tafamidis group at month 18 was also observed for TQOL.

The  description  of  the  transplanted  population  showed  that  transplanted  patients  presented  with  a more  severe  disease  and  longer  disease  duration  than  non  transplanted  patients,  but  were  not differently represented in the two groups. In addition, there were no major differences in the interval to  transplantation  between  tafamidis  and  placebo  group.  The  efficacy  data  did  not  seem  to  show significant  differences  between transplanted and non transplanted patients, but the interpretation of these  data  was  considered  difficult  due  to  the  low  number  of  patients  per  group.  Nevertheless,  the CHMP was of the view that transplantation does not seem to be related to the treatment group.

A  sensitivity  analysis  was  conducted  to  impute  patients  who  underwent  liver  transplantation.  The approach  used  by  the  applicant  was  confirmed  by  supplementary  analyses  with  other  imputation methods and was considered supportive, as statistically significant difference for mean NIS-LL change from baseline, favouring tafamidis, was shown.

The CHMP considered that the familial amyloid polyneuropathy is a length-dependent condition with a pre-dominant progressive sensory loss. On the NIS-LL score, the maximum total score possible for the sensory  component  is  16/88  points  compared  to  the  maximum  total  score  possible  for  the  motor component of 64/88. Since the condition manifests predominantly as a sensory neuropathy, the ability of NIS-LL to properly evaluate disease progression in ATTR-PN was considered by the CHMP. In order to  provide  more  data  on  the  clinical  relevance  of  the  criteria  chosen,  i.e  NIS-LL  and  Norfolk,  the applicant  provided  comparison  between  groups  on  yearly  rate  of  disease  progression,  based  on  a regression model from the cross sectional observational study Fx1A-OS-001 and the data obtained in the Fx-005 study.

The results on annual progression based on both scores as observed in study Fx-005 were consistent with the estimated rate of change from Study Fx1A-OS-001 and supported the utility of the NIS-LL and TQOL in documenting disease progression in ATTR-PN. Thus, the CHMP considered the effects observed on the co-primary parameters clinically relevant.

The CHMP discussed the duration of the pivotal study and the proposed primary time-point (month 18), which was determined empirically. In this context, the CHMP considered that the regression model used to determine the yearly rate of disease progression was valid and was of the view that the study duration can be accepted as sufficient to show an effect in the ATTR-PN patients.

The CHMP also took into consideration results of  the  open-label  studies  in  ATTR-PN  V30M;  patients were evaluated  by  comparing  the  disease  rate  of  progression  in  tafamidis  treated  patients  for  both NIS-LL  and  TQOL  between  the  treatment  period  of  each  study  and  the  disease  rate  progression calculated with the placebo arm of the Fx-005 study. These results suggested stability of the disease and maintenance of effect. Nevertheless, the CHMP considered that results of open studies are not as robust  as  results  of  controlled  studies,  that  the  analyses  performed  did  not  follow  the  multiple imputation  technique  and  that  there  were  uncertainties  regarding  data  handling.  However,  when comparing  the  evolution  of  NIS-LL  in  tafamidis  treated  patients  during  the  18-month  double-blind period and the 12-month open-label period, the rate of change in the NIS-LL score was similar for both periods.

The population enrolled in the pivotal study were patients with V30M mutation at an early stage 1 of the  disease;  the  data  on  patients  with  non-V30M  ATTR-PN  patients  originated  only  from  a  non-

<div style=\"page-break-after: always\"></div>

controlled study (Fx1A-201). This study was conducted in 21 patients with non V30M ATTR-PN, which constitutes  a  population  different  from  the  V30M  ATTR-PN  patients  (older  patients,  more  severe disease, more cardiac impairment). These patients were included at late stage 1 of the disease (mean NIS-LL  of  27.6  at  inclusion).  In  this  context,  the  CHMP  pointed  at  limitations  of  comparisons  made between different studies (Fx-005 and Fx1A-201) and different patient populations (V30M versus non V30M mutation).  However,  as  the  applicant  also  provided  comparison  between  the  monthly  rate  of change on the NIS score before vs after treatment with tafamidis and the TTR stabilisation data were favourable  irrespective  of  the  mutation,  the  CHMP  considered  that  extrapolation  from  V30M  to  non V30M  patients  was  acceptable.  The  SmPC  section  5.1  is  phrased  accordingly,  i.e.  addressing  the expected beneficial effect in patients with mutations other than V30M.

## Risks

## Unfavourable effects

Overall, no major safety concerns were identified in the target population treated with tafamidis. The adverse  events  were  generally  mild  to  moderate  in  severity,  mostly  represented  by  urinary  tract infection, infections (mainly respiratory infections), diarrhoea, upper abdominal pain, headache, pain in the extremity and vomiting.

Infections (mainly represented by the urinary tract infections) and infestations were the main events reported in the tafamidis group in the pivotal study Fx-005.  In this study, the UTIs were observed in 23.1%  of  patients  in  tafamidis  group  versus  12.7%  in  placebo  group.  The  majority  of  events  was responsive to antibiotics and did not require interruption or discontinuation of the study drug. Given the higher incidence of UTIs in the tafamidis group, a causal relationship between tafamidis and UTI could not be ruled out and the UTIs were considered as an important identified risk by the CHMP.

A  higher  incidence  of  vaginal  infections  in  women  was  observed  in  tafamidis  (18.2%)  vs  placebo (8.1%) in the pivotal study; all vaginal infections were mild and non-serious and none required study drug  interruption  or  discontinuation.  Although  the  mechanism  of  this  event  is  not  known,  vaginal infection is considered as an important identified risk.

Diarrhoea was reported more frequently in patients treated with tafamidis. Among the two cases of diarrhoea  which  were  considered  severe,  one  led  to  drug  discontinuation  due  to  worsening  of diarrhoea. The role of tafamidis in this case remained unclear. Despite diarrhoea being typical of ATTRPN, given the higher incidence of diarrhoea in the tafamidis group, the CHMP concluded that a causal relationship could not be ruled out and diarrhoea was considered as an identified risk.

Conduction  and  rhythm  disorders  were  thoroughly  analyzed  by  the  applicant.  Based  on  the  data provided, no increased risk of conduction or rhythm abnormalities associated with the use of tafamidis was identified in the studies.

## Uncertainty in the knowledge about the unfavourable effects

Based on one case of liver function test abnormalities, hepatoxicity was considered as an important potential  risk.  Several  possible  mechanisms  (enzyme  induction,  metabolism  and  thyroid  hormone disruption)  were  proposed  as  underlying  the  potential  hepatotoxicity,  but  the  relationship  remains uncertain. Although a negative re-challenge was eventually observed in study Fx1A-303 in the affected patient,  this  unfavourable  effect  was  taken  into  account  in  the  context  of  a  limited  exposure  to tafamidis in the pivotal study (65 patients).

<div style=\"page-break-after: always\"></div>

The  CHMP  considered  that  data  on  special  populations,  such  as  the  elderly  and  patients  with  renal impairment  are  scarce,  but  considered  this  in  the  context  of  the  rare  nature  of  the  disorder  as acceptable. Only one pregnancy in a patient treated with tafamidis was reported, with no congenital abnormality  in  the  newborn.  Due  to  the  limited  data  on  pregnancy,  no  conclusions  on  the  use  of tafamidis could be made and the use of the product during pregnancy was not recommended.

The effect on the thyroid function was also discussed in detail by the CHMP. In the pivotal study Fx005 no significant changes for thyroid functions were seen from baseline and mean change was similar to  placebo  treated  patients  at  all  time  points.  The  values  of  thyroid  function  parameters  were  also within  the  normal  ranges  at  baseline  and  at  all  time  points  during  study  Fx-006.  Based  on  these observations  the  CHMP  considered  that  the  theoretical  risk  of  tafamidis  on  thyroid  function  was unlikely, but could not be completely ruled out. In particular, the CHMP was of the opinion that despite absence of relevant effect on the thyroid function, tafamidis treatment may have subtle impact on the thyroid function due to the competition to the binding proteins. In this context, the CHMP was of the opinion,  that  changes  of  thyroid  function  should  be  considered  as  an  important  potential  risk  in  the RMP.

The CHMP noted that in the chromosomal aberration assay in human peripheral lymphocytes, a dosedependant  increase  of  polyploidy  was  observed  in  the  presence  of  S9.  Considering  the  unclear relevance of the finding and the large safety margins regarding micronucleus induction (&gt;70) as well as  the  safety  margin  regarding  polyploidy  in  the  chromosome  aberration  assay  (=18),  the  CHMP concluded that in the context of a serious disease with a lack of therapeutic options, this finding did not impact  negatively  on  the  benefit-risk  balance  of  tafamidis.  One  impurity  with  an  unclear  genotoxic potential was seen in the study on impurities. Due its negligible levels in the final product, the CHMP was of the opinion that this finding would not impact on the benefit-risk balance, either.

## Benefit-risk balance

## Importance of favourable and unfavourable effects

Tafamidis is the first oral pharmacological treatment proposed in the treatment of ATTR-PN patients, which is a severe, progressive orphan disease, with a fatal evolution in around 10 years. The mode of action of tafamidis is linked to the pathophysiology of the disease, with a TTR stabilisation effect on several TTR mutations and wild-type TTR. One pivotal double blind placebo controlled study has been conducted  in  128  ATTR-PN  patients  with  V30M  mutation.  This  study  failed  to  attain  its  primary objectives.  However,  the  other  pre-specified  analyses  and  results  on  secondary  criteria  showed statistically significant differences in favour of tafamidis. Analyses with multiple imputations showed a statistically  significant  difference  in  mean  change  from  baseline  for  the  NIS-LL  score.  The  effects observed  were  considered  clinically  relevant.  Supplementary  analyses  performed  by  the  applicant, determining the yearly rate of progression of the disease and analyses of efficacy according to different thresholds for responders also allowed to validate the clinical relevance of the effect.

Tafamidis  was  well  tolerated  across  studies  in  both  healthy  volunteers  and  patients  with  ATTR-PN. Overall, no major safety concerns were identified in the target population treated with tafamidis. The adverse events were generally mild to moderate in severity. Identification of one case of hepatotoxicity might be of clinical relevance. In this context, the CHMP concluded that hepatotoxicity will be further monitored in the post-authorisation setting by means of routine pharmacovigilance activities including use  of  data  capture  aid  for  hepatotoxicity,  collection  of  data  in  the  ongoing  study  Fx1A-303  and collection  of  data  on  adverse  events  in  the  TTR-associated  amyloidosis  outcomes  survey  (THAOS).

<div style=\"page-break-after: always\"></div>

These pharmacovigilance measures were deemed satisfactory by the CHMP to further characterize this potential risk.

The benefit-risk of tafamidis in ATTR-PN patients with non V30M mutation is based on an open label study  and  the  data  are  therefore  not  robust.  However,  the  applicant  provided  a  comparison  of  the monthly rate of change on NIS before and after treatment with tafamidis and the CHMP agreed that this,  together  with  the  TTR  stabilisation  data,  is  supportive  of  the  extrapolation  from  V30M  to  non V30M patients. In order to collect more information on the efficacy and safety of tafamidis in non V30M patients, the CHMP requested that a dedicated sub-study shall be performed by the applicant to further evaluate  tafamidis  safety  in  non  V30M  patients  and  to  collect  further  clinical  data  on  the  patients´ neurologic status.

## Discussion on the benefit-risk balance

The pivotal phase II/III study did not show statistically significant differences on the primary analysis, conducted with a conservative approach, i.e., with patients undergoing liver transplantation during the study  considered  as  treatment  failures.  The  other  pre-specified  and  supplementary  (with  multiple imputations) analyses and results on secondary criteria showed statistically significant differences in favour  of  tafamidis.  Furthermore,  other  supplementary  analyses  performed  by  the  applicant,  i.e. determination  of  yearly  rate  of  progression  of  the  disease  and  analyses  of  efficacy  according  to different thresholds for responders allowed to validate the clinical relevance of the effect.

The data on patient exposure showed that 308 individuals received at least one dose of tafamidis, 147 ATTR patients for at least 6 months, 113 for at least 12 months and 43 for at least 2 years. The safety of tafamidis, evaluated in the patients included in the studies and in healthy volunteers, is re-assuring and no strong signal seemed to emerge. The CHMP considered that identified risks will be monitored and are manageable in the post-authorisation setting as described in the Risk Management Plan. The CHMP  also  took  into  consideration  that  data  from  the  THAOS  registry  with  respect  to  the  V30M mutation will be provided on an annual basis by the MAH; this is reflected in the RMP accordingly. In addition, the CHMP considered that treatment with tafamidis should be initiated by and remain under the  supervision  of  a  physician  knowledgeable  in  the  management  of  patients  with  transthyretin amyloid polyneuropathy.

With respect to the benefit-risk balance in ATTR-PN patients including those with the rare (non-V30M) mutations, the CHMP pointed out that the clinical data on the rare mutations originated in an open (uncontrolled) setting and were thus not robust. However, at the same time the CHMP considered the data comparing the monthly rate of change on the NIS-LL score before and after treatment re-assuring and agreed that the mechanism of action together with the results of TTR stabilisation data (clinical pharmacology) were supportive of the extrapolation from V30M to non-V30M patients. In their review, the CHMP concluded that the dataset was sufficient to conclude on a positive benefit-risk balance of tafamidis  in  the  treatment  of  transthyretin  amyloidosis  in  adult  patients  with  stage  1  symptomatic polyneuropathy to delay peripheral neurologic impairment. Taking into due consideration the rarity of the  disease,  the  CHMP  requested  the  marketing  authorisation  to  be  granted  under  exceptional circumstances.  In particular, the CHMP took into account the fact that due to the rarity of the nonV30M patient population a standard double-blind placebo study is not feasible and that the applicant cannot be expected to provide comprehensive evidence. In this context, the CHMP concluded that the marketing  authorisation  under  exceptional  circumstances  should  be  granted  subject  to  a  specific obligation to follow non-V30M patients in a proposed sub-study of the THAOS registry:

<div style=\"page-break-after: always\"></div>

Specific obligation:

'Within the planned post-authorisation sub-study of the THAOS registry the MAH shall evaluate in nonV30M patients the effects of Vyndaqel on disease progression and its long term safety as detailed in a CHMP agreed protocol, and shall provide yearly updates on the collected data within the annual reassessment.'

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by concensus that the risk-benefit balance of Vyndaqel in the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment is favourable and therefore recommends  the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)

## Conditions and requirements of the Marketing Authorisation

## Risk Management System and PSUR cycle

The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1 of the marketing authorisation, is in place and functioning before and whilst the product is on the market.

The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the Risk Management Plan (RMP) presented in Module 1.8.2 of the marketing authorisation and any subsequent updates of the RMP agreed by the CHMP.

As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).

In addition, an updated RMP should be submitted:

-  When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities
-  Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached
-  at the request of the EMA

The PSUR cycle for the medicinal product should follow the standard requirements until otherwise agreed by the CHMP.

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

The Marketing Authorisation Holder shall agree the format and content of the physician information leaflet with the National Competent Authority prior to launch in the Member State.

The Marketing Authorisation Holder shall ensure that all physicians who are expected to prescribe or use Vyndaqel are provided with the healthcare professional educational pack containing the following:

-  The Summary of Product Characteristics
-  The Physician Information Leaflet

The Physician Information Leaflet should contain the following key messages:

-  The need to counsel patients on important risks associated with Vyndaqel therapy and appropriate precautions when using the medicine, particularly the avoidance of pregnancy and the need for effective contraception.
-  That patients should be advised to contact their doctor about adverse events and that physicians/pharmacists should report suspected adverse reactions to Vyndaqel since there is limited knowledge about the clinical safety due to the rare nature of transthyretin amyloidosis.
-  That physicians are encouraged to enter patients in the Transthyretin Amyloidosis Outcome Survey (THAOS) and provided with details how to enroll patients into this international disease registry.
-  The existence and scope of the Tafamidis Enhanced Surveillance for Pregnancy Outcomes (TESPO) program and the details how to report pregnancies in women who are being treated with Vyndaqel.

## Specific Obligation to complete post-authorisation measures for the marketing authorisation under exceptional circumstances

This being an approval under exceptional circumstances and pursuant to Article 14(8) of Regulation (EC) No 726/2004, the MAH shall conduct, within the stated timeframe, the following measure:

| Description                                                                                                                                                                                                                                                                                                                | Due date              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| 'Within the planned post-authorisation sub-study of the THAOS registry the MAH shall evaluate in non-V30M patients the effects of Vyndaqel on disease progression and its long term safety as detailed in a CHMP agreed protocol, and shall provide yearly updates on the collected data within the annual re-assessment.' | Annual re- assessment |

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

The Member States shall agree the final educational material with the Marketing Authorization Holder (MAH) prior to launch of the product in their territory.

The Member States shall ensure that the MAH provides all physicians who are expected to prescribe or use Vyndaqel with a healthcare professional educational pack containing the following:

-  The Summary of Product Characteristics
-  The Physician Information Leaflet

<div style=\"page-break-after: always\"></div>

The Physician Information Leaflet should contain the following key messages:

-  The need to counsel patients on important risks associated with Vyndaqel therapy and appropriate precautions when using the medicine, particularly the avoidance of pregnancy and the need for effective contraception.
-  That patients should be advised to contact their doctor about adverse events and that physicians/pharmacists should report suspected adverse reactions to Vyndaqel since there is limited knowledge about the clinical safety due to the rare nature of transthyretin amyloidosis.
-  That physicians are encouraged to enter patients in the Transthyretin Amyloidosis Outcome Survey (THAOS) and provided with details how to enroll patients into this international disease registry.
-  The existence and scope of the Tafamidis Enhanced Surveillance for Pregnancy Outcomes (TESPO) program and the details how to report pregnancies in women who are being treated with Vyndaqel.

## New Active Substance Status

Based on the CHMP review of data on the quality, non-clinical and clinical properties of the active substance, the CHMP considers that tafamidis is to be qualified as a new active substance.